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Abstract: Summary Cancer has traditionally been viewed as a set of diseases that are driven by the
accumulation of genetic mutations that have been considered the major causes of neoplasia. However,
this paradigm has now been expanded to incorporate the disruption of epigenetic regulatory mechanisms
that are prevalent in a wide variety of human cancers. The reversible nature of epigenetic modifications
provides exciting new avenues for cancer research. Particularly, the reactivation of tumor suppressor
genes has made them attractive targets for cancer treatment. A recent outcome of whole exome sequenc-
ing of thousands of human cancers has been the unexpected discovery of many inactivating mutations
in genes that control the epigenome. These mutations have the potential to disrupt DNA methylation
patterns, histone modifica- tions, and nucleosome positioning which in turn deregulate genes critical to
cancer pathogen- esis. These alterations are now recognized as key events governing the tumor cell phe-
notype. However, prostate cancer is characterized by a low frequency of somatic mutations, making it
unclear how its aberrant epigenetic signature is established. Understanding this process has not only
the potential to establish new approaches for prostate cancer therapy but also to shed light on the most
vital question in the current treatment paradigm of prostate cancer: how to distinguish indolent and
aggressive tumors? Prostate cancer is the most common non-cutaneous malignancy in men over the age
of 50. Prediction of clinical behavior remains challenging using the currently available histopatho- logical
and biochemical (prostate-specific antigen; PSA) markers. Thus, novel molecular- based approaches will
likely improve prognostic accuracy in this disease. Particularly, the ab- sence of early prognostic markers
able to distinguish between indolent tumors and those that will become truly aggressive, as well as the
lack of efficient therapies for advanced prostate cancer, remain a major health problem. Previous studies
have shown that elevated expression of the epigenetic regulator EZH2 (Enhancer of zeste homolog 2) is
highly correlated with prostate cancer progression and poor outcome. EZH2 is a subunit of the Polycomb
repressive complex 2 (PRC2) that catalyzes a repressive histone mark, the trimethylation of lysine 27
on histone H3 (H3K27me3). Howev- er, how EZH2 is aberrantly recruited to specific genes during the
neoplastic process is yet to be elucidated. This work has investigated the function of TIP5 in cancer.
TIP5 is the largest subunit of the nucleolar complex NoRC (nucleolar remodeling complex), known to
establish epigenetic silencing and transcriptional repression at the ribosomal (rRNA) genes through the
associa- tion with DNA methyltransferases and histone modifier complexes. Analysis of expression pro-
files of benign, clinically localized and metastatic prostate cancer revealed that TIP5 is up- regulated in
metastatic prostate cancer. TIP5 is paradoxically involved in maintaining prostate cancer cell growth,
a feature that is specific to cancer cells. Moreover, TIP5 is required for migration, invasion and stem
cell-like features of prostate cancer cells, which are important properties in metastasis formation and
cancer recurrence. Transcriptomic profiling has demonstrated a significant overlap (30%) of TIP5- and
EZH2-regulated genes in metastatic prostate cancer. A combination of epigenomic and transcriptomic
analyses has revealed that TIP5 cooperates with the Polycomb group protein EZH2. TIP5 and EZH2
together establish repressive epigenetic signatures such as H3K27me3 and repress the transcription of
develop- mental and tumor suppressor genes, which are frequently silenced in metastatic prostate can-
cer. Interestingly, depletion of TIP5 impairs EZH2 recruitment and decreases H3K27me3 lev- els, sug-
gesting a role for TIP5 in guiding EZH2 to genes that are critical for prostate cancer aggressiveness.
Importantly, TIP5 overexpression is tightly associated with a prostate cancer subtype displaying a CpG
island methylator phenotype (CIMP). Finally, high TIP5 levels serve as an independent predictor of
biochemical recurrence in a cohort of 7,682 individuals with prostate cancer. This work defines a mech-
anistic and functional crosstalk between TIP5 and Polycomb-mediated epigenetic silencing in prostate
cancer. Thus, these data indicate a novel aberrant role for the epigenetic regulator TIP5, which can also
serve as a useful bi- omarker to determine aggressive/metastatic potential in prostate cancer. Zusam-
menfassung Krebs wurde traditionell als eine Reihe von Krankheiten gesehen, die durch die Anhäufung
von genetischen Mutationen entstehen, welche bislang als Hauptursache einer Neoplasie be- trachtet
wurden. Dieses Paradigma wurde erweitert und umfasst nun auch Störungen in epi- genetischen reg-
ulatorischen Mechanismen, welche weit verbreitet in verschiedenen humanen Krebserkrankungen sind.
Epigenetische Modifizierungen können rückgängig gemacht wer- den, eine Eigenschaft, die neue Wege
in der Krebsforschung eröffnet. Insbesondere die Re- Aktivierung von Tumorsuppressor-Genen macht
sie zu einem attraktiven Angriffspunkt in der Krebsbehandlung. Kürzlich durchgeführte Studien von
vollständigen Exom-Sequenzierungen von tausenden humanen Tumoren machten die unerwartete Ent-
deckung, dass es viele inakti- vierende Mutationen in Genen gibt, welche das Epigenom kontrollieren.
Diese Mutationen können potenzielle Störungen in DNA-Methylierungsmustern, Histonmodifikationen,
und Nukleosom-Positionierung verursachen, welche im Gegenzug zur Deregulierung von Genen führen,
die kritisch in der Pathogenese von Krebs sind. Diese Veränderungen werden nun als Schlüsselereignis
für die Ausprägung des Phänotyps einer Krebszelle betrachtet. Prostata- krebs ist jedoch durch eine
geringe somatische Mutationsrate charakterisiert, es ist daher un- klar, wie die veränderte epigenetische
Signatur hier etabliert wird. Das Verständnis dieses Prozesses hat nicht nur das Potenzial neue Ansätze
in der Krebstherapie zu finden, sondern gibt auch Aufschluss über die entscheidende Frage im derzeitigen
Behandlungsparadigma von Prostatakrebs: wie kann man indolente von aggressiven Tumoren unterschei-
den? Prostatakrebs ist die häufigste, nicht-dermatologische Erkrankung unter Männern im Alter über
50 Jahren. Die Vorhersage des klinischen Verlaufs mit der Verwendung der derzeitigen histopatholo-
gischen und biochemischen (Prostataspezifisches Antigen; PSA) Markern bleibt eine Herausforderung.
Daher werden neue molekular-basierte Ansätze die prognostische Ge- nauigkeit für diese Erkrankung
wahrscheinlich verbessern. Besonders das Fehlen von frühen prognostischen Markern, die in der Lage
sind zwischen indolenten Tumoren und Tumoren, die wirklich aggressiv werden, zu unterscheiden, sowie
das Nichtvorhandensein von effizien- ten Therapien für Patienten mit fortgeschrittenem Prostatakrebs
stellen ein bedeutendes Ge- sundheitsproblem dar. Vergangene Studien haben gezeigt, dass die verstärkte
Expression des epigenetischen Re- gulators EZH2 (Enhancer of zeste homolog 2) mit der Progression von
Prostatakrebs und einer schlechten Diagnose korreliert ist. EZH2 ist eine Untereinheit des Polycomb
repressive complex 2 (PRC2) welche die Trimethylierung von Lysin 27 des Histons H3 (H3K27me3), eine
repressive Histonmodifikation, katalysiert. Jedoch ist bislang unklar, wie die anormale Rekrutierung von
EZH2 zu den spezifischen Genen während des neoplastischen Prozesses stattfindet. Diese Arbeit unter-
suchte die Funktion von TIP5 in Krebs. TIP5 ist die grösste Unterein- heit des nukleolaren Komplexes
NoRC (nucleolar remodeling complex), welcher durch die Assoziation mit DNA-Methyltransferasen und
Histon-Modifizierungs-Komplexen die Etab- lierung von epigenetischem Inaktivierungen und transkrip-
tionelle Repression an den riboso- malen (rRNA) Genen ausführt. Die Analyse von Expressionsprofilen
von gutartigen, klinisch lokalisierten und metastatischen Prostatakrebs zeigte, dass TIP5 in metastatis-
chem Prostata- krebs stark erhöht ist. Paradoxerweise ist TIP5 in der Aufrechterhaltung des Wachstums
von Prostatakrebszellen involviert und diese Eigenschaft ist spezifisch für Krebszellen. Zudem wird TIP5
für die Migration, Invasion und stammzell-ähnliche Eigenschaften von Prostata- krebszellen benötigt,
allesamt Eigenschaften welche bedeutend für die Bildung von Metasta- sen und das erneute Auftreten
von Krebs sind. Transkriptomische Analysen deckten eine sig- nifikante Überlappung (30%) von TIP5-
und EZH2-regulierten Genen in metastatischem Prostatakrebs auf. Eine Kombination von epigenomis-
chen und transkriptomischen Analysen zeigte auf, dass TIP5 mit dem Polycomb Group Protein EZH2
kooperiert. TIP5 und EZH2 etablieren zusammen epigenetische Signaturen wie z. B. H3K27me3 und
hemmen die Tran- skription von Entwicklungs-Genen und Tumorsuppressor-Genen, welche in metas-
tatischem Prostatakrebs häufig ausgeschaltet sind. Interessanterweise beeinträchtigt das Ausschalten
von TIP5 die Rekrutierung von EZH2 und reduziert die Werte von H3K27me3. Diese Ergeb- nisse
weisen auf eine Funktion von TIP5 bei der Rekrutierung von EZH2 zu Genen hin, die kritisch für die
Aggressivität von Prostatakrebs sind. Von grosser Bedeutung ist die Beobach- tung, dass die verstärkte
Expression von TIP5 stark mit einem Subtyp von Prostatakrebs, der einen Phänotypen mit der Beze-
ichnung „CpG Island Methylator Phenotype“ (CIMP) zeigt, assoziiert ist. Schliesslich konnte in einer
Kohorte von 7’682 Prostatakrebspatienten gezeigt werden, dass hohe Mengen von TIP5 zur unabhängigen
Vorhersage des biochemischen Wie- derauftreten des Tumors verwendet werden können. Die vorliegende
Arbeit beschreibt ein funktionales Zusammenspiel zwischen TIP5 und einer Polycomb-vermittelten epi-
genetischen Inaktivierung in Prostatakrebs. Diese Ergebnisse weisen somit auf eine neue anormale Rolle
des epigenetischen Regulators TIP5 hin, welcher als nützlicher Biomarker zur Bestimmung des aggres-
siven/metastatischen Potenzials von Prostatakrebs verwendet werden kann.
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Summary 
Cancer has traditionally been viewed as a set of diseases that are driven by the accumulation 
of genetic mutations that have been considered the major causes of neoplasia. However, this 
paradigm has now been expanded to incorporate the disruption of epigenetic regulatory 
mechanisms that are prevalent in a wide variety of human cancers. The reversible nature of 
epigenetic modifications provides exciting new avenues for cancer research. Particularly, the 
reactivation of tumor suppressor genes has made them attractive targets for cancer treatment. 
A recent outcome of whole exome sequencing of thousands of human cancers has been the 
unexpected discovery of many inactivating mutations in genes that control the epigenome. 
These mutations have the potential to disrupt DNA methylation patterns, histone modifica-
tions, and nucleosome positioning which in turn deregulate genes critical to cancer pathogen-
esis. These alterations are now recognized as key events governing the tumor cell phenotype. 
However, prostate cancer is characterized by a low frequency of somatic mutations, making it 
unclear how its aberrant epigenetic signature is established. Understanding this process has 
not only the potential to establish new approaches for prostate cancer therapy but also to shed 
light on the most vital question in the current treatment paradigm of prostate cancer: how to 
distinguish indolent and aggressive tumors? 
 Prostate cancer is the most common non-cutaneous malignancy in men over the age of 50. 
Prediction of clinical behavior remains challenging using the currently available histopatho-
logical and biochemical (prostate-specific antigen; PSA) markers. Thus, novel molecular-
based approaches will likely improve prognostic accuracy in this disease. Particularly, the ab-
sence of early prognostic markers able to distinguish between indolent tumors and those that 
will become truly aggressive, as well as the lack of efficient therapies for advanced prostate 
cancer, remain a major health problem. 
 Previous studies have shown that elevated expression of the epigenetic regulator EZH2 
(Enhancer of zeste homolog 2) is highly correlated with prostate cancer progression and poor 
outcome. EZH2 is a subunit of the Polycomb repressive complex 2 (PRC2) that catalyzes a 
repressive histone mark, the trimethylation of lysine 27 on histone H3 (H3K27me3). Howev-
er, how EZH2 is aberrantly recruited to specific genes during the neoplastic process is yet to 
be elucidated. 
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 This work has investigated the function of TIP5 in cancer. TIP5 is the largest subunit of 
the nucleolar complex NoRC (nucleolar remodeling complex), known to establish epigenetic 
silencing and transcriptional repression at the ribosomal (rRNA) genes through the associa-
tion with DNA methyltransferases and histone modifier complexes. Analysis of expression 
profiles of benign, clinically localized and metastatic prostate cancer revealed that TIP5 is up-
regulated in metastatic prostate cancer. TIP5 is paradoxically involved in maintaining prostate 
cancer cell growth, a feature that is specific to cancer cells. Moreover, TIP5 is required for 
migration, invasion and stem cell-like features of prostate cancer cells, which are important 
properties in metastasis formation and cancer recurrence. Transcriptomic profiling has 
demonstrated a significant overlap (30%) of TIP5- and EZH2-regulated genes in metastatic 
prostate cancer. A combination of epigenomic and transcriptomic analyses has revealed that 
TIP5 cooperates with the Polycomb group protein EZH2. TIP5 and EZH2 together establish 
repressive epigenetic signatures such as H3K27me3 and repress the transcription of develop-
mental and tumor suppressor genes, which are frequently silenced in metastatic prostate can-
cer. Interestingly, depletion of TIP5 impairs EZH2 recruitment and decreases H3K27me3 lev-
els, suggesting a role for TIP5 in guiding EZH2 to genes that are critical for prostate cancer 
aggressiveness. Importantly, TIP5 overexpression is tightly associated with a prostate cancer 
subtype displaying a CpG island methylator phenotype (CIMP). Finally, high TIP5 levels 
serve as an independent predictor of biochemical recurrence in a cohort of 7,682 individuals 
with prostate cancer. This work defines a mechanistic and functional crosstalk between TIP5 
and Polycomb-mediated epigenetic silencing in prostate cancer. Thus, these data indicate a 
novel aberrant role for the epigenetic regulator TIP5, which can also serve as a useful bi-
omarker to determine aggressive/metastatic potential in prostate cancer. 
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Zusammenfassung 
Krebs wurde traditionell als eine Reihe von Krankheiten gesehen, die durch die Anhäufung 
von genetischen Mutationen entstehen, welche bislang als Hauptursache einer Neoplasie be-
trachtet wurden. Dieses Paradigma wurde erweitert und umfasst nun auch Störungen in epi-
genetischen regulatorischen Mechanismen, welche weit verbreitet in verschiedenen humanen 
Krebserkrankungen sind. Epigenetische Modifizierungen können rückgängig gemacht wer-
den, eine Eigenschaft, die neue Wege in der Krebsforschung eröffnet. Insbesondere die Re-
Aktivierung von Tumorsuppressor-Genen macht sie zu einem attraktiven Angriffspunkt in der 
Krebsbehandlung. Kürzlich durchgeführte Studien von vollständigen Exom-Sequenzierungen 
von tausenden humanen Tumoren machten die unerwartete Entdeckung, dass es viele inakti-
vierende Mutationen in Genen gibt, welche das Epigenom kontrollieren. Diese Mutationen 
können potenzielle Störungen in DNA-Methylierungsmustern, Histonmodifikationen, und 
Nukleosom-Positionierung verursachen, welche im Gegenzug zur Deregulierung von Genen 
führen, die kritisch in der Pathogenese von Krebs sind. Diese Veränderungen werden nun als 
Schlüsselereignis für die Ausprägung des Phänotyps einer Krebszelle betrachtet. Prostata-
krebs ist jedoch durch eine geringe somatische Mutationsrate charakterisiert, es ist daher un-
klar, wie die veränderte epigenetische Signatur hier etabliert wird. Das Verständnis dieses 
Prozesses hat nicht nur das Potenzial neue Ansätze in der Krebstherapie zu finden, sondern 
gibt auch Aufschluss über die entscheidende Frage im derzeitigen Behandlungsparadigma 
von Prostatakrebs: wie kann man indolente von aggressiven Tumoren unterscheiden? 
 Prostatakrebs ist die häufigste, nicht-dermatologische Erkrankung unter Männern im Alter 
über 50 Jahren. Die Vorhersage des klinischen Verlaufs mit der Verwendung der derzeitigen 
histopathologischen und biochemischen (Prostataspezifisches Antigen; PSA) Markern bleibt 
eine Herausforderung. Daher werden neue molekular-basierte Ansätze die prognostische Ge-
nauigkeit für diese Erkrankung wahrscheinlich verbessern. Besonders das Fehlen von frühen 
prognostischen Markern, die in der Lage sind zwischen indolenten Tumoren und Tumoren, 
die wirklich aggressiv werden, zu unterscheiden, sowie das Nichtvorhandensein von effizien-
ten Therapien für Patienten mit fortgeschrittenem Prostatakrebs stellen ein bedeutendes Ge-
sundheitsproblem dar. 
 Vergangene Studien haben gezeigt, dass die verstärkte Expression des epigenetischen Re-
gulators EZH2 (Enhancer of zeste homolog 2) mit der Progression von Prostatakrebs und ei-
Zusammenfassung 
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ner schlechten Diagnose korreliert ist. EZH2 ist eine Untereinheit des Polycomb repressive 
complex 2 (PRC2) welche die Trimethylierung von Lysin 27 des Histons H3 (H3K27me3), 
eine repressive Histonmodifikation, katalysiert. Jedoch ist bislang unklar, wie die anormale 
Rekrutierung von EZH2 zu den spezifischen Genen während des neoplastischen Prozesses 
stattfindet. 
 Diese Arbeit untersuchte die Funktion von TIP5 in Krebs. TIP5 ist die grösste Unterein-
heit des nukleolaren Komplexes NoRC (nucleolar remodeling complex), welcher durch die 
Assoziation mit DNA-Methyltransferasen und Histon-Modifizierungs-Komplexen die Etab-
lierung von epigenetischem Inaktivierungen und transkriptionelle Repression an den riboso-
malen (rRNA) Genen ausführt. Die Analyse von Expressionsprofilen von gutartigen, klinisch 
lokalisierten und metastatischen Prostatakrebs zeigte, dass TIP5 in metastatischem Prostata-
krebs stark erhöht ist. Paradoxerweise ist TIP5 in der Aufrechterhaltung des Wachstums von 
Prostatakrebszellen involviert und diese Eigenschaft ist spezifisch für Krebszellen. Zudem 
wird TIP5 für die Migration, Invasion und stammzell-ähnliche Eigenschaften von Prostata-
krebszellen benötigt, allesamt Eigenschaften welche bedeutend für die Bildung von Metasta-
sen und das erneute Auftreten von Krebs sind. Transkriptomische Analysen deckten eine sig-
nifikante Überlappung (30%) von TIP5- und EZH2-regulierten Genen in metastatischem 
Prostatakrebs auf. Eine Kombination von epigenomischen und transkriptomischen Analysen 
zeigte auf, dass TIP5 mit dem Polycomb Group Protein EZH2 kooperiert. TIP5 und EZH2 
etablieren zusammen epigenetische Signaturen wie z. B. H3K27me3 und hemmen die Tran-
skription von Entwicklungs-Genen und Tumorsuppressor-Genen, welche in metastatischem 
Prostatakrebs häufig ausgeschaltet sind. Interessanterweise beeinträchtigt das Ausschalten 
von TIP5 die Rekrutierung von EZH2 und reduziert die Werte von H3K27me3. Diese Ergeb-
nisse weisen auf eine Funktion von TIP5 bei der Rekrutierung von EZH2 zu Genen hin, die 
kritisch für die Aggressivität von Prostatakrebs sind. Von grosser Bedeutung ist die Beobach-
tung, dass die verstärkte Expression von TIP5 stark mit einem Subtyp von Prostatakrebs, der 
einen Phänotypen mit der Bezeichnung „CpG Island Methylator Phenotype“ (CIMP) zeigt, 
assoziiert ist. Schliesslich konnte in einer Kohorte von 7'682 Prostatakrebspatienten gezeigt 
werden, dass hohe Mengen von TIP5 zur unabhängigen Vorhersage des biochemischen Wie-
derauftreten des Tumors verwendet werden können. Die vorliegende Arbeit beschreibt ein 
funktionales Zusammenspiel zwischen TIP5 und einer Polycomb-vermittelten epigenetischen 
Inaktivierung in Prostatakrebs. Diese Ergebnisse weisen somit auf eine neue anormale Rolle 
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des epigenetischen Regulators TIP5 hin, welcher als nützlicher Biomarker zur Bestimmung 
des aggressiven/metastatischen Potenzials von Prostatakrebs verwendet werden kann. 
 14 
Abbreviations 
__________________________________________________________________________________________ 
15 
Abbreviations 
 
5caC     5-carboxycytosine 
5fC     5-formylcytosine 
5hmC     5-hydroxymethylcytosine 
5mC     5-methylcytosine 
ALL     acute lymphoblastic leukemia 
AML     acute-myeloid leukemia 
AR     androgen receptor 
ATP     adenosine triphosphate 
BAZ2A    bromodomain adjacent to zinc finger 2A 
BET     bromodomain and extraterminal 
bp      base pairs 
CGI     CpG island  
CIMP     CpG island methylator phenotype 
CpG     C-phosphate-G 
CTCL     cutaneous T cell lymphoma 
DMR     differentially methylated region 
DNA     deoxyribonucleic acid 
DNMT    DNA methyltransferase 
ESC     embryonic stem cell 
EZH2     Enhancer of zeste 2 
HATs     histone acetyltransferase 
HDAC    histone deacetylase 
HDM     histone demethylase 
HMT     histone methyltransferase 
HP1     heterochromatin protein 1 
LOI     loss of imprinting 
MBT     malignant brain tumor 
ncRNA    non-coding ribonucleic acid 
NoRC     nucleolar remodeling complex 
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O-Glc-NAc   β-N-acetylglucosamine 
Pc      Polycomb 
PcG     Polycomb group  
PGC     primordial germ cell 
PHD     plant homeodomain 
PhoRC    PHO-repressive complex 
PR-DUB    polycomb repressive deubiquitinase 
PRC1     polycomb repressive complex 1 
PRC2     polycomb repressive complex 2 
PRE     polycomb response element 
PSA     prostate-specific antigen 
PTM     posttranslational modification 
RB     retinoblastoma protein 
RNA     ribonucleic acid 
rRNA     ribosomal RNA 
SAM     S-Adenosyl methionine 
SWI/SNF    SWItch/Sucrose NonFermentable 
TDG     thymine-DNA glycosylase 
TET     ten-eleven translocation 
TIP5     TTF1-interacting protein 5 
TrxG     Trithorax group 
α-KG     α-ketoglutarate 
 
Table of Contents 
__________________________________________________________________________________________ 
17 
Table of Contents 
 
Acknowledgements .................................................................................................................. 7	  
Summary ................................................................................................................................... 9	  
Zusammenfassung .................................................................................................................. 11	  
Abbreviations ......................................................................................................................... 15	  
Table of Contents ................................................................................................................... 17	  
1 Introduction ......................................................................................................................... 19	  
1.1 Epigenetics ..................................................................................................................... 19	  
1.1.1 Histone modifications .............................................................................................. 21	  
1.1.1.1 Polycomb group proteins ................................................................................... 23	  1.1.1.1.1	  Evolution	  of	  PRC2	  .........................................................................................................	  25	  1.1.1.1.2	  Transcriptional	  repression	  by	  PRCs	  .....................................................................	  25	  1.1.1.1.3	  Targeting	  of	  PRC	  to	  genomic	  loci	  ...........................................................................	  27	  
1.1.2 DNA methylation ..................................................................................................... 29	  
1.2 Epigenetics in Cancer ................................................................................................... 32	  
1.2.1 Histone modifications and cancer ............................................................................ 32	  
1.2.2 DNA methylation and cancer ................................................................................... 36	  
1.2.3 Chromatin remodeling and cancer ........................................................................... 38	  
1.2.4 Epigenetic therapies ................................................................................................. 39	  
1.2.5 Epigenetic silencing of tumor suppressor genes ...................................................... 42	  
1.2.6 CpG island methylator phenotype ............................................................................ 46	  
1.3 Prostate Cancer ............................................................................................................. 47	  
1.3.1 Epigenetics in prostate cancer .................................................................................. 51	  
1.4 The epigenetic regulator TIP5 ..................................................................................... 53	  
2 Aim of the work ................................................................................................................... 57	  
3 Results .................................................................................................................................. 59	  
3.1 BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its 
overexpression predicts disease recurrence ..................................................................... 59	  
Table of Contents 
__________________________________________________________________________________________ 
18 
3.2 lncRNA maturation to initiate heterochromatin formation in the nucleolus is 
required for exit from pluripotency in ESCs ................................................................... 60	  
3.3 The epigenetic modifier EZH2 controls melanoma growth and metastasis through 
silencing of distinct tumour suppressors .......................................................................... 60	  
3.4 Methylation-dependent SOX9 expression mediates invasion in human melanoma 
cells and is a negative prognostic factor in advanced melanoma ................................... 61	  
3.5 DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with 
ARTD8 survival and proliferation of metastatic prostate cancer cells ......................... 61	  
4 Discussion ........................................................................................................................... 237	  
5 References .......................................................................................................................... 241	  
6 Curriculum vitae ............................................................................................................... 265	  
 
1 Introduction 
__________________________________________________________________________________________ 
19 
1 Introduction 
 The human body consists of approximately 3 × 1013 cells which all carry a compete copy 
of the genome within the cell nucleus. In humans, each cell normally contains 23 pairs of 
chromosomes, for a total of 46. Twenty-two of these pairs, called autosomes, look the same in 
both males and females. The 23rd pair, the sex chromosomes, differs between males and fe-
males (one X chromosome in males, two in females; in males only, one Y chromosome). The 
stretched linear double helix consists of about three billion nucleotide base pairs (bp) and 
would measure 1.8 m (Ball, 2003). In order to fit a fully extended DNA molecule within the 
nucleus, DNA has to be compacted 100,000 times (Razin et al., 2007). To achieve this enor-
mous compartmentalization and compaction, DNA is associated with proteins forming a 
complex called chromatin. Around 1880, Walther Flemming proposed the term chromatin 
(from the Greek χρῶµα, chroma = color) based on his work using aniline dyes to visualize the 
threadlike structures in the cell nucleus. The overall structure of chromatin depends on the 
stage of the cell cycle. During cell division chromatin can be seen as individual compact 
chromosomes; whereas in non-dividing (interphase) cells it is distributed throughout the nu-
cleus and organized into highly condensed (heterochromatin) and the more open regions (eu-
chromatin) (Felsenfeld and Groudine, 2003). Chromatin is a dynamic structure and exerts 
profound control on DNA-related metabolic processes including transcription, recombination, 
DNA repair, replication, kinetochore and centrosome formation and other fundamental cellu-
lar processes. 
 The DNA molecule as “the instruction manual of life” directs how a fertilized egg turns 
into the specific cells, tissues and organs (Marx, 2012). How does each cell type interpret this 
common manual to achieve specific identity? Although the human genome project was com-
pleted in 2001, yet the primary DNA sequence is only a basis for our understanding how the 
genome is read. Superimposed upon primary DNA sequence is a second layer of heritable 
“epigenetic” information. 
1.1 Epigenetics 
Epigenetics has been defined as ‘the study of mitotically and/or meiotically heritable changes 
in gene function that cannot be explained by changes in DNA sequence’ (Russo et al., 1996). 
In other words, epigenetic inheritance involves the transmission of information not encoded in 
DNA sequences from mother to daughter cells or from generation to generation (‘epi-’ is de-
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rived from the Greek for ‘above’; hence, ‘above genetics’). This mechanism involves modifi-
cations to either DNA or histones that control the transcriptional program of each cell by reg-
ulating the chromatin structure (Figure 1). For example, modifications promoting chromatin 
compaction do not allow access by the transcription machinery, whereas others acts as signals 
that modulate gene expression. 
 The functional subunit of chromatin is the nucleosome that consists of 147 bp of DNA 
wrapped in two super-helical turns around an octamer of core histones (two each of histones 
H2A, H2B, H3 and H4 (Kornberg, 1974; Luger et al., 1997; Van Holde et al., 1980). Each 
nucleosome is connected to its neighbors by a variable length of linker DNA (about 10-80 bp 
in length) forming the so-called “beads on a string”-like structure. Further compaction is 
achieved by incorporation of the linker histone H1, which binds to each nucleosome and to its 
adjacent linker giving rise to a 30 nm chromatin fiber (Felsenfeld and Groudine, 2003). 
 
 
Figure 1. Structure of chromatin. DNA molecule wrapped around nucleosomes gives rise to a higher order 
structure allowing for compaction into the characteristic chromatin fibre and chromosomes. DNA methylation 
influences which genes are expressed, and other epigenetic factors (e.g. histone modifications) determine the 
compaction status of Chromatin. Hence, both epigenetic marks control the transcriptional and compaction state 
of DNA without changing the underlying DNA sequence. From (Marx, 2012). 
 
 Besides the canonical core histones H2A, H2B, H3 and H4, several histones variants have 
evolved for diverse cellular functions like transcriptional activation/repression, kinetochore 
assembly, DNA repair and recombination, gene expression, chromosome segregation and X 
chromosome inactivation (Malik and Henikoff, 2003; Sarma and Reinberg, 2005). 
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1.1.1 Histone modifications 
Modifications or epigenetic marks are found on both histones and DNA. However, DNA can 
be primarily methylated, whereas histones are subject to a wide array of post-translational 
modifications (PTMs), which were discovered by Allfrey and coworkers more than 50 years 
ago (Allfrey et al., 1964). 
 The core histones are predominantly globular except for their highly basic amino-terminal 
extensions (histone “tails”) which are unstructured (Kouzarides, 2007). The histone tails are 
highly conserved across species and protrude from the surface of the chromatin polymer, thus 
providing an exposed surface for PTMs and potential interactions with other proteins (Strahl 
and Allis, 2000). The tails of histone H3 and H4 as well as sites within the globular domains 
of all four core histones and the linker histone H1 are subject to various PTMs (Figure 2). 
There are at least eight distinct modifications such as methylation (me) of lysine (K) and argi-
nine (R); acetylation (ac), ubiquitylation (ub) and sumoylation (su) of lysine (K) residues; 
phosphorylation (ph) of serine (S), theronine (T) and tyrosine (Y) (Basnet et al., 2014); and 
mono- and poly-ADP ribosylation of glutamate (E) and arginine (R) residues (Kouzarides, 
2007). The methylation of lysine and arginine occurs in the fashion of mono- and dimethyla-
tion, whereas trimethylation is only found on lysine residues. Other modifications involve the 
deimination by conversion of arginine to citrulline and the isomerization of proline residues 
(Bannister and Kouzarides, 2011). Recently, histones H2A, H2B and H4 have been shown to 
be modified by β-N-acetylglucosamine (O-GlcNAc) sugar residues (Sakabe et al., 2010). 
Based on the diversity and biological specificity associated with distinct patterns of covalent 
histone marks, histone modifications have been proposed to function as a ‘histone code’ to 
coordinate the recruitment of proteins that trigger selective effects on transcription, replication 
and other chromatin-related processes (Jenuwein and Allis, 2001; Strahl and Allis, 2000; 
Taverna et al., 2007). 
 The histone PTMs can be found in the promoter region as well as in gene bodies. Histone 
modifications promoting transcription, so-called ‘active’ marks, include marks such as 
H3K4me1/3, H3K9me1, H3K9ac, H3K14ac, H3K27me1, H3K27ac and H3K79me1/2, 
H3K36me3, H4K20me, H2BK5me1, whereas ‘repressive’ marks such as H3K9me2/3, 
H3K27me2/3, H3K79me3, H2BK5me3 are correlating with transcriptional repression. The 
large number of modifications gives an enormous potential for functional responses, but not 
all these modifications will be located on the same histone at the same time. The appearance 
of histone PTMs will depend on the signaling conditions within a cell. A special case was 
1 Introduction 
__________________________________________________________________________________________ 
22 
found in embryonic stem cells (ESCs) (and other stem cells) where many promoters carry 
both active H3K4me3 and repressive H3K27me3 marks. These ‘bivalent promoters’ are con-
sidered to poise the transcription of developmental genes. Upon differentiation these ‘bivalent 
promoters’ allow a rapid resolution to either an active or repressive state depending on the 
chosen lineage. 
 Histone PTMs are mediated and regulated by a variety of enzymes that modify (‘writers’) 
or revert a modification (‘erasers’). Epigenetic ‘writers’ include enzymes such as histone me-
thyltransferases (HMTs), histone acetyltransferases (HATs) and kinases; whereas histone de-
methylases (HDMs), histone deacetylases (HDACs) and phosphatases are examples for ‘eras-
er’ enzymes. Most of these enzymes act in protein complexes such as Trithorax group (TrxG) 
and Polycomb group (PcG) complexes (see 1.1.1.1) that are required for maintenance of gene 
expression patters. The histone modifications serve as a platform for the recruitment of pro-
teins or protein complexes (‘readers’), which influence chromatin dynamics and function. Re-
cruitment of ‘reader’ proteins to the side of modifications is based on their binding via specif-
ic domains. Readers of methylation include proteins that contain specific methyl histone-
binding domains, such as chromodomains, PHD (plant homeodomain) domains, or Tudor 
domains (Kouzarides, 2007). Acetylation is read by proteins containing a bromodomain, and 
phosphorylation is recognized by a domain within 14-3-3 proteins (Kouzarides, 2007). 
 
 
Figure 2. Sites of post-transcriptional modifications on the histone tails. Modifications shown include acet-
ylation (purple), methylation (red), phosphorylation (cyan), and ubiquitination (orange). From (Zhang and 
Reinberg, 2001). 
 
 Besides PTMs of histones, other factors – including DNA methylation (see 1.1.2), histone 
variants, nucleosome positioning, noncoding RNAs and histone chaperones - are responsible 
for fine-tuning chromatin structure and function, and together they constitute the powerful 
and dynamic epigenetic machinery (Musselman et al., 2012). Changes in epigenetic modifica-
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tions can be linked to cancer initiation and progression involving aberrant histone modifica-
tions or the dysregulation of the associated epigenetic enzymes (see 1.2). 
 
1.1.1.1 Polycomb group proteins 
Polycomb group proteins were first discovered in Drosophila melanogaster, where the term 
Polycomb (Pc) initially referred to a Drosophila mutant that displayed improper body seg-
mentation (Lewis, 1949). Later, Polycomb was proposed to encode a negative regulator of the 
homeotic (Hox) genes that are required for segmentation (Lewis, 1978). More genes charac-
terized by mutations that result in similar phenotypes to those of Polycomb were found in the 
1980s suggesting that these genes belong to a group of repressors, the Polycomb group (PcG), 
which are required to prevent inappropriate activation of Hox genes (Duncan, 1982; Jürgens, 
1985; Struhl, 1981). The PcG proteins are essential regulators of epigenetic gene silencing 
(Schwartz and Pirrotta, 2007; Simon and Kingston, 2009; Sparmann and van Lohuizen, 2006) 
having key roles in developmental pattering, X chromosome inactivation and stem cell 
maintenance (Lee et al., 2006; Plath et al., 2003; Shen et al., 2009). PcG proteins regulate ep-
igenetically mediated transcriptional silencing of hundreds of genes encoding crucial devel-
opmental regulators in organisms ranging from plants to humans (Simon and Kingston, 
2009). Polycomb-mediated silencing is based on the formation of chromatin-modifying com-
plexes implicated in the regulation of chromatin structure in part through PTM of histones. 
The essential role of PcG proteins during development is highlighted by early embryonic le-
thality in mice upon deletion of Eed, Ezh2, Suz12 and Ring1B (Rnf2) (Faust et al., 1995; 
O'Carroll et al., 2001; Pasini et al., 2004; Voncken et al., 2003). Loss of Eed, Ezh2, or Suz12 
has been shown to be associated with severe defects during gastrulation, consistent with the 
role of PRC2 in the repression of genes involved in lineage specification (Bracken and Helin, 
2009). 
 In mammals, two main PcG complexes exist: Polycomb repressive complex 1 (PRC1) and 
Polycomb repressive complex 2 (PRC2). PRC1 catalyzes monoubiquitylation of histone H2A 
K119 (H2AK119ub1) via the ubiquitin ligases RING1A and RING1B (Figure 3a) leading to 
chromatin compaction (Cao et al., 2005; Wang et al., 2004a). PRC2 is responsible for the di- 
and trimethylation of histone H3K27 (H3K27me2/3) through its subunits EZH1/2 having a 
catalytic SET domain (Figure 3b). 
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 The core of PRC2 consists of four components: EZH1/2, SUZ12, EED and RbAp46/48 
(also known as RBBP7/4) and is conserved from Drosophila to mammals (Figure 3b). Sev-
eral other polypeptides were shown to be associated with PRC2 such as AEBP2, PCLs and 
JARID2 (Figure 3b). AEBP2, a zinc-finger protein was reported to enhance PRC2 enzymatic 
activity (Cao and Zhang, 2004) and to co-localize with PRC2 at some target genes (Kim et al., 
2009). PCL1, 2 and 3, the mammalian orthologues of Drosophila Polycomb-like (PCL), have 
a tudor domain and two PHD finger domains. They were shown to interact with EZH2, 
SUZ12 and the histone chaperone RbAp46/48 (Nekrasov et al., 2007) and have been suggest-
ed to regulate PRC2 enzymatic activity (Nekrasov et al., 2007; Sarma et al., 2008) and re-
cruitment (Savla et al., 2008; Walker et al., 2010). JARID2 is a member of the Jumonji pro-
tein family catalyzing the demethylation of histones but JARID2 lacks enzymatic activity. It 
was demonstrated to interact with EZH2 and the recruitment of JARID2 and PRC2 seems to 
be partially interdependent (Landeira et al., 2010; Li et al., 2010; Pasini et al., 2010; Peng et 
al., 2009; Shen et al., 2009). 
 
          a                PRC1  b          PRC2 
 
 
 
 
Figure 3. Polycomb complexes PRC1 and PRC2. Graphics showing the composition of PRC1 and PRC2. a. 
In PRC1, the classical PRC1 complex is depicted on the left, while those on the right correspond to the so-
called PRC1-like complexes. Based on their homogly with Drosophila PSC protein, BMI1, MEL18 and 
NSPC1-containing PRC1 complexes are assumed to compact chromatin. CBX proteins specifically recognize 
H3K9/27me3 as represented by the ‘pocket’ shape. HPH1, 2, and 3 indicate human polyhomeotic homolog 1, 
2, and 3. X, Y and Z denominate various proteins such as SCMH1/2, FBXL10, E2F6 and JARID1D, which are 
supposed to contribute to the formation of PRC1-like complexes. b. PRC2 with the core subunits EZH1/2, 
EED, SUZ12 and RbAp46/48 and the associated polypeptides AEBP2, PCL and JARID2. Modified from 
(Margueron and Reinberg, 2011). 
 
Compared to PRC2, the composition of PRC1 is more variable, with only two core compo-
nents: RING1A/B together with BMI1, MEL18 (PCGF2) or NSPC1 (PCGF1) (Figure 3a) 
(Margueron and Reinberg, 2011). In Drosophila two other PcG complexes were described, 
PHO-repressive complex (PhoRC) and Polycomb repressive deubiquitinase (PR-DUB). How-
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ever, the conservation of their function in mammalian orthologues has not yet been studied. 
PRC1 was shown to specifically bind to H3K27me3 via its subunit Pc (known as CBX in 
mammals) leading to the hypothesis that PRC1 might function downstream of PRC2. Howev-
er, this mechanism is equivocal since there are genes that are targeted by PRC1 without PRC2 
and vice versa (see 1.1.1.1.2) (Margueron and Reinberg, 2011). PRC2-EZH1 complexes were 
reported to have a lower methyltransferase activity when compared to PRC2-EZH2 complex-
es indicating that the latter is involved in establishing H3K27me2/3 levels through EZH2 and 
that PRC2-EZH1 is implicated in the restoration of H3K27me2/3 that has been lost after his-
tone exchange or through demethylase activity (Margueron et al., 2008). Shen and coworkers 
have reported that non-canonical EZH1-mediated PRC2 coexists with the classic EZH2-
mediated PRC2 in catalyzing H3K27me3 at overlapping genes in mouse ESCs (Shen et al., 
2008b). 
 
1.1.1.1.1 Evolution of PRC2 
Compared to mammals, PRC2 evolved to a greater complexity in plants, e.g. in Arabidopsis 
thaliana up to 12 homologues of PRC2 components were identified (Margueron and 
Reinberg, 2011). Interestingly, a mammalian homologue of Heterochromatin Protein 1 (HP1) 
that binds to H3K9me3 was found in Arabidopsis thaliana, named LH1, and was shown to 
bind H3K27me3 and to interact with the RING1 homologues AtRING1A and AtRING1B. 
These results suggest the existence of a PRC1-like complex in plants (Hennig and 
Derkacheva, 2009). Hence, it was proposed that PRC2 might have evolved from a function, 
partially redundant with gene silencing though H3K9me3 pathway, yielding in a more specif-
ic role for the acquisition of diverse cell lineages in higher organisms (Margueron and 
Reinberg, 2011). 
 
1.1.1.1.2 Transcriptional repression by PRCs 
Polycomb-mediated gene silencing is thought to rely mostly on regulation of chromatin struc-
ture, in part through post-translational modification (PTM) of histones. Hence, the PRC2 
complex is responsible for the methylation (di- and tri-) of lysine 27 of histone H3 
(H3K27me2/3) via its enzymatic subunits EZH1 and EZH2, whereas the PRC1 complex 
mono-ubiquitylates lysine 119 of histone H2A (H2AK119ub) via the ubiquitin ligases 
RING1A or RING1B. In addition, some PRC1 complexes can regulate gene expression by 
compacting chromatin in a manner independent of enzymatic activity (Eskeland et al., 2010). 
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The PRC1 component Pc (CBX in mammals), binds specifically to the product of PRC2 ca-
talysis, H3K27me3, leading to the hypothesis that PRC1 functions downstream of PRC2. Alt-
hough this logical premise is still cited in the literature, its operational status is equivocal as 
there are genes targeted by PRC2 that lack H2AK119ub (Ku et al., 2008) an genes targeted by 
PRC1 in the absence of PRC2 (Schoeftner et al., 2006; Sing et al., 2009). Notwithstanding, 
PRC2 and PRC1 are often both required to maintain gene repression. 
 In general, histone PTMs regulate biological processes either by altering chromatin struc-
ture (i.e. by loosening DNA/histone interaction) or by contributing to the recruitment of addi-
tional regulatory factors. Thus far, H3K27me3 has been implicated only in the latter mecha-
nism of action suggesting that additional factors such as PRC1 are required to maintain gene 
repression (Margueron and Reinberg, 2011). Yet, H3K27me3 might also indirectly regulate 
transcription by sterically preventing proteins from binding to chromatin. Enrichment of 
H3K27me3 correlates with gene silencing (Barski et al., 2007), and this observation is sup-
ported by the finding that H3K27me3 and H3K36me3, a mark that is linked to transcription 
elongation, exhibit distinct localizations (Mikkelsen et al., 2007). Yet, RNA polymerase II 
(RNA PolII) that is phosphorylated at Ser-5 of its C-terminal domain is present at a substan-
tial fraction of H3K27me3 enriched promoters (Stock et al., 2007) and low levels of tran-
scripts are detected (Zhao et al., 2007), leading to the suggestion that RNA PolII could be 
paused at PcG targeted genes (Margueron and Reinberg, 2011). Indeed, a number of PcG-
regulated genes in Drosophila and mammals can recruit the RNA PolII transcription complex 
to their respective promoters and engage in early transcription, yet these polymerases encoun-
ter an early block to elongation. A recent report has proposed that short transcripts that are 
generated upon transcription and remain bound to a paused RNA PolII could recruit PRC2 
(Kanhere et al., 2010). This result suggests that PRC2 and H3K27me3 might affect gene ex-
pression by controlling an engaged RNA PolII during promoter escape or elongation, rather 
than by regulating the initiation phase of transcription. Taken together, these different PRC2-
mediated repression mechanisms strongly suggest that PRC2 can repress transcription by dif-
ferent ways and this may be gene-specific (Margueron and Reinberg, 2011). 
 DNA methylation (see also 1.1.2) and H3K27me3 are both involved in the establishment 
and maintenance of epigenetic gene silencing. There are data showing coordinate regulation 
between these marks. Some evidence points toward a cooperative relationship. For example, 
EZH2 has been shown to positively regulate DNA methylation (Vire et al., 2006). In these 
studies, EZH2 was observed to interact with DNA methyltransferases (DNMTs) and was re-
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quired for DNA methylation of EZH2-target promoters. Alternatively, several lines of evi-
dence suggest the coordination between DNA methylation and H3K27me3 may be antagonis-
tic. A proteomic analysis has shown that the PRC2 components EED and SUZ12 are excluded 
from methylated DNA (Bartke et al., 2010), and in neural stem cells Dnmt3a deficiency leads 
to increased H3K27me3 (Wu et al., 2010). Finally, additional studies suggest that an im-
portant relationship between DNA methylation and H3K27me3 is disrupted in cancer cells. 
Polycomb group targets are more likely to have cancer-specific promoter DNA hypermethyla-
tion than non-targets (Gal-Yam et al., 2008; Schlesinger et al., 2007; Widschwendter et al., 
2007). However, embryonic carcinoma cells lack DNA hypermethylation at PRC targets 
(Ohm et al., 2007), and knockdown of EZH2 in cancer cells may lead to hypomethylation 
(McGarvey et al., 2007). Thus, the evidence of interaction is conflicting, but it is clear that the 
relationship between these marks is important in both normal and cancerous cells. 
 
1.1.1.1.3 Targeting of PRC to genomic loci  
In Drosophila, Polycomb complexes are recruited to Polycomb response elements (PREs), 
that contain several hundreds of base pairs (Ringrose and Paro, 2007) and often contain clus-
ters of GAGAG motifs (Schwartz and Pirrotta, 2007). PREs can be bound by sequence-
specific DNA-binding factors such as GAGA factor (GAF), Pipsqueak (PSQ), both BTP/POZ 
proteins, Pleiohomeotic (PHO) and the related PHO-like (PHOL) (Ringrose and Paro, 2004; 
Schwartz and Pirrotta, 2007). 
 Besides the critical implication of PcG proteins in development and cell fate specification 
(Schuettengruber et al., 2007), PRC2 has gained much of attention since aberrant human 
PRC2 expression was shown to be linked to cancer and disease (Bernardi and Pandolfi, 2007; 
Rajasekhar and Begemann, 2007; Simon and Lange, 2008; Sparmann and van Lohuizen, 
2006). In contrast to Drosophila, the recruitment of mammalian PRC2 remains poorly under-
stood. As described earlier, JARID2 has been proposed to have a potential function in PRC2 
recruitment. JARID2 binds to DNA with a slight bias towards CG-rich sequences (Li et al., 
2010), which were reported to represent a sequence composition of PRC2 target genes (Ku et 
al., 2008). Therefore, it has been suggested that PRC2 recruitment in mammals involves ge-
nome-wide CpG islands (Deaton and Bird, 2011; Ku et al., 2008; Riising et al., 2014). Inter-
estingly, the histone variant H2AZ, usually associated with active genes, was shown to co-
localize with PRC2 in ESCs (Creyghton et al., 2008). Furthermore, the authors demonstrated 
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that H2AZ and PcG protein occupancy is interdependent at promoters, and that H2AZ is nec-
essary for ES cell differentiation. 
 PcG recruitment via PREs does not seem to be generally conserved in mammals. So far, 
very few DNA binding factors have been described to have the ability to recruit PcG proteins 
to specific chromatin sites in mammals and Yin and yang 1 (YY1), the mammalian 
orthologue of PHO, is one of the best candidates (Bracken and Helin, 2009). Similar to PcG 
proteins, YY1 activity is required for mammalian development, as YY1-null embryos die at 
the peri-implantation stages of embryogenesis (Donohoe et al., 1999). Two studies have iden-
tified a PRE in mammalian cells and have suggested an important role for YY1 (Sing et al., 
2009; Woo et al., 2010). Along this line, the RYBP protein was shown to interact with both 
YY1 and PRC1, and is suggested to be required for PRC1 and PRC2 recruitment (Woo et al., 
2010). YY1 was shown to directly interact with EED in Burkitt’s lymphoma cells (Satijn et 
al., 2001), to mediate EZH2 recruitment during myoblasts differentiation (Caretti et al., 2004) 
and during muscles regeneration from satellite stem cells (Palacios et al., 2010), and to act as 
a DNA–RNA binding factor during X chromosome inactivation, that links PcG-Xist to the 
inactive X chromosome (Jeon and Lee, 2011). However, several reports suggest that YY1 has 
PcG-independent functions (Cai et al., 2007; Gordon et al., 2006; He et al., 2011a; Sui et al., 
2004; Wu et al., 2007). In addition, a recent study has shown that YY1 does not share physi-
cal and functional properties with PcG proteins in ESCs; it preferentially associates with the 
CG-rich promoters of actively transcribed genes (Vella et al., 2012). Nevertheless, genome-
wide analysis did not confirm a significant overlap between YY1 and Polycomb target genes 
(Xi et al., 2007). PRC2 was even shown to be under-represented at YY1-response elements 
(Ku et al., 2008). Although, YY1 binding sites contribute to the repression of some loci, there 
is no strong evidence that transcription factors are involved in PRC2 recruitment in mammals 
suggesting that other factors might be involved in the regulation of these loci (Margueron and 
Reinberg, 2011). 
 Recently, long noncoding RNAs (long ncRNAs) have emerged as important players in 
epigenetic regulation and in PRC2 function. Several PRC2 subunits have RNA-binding mo-
tifs that could mediate functional interactions between RNAs and PRC2 (Bernstein and Allis, 
2005; Bernstein et al., 2006; Denisenko et al., 1998). Suz12 contains a zinc finger domain that 
can bind to RNA (Hall, 2005), and EZH2 and EED both have been shown to have in vitro 
RNA binding activity (Denisenko et al., 1998). For example, the human HOX-D locus is 
regulated in trans by HOTAIR RNA, which arises from the unlinked HOX-C locus (Rinn et 
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al., 2007). Tsix, RepA, and Xist RNAs have been shown to target PRC2 in cis during X 
chromosome inactivation (Zhao et al., 2008). Similarly, KCNQ1OT1 RNA mediates spread-
ing of PRC2 in cis in order to maintain the imprinted expression of the KCNQ1 domain 
(Pandey et al., 2008). Kanhere and colleagues have identified several short candidate RNAs 
of 50-200 nt in length that regulate PRC2 via Suz12 (Kanhere et al., 2010). Another study by 
Zhao and co-workers, which aimed to identify genome-wide Polycomb-associated RNAs, 
proposed a PRC2-RNA interaction to occur most likely via the EZH2 subunit (Zhao et al., 
2010). It was also suggested that PRC1 regulation is based on RNA (Yap et al., 2010). In 
summary, these studies support the idea that long ncRNAs represent a platform for the target-
ing of PcG complexes to specific sites in the genome but the molecular mechanisms remain 
yet unclear. On basis of these observations, a model was proposed, in which the sum of weak 
interactions by the subunits of the PRC2 holoenzyme complex function together to accom-
plish the necessary energy to guide PRC2 to its target genes (Margueron and Reinberg, 2011). 
 
1.1.2 DNA methylation 
DNA methylation belongs to the most studied epigenetic modification and has a profound 
impact on mammalian development, transcription and genome stability. Methylation at the 
carbon 5-position of cytosine (5mC) is well conserved among most plants, animals and fungi 
(Feng et al., 2010) and affects gene activity directly by inhibiting the binding of transcription 
factors and indirectly by recruiting repressive chromatin-associated proteins (Bell et al., 
2011). 5mC mediates long-term gene silencing and is involved in cell-lineage specification, 
genomic imprinting, X chromosome inactivation and the suppression of mobile genetic ele-
ments (Bestor and Bourc'his, 2004; Jaenisch and Bird, 2003; Wu and Zhang, 2010). Although 
it is an ubiquitous mechanism in multicellular organisms, DNA methylation is undetectable in 
Saccharomyces cerevisiae and adult Drosophila melanogaster (Issa, 2004). In mammals, 
DNA methylation is mainly restricted to symmetrical CpG dinucleotides (Ramsahoye et al., 
2000; Ziller et al., 2011) and deposited by DNA methyltransferase (DNMT) enzymes, which 
use S-adenosyl methionine (SAM) as the methyl donor (Goll and Bestor, 2005). DNA meth-
ylation is catalyzed either by the maintenance methyltransferase DNMT1, which methylates 
hemimethylated CpGs during replication, or by the de novo methyltransferases DNMT3A and 
DNMT3B, making it a long-term and potentially heritable mark (Goll and Bestor, 2005) 
(Figure 4). The importance of DNA methylation is reflected by the fact that all three enzymes 
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are essential for normal development (Kaneda et al., 2004; Li et al., 1992; Okano et al., 1999), 
for example, mouse DNMT1 null embryos die at day 11-12 of gestation (Li et al., 1992). 
 The mammalian genome is globally CpG-depleted, and in humans about 60-80% of the 
roughly 28 million CpGs are methylated (Smith and Meissner, 2013). CpGs can be located in 
CpG-dense regions, termed CpG islands (CGIs). However, this only accounts for less than 
10% of CpGs sites. CGI are located at transcription start sites of housekeeping and develop-
mental genes where they are largely resistant to methylation (Deaton and Bird, 2011). In con-
trast to methylation in promoter regions, methylation of CpG sites within gene bodies, most 
of them are not CGIs, was shown to be a feature of transcribed genes (Wolf et al., 1984). 
Thus, methylation in gene promoters is inversely correlated with gene expression, while 
methylation in gene bodies is positively correlated with expression (Jones, 1999). 
 
 
Figure 4. DNA methylation and gene silencing. DNA is largely unmethylated in early embryogenesis (top 
left). After implantation, de novo methylation starts (red circles), primarily mediated by DNMT3A and 
DNMT3B (top). At CpG islands, methyl-binding proteins trigger a silencing cascade (activity illustrated by 
green stars) whereby histone H3K9 is sequentially deaceylated and then methylated, allowing binding of 
heterochromatin protein 1 (HP1); eventually resulting in a closed chromatin structure (bottom right). After 
DNA replication, newly synthesized DNA (in green) is unmethylated. DNMT1 scans DNA and deposits methyl 
groups on newly synthesized DNA, according to the hemi-methylated pattern present on the old strand. This 
ensures faithful replication of methylation patterns (bottom left) and the maintenance of silencing. Adult 
methylation patterns are erased by epigenetic reprogramming in early embryogenesis (top left). From (Issa, 
2004). 
 
 Methylation occurs in a highly specific manner as evident by differentially methylated re-
gions (DMRs), which are regions in the genome where multiple adjacent CpG sites show dif-
ferential methylation patterns compared to other samples. This does not apply to CGIs, as 
most of them are unmethylated. There are several types of DMRs: imprinting-specific 
(iDMR), tissue-specific (tDMR), reprogramming-specific (rDMR), cancer-specific (cDMR) 
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and ageing-specific differentially methylated region (aDMR) (Rakyan et al., 2011). Methylat-
ed DNA can be recognized by proteins harboring a methyl-CpG-binding domain (MBD) such 
as MeCP2, MBD1, MBD2, MBD4. These proteins in turn recruit further chromatin modifiers 
such as HDACs or methyltransferases (Bird and Wolffe, 1999). On the other hand, transcrip-
tional activators like TrxG proteins can bind to unmethylated CpGs with high affinity via 
their zinc-finger CXXC (zf-CXXC) domain (Voo et al., 2000). 
 DNA methylation represents a relatively stable mark when compared with most histone 
modifications. However, methylation can be removed from DNA by a process named DNA 
demethylation, which is involved in different biological processes. Recently, the discovery of 
the ten-eleven translocation (TET) family enzymes has shed light on a potential mechanism of 
DNA demethylation. TET enzymes catalyze the iterative oxidation of 5mC to 5-
hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito 
et al., 2011), whereby 5hmC was suggested to be the key intermediate in the active demethyl-
ation pathway (Ito et al., 2010; Ito et al., 2011; Kriaucionis and Heintz, 2009; Tahiliani et al., 
2009). By using molecular oxygen as a substrate to catalyze oxidative decarboxylation of α-
ketoglutarate (α-KG), TET enzymes generate a reactive high-valent enzyme-bound Fe(IV)-
oxo intermediate that converts 5mC to 5hmC (Kohli and Zhang, 2013). 5hmC can either be 
actively removed by its reversion to cytosine through iterative oxidation followed by base ex-
cision repair by thymine-DNA glycosylase (TDG) (He et al., 2011b), or passively depleted in 
consecutive rounds of replication in the absence of the DNA methylation maintenance ma-
chinery (Kohli and Zhang, 2013). Like DNMTs, TDG, in contrast to other DNA glycosylases, 
is also required for embryonic development (Cortazar et al., 2011; Cortellino et al., 2011). 
DNA demethylation plays a crucial role in early embryonic development. During fertilization 
of the egg, before paternal and maternal genomes merge, the paternal genome undergoes 
complex remodeling processes including deposition of histone H3.3 and reshaping of DNA 
methylation patterns by a rapid erasure of 5mC (Jenkins and Carrell, 2012). The loss of 5mC 
is specific to the paternal genome as it does not take place in the maternal genome, and was 
therefore suggested to reflect an active 5mC editing mechanism (Mayer et al., 2000; Oswald 
et al., 2000). After implantation of the embryo, a fraction of posterior epiblast cells become 
primordial germ cells (PGCs) that go through an erasure of genome-wide DNA methylation 
patterns (Hackett et al., 2012) to prime them for germ-cell-specific processes, like meiosis. 
DNA demethylation is relevant not only in zygotes and PGCs, it was also reported at specific 
loci in response to environmental stimuli or in post-mitotic cells, even in the absence of repli-
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cation (Kangaspeska et al., 2008; Metivier et al., 2008; Thillainadesan et al., 2012). These ob-
servations allow the postulation of a model compromising methylation, oxidation and repair 
that seems to be of great significance for biological processes known to involve active DNA 
demethylation (Kohli and Zhang, 2013). 
 Aberrant DNA methylation patterns are a prevalent feature of cancer cells (Baylin and 
Jones, 2011), suggesting that methylation/demethylation pathways may contribute to cancer 
development (Cimmino et al., 2011) (see 1.2.2). 
 
1.2 Epigenetics in Cancer 
Cancer evolution at all stages is driven by both epigenetic abnormalities as well as genetic 
alterations. Dysregulation of epigenetic control events may lead to abnormal patterns of DNA 
methylation and chromatin configurations, both of which are critical contributors to the path-
ogenesis of cancer. There is evidence that this can occur via at least two mechanisms; (i) by 
the alteration of gene expression programs, including aberrant regulation of oncogenes and/or 
tumor suppressor genes, and (ii) on a more global level, histone modifications may affect ge-
nome integrity and/or chromosome segregation (Bannister and Kouzarides, 2011). Recently, 
cancer genome sequencing studies have revealed an abundance of somatic mutations in genes 
encoding chromatin-modifying proteins, suggesting a crucial role of epigenetic gene regula-
tion. The mechanisms by which these mutations could contribute to tumor fitness have thus 
become a major challenge in cancer research (Ryan and Bernstein, 2012). Undoubtedly, most 
chromatin modifying proteins bind to thousands of loci within the genome thereby influenc-
ing (directly or indirectly) the gene expression of various genes and pathways. Hence, the re-
versible nature of epigenetic marks, such as aberrant DNA methylation and histone modifica-
tion patterns, has made them attractive targets for therapeutic intervention in cancer (Kelly et 
al., 2010). 
 
1.2.1 Histone modifications and cancer 
Several studies provide evidence that aberrant histone modification profiles are intimately 
linked to the initiation stage of cancer development. A work by Huntly and co-workers has 
investigated the MOZ-TIF2 fusion, which is associated with acute myeloid leukemia (AML) 
(Carapeti et al., 1998; Liang et al., 1998). MOZ was identified as a HAT, and TIF2 is a nucle-
ar receptor coactivator that is able to bind to another HAT, CBP (Torchia et al., 1997). The 
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transduction of the MOZ-TIF2 fusion protein into normal committed murine hematopoietic 
progenitor cells lacking self-renewal capacity was sufficient to confer self-renewal in vitro 
and to develop AML in vivo (Huntly et al., 2004). Another example is given by studies show-
ing that JAK2-mediated phosphorylation of H3Y41, preventing HP1α-binding to H3, relieves 
lmo2 gene expression (Dawson et al., 2009), a key oncogene in hematopoietic cancers 
(McCormack and Rabbitts, 2004; Yamada et al., 1998). JAK2 has been reported to be fre-
quently activated in hematological malignancies by chromosomal translocations or point mu-
tations (Dawson et al., 2009). 
 
 
Figure 5. Alteration of epigenetic regulators in cancer. List of epigenetic regulators frequently mutated, up- 
or downregulated in cancers that affect transcriptional regulation, genome stability, telomere maintenance, and 
other aspects of cell physiology. From (Ryan and Bernstein, 2012). 
 
 A prominent alteration in histone modifications in tumor cells is the global loss of H4K16 
monoacetylation (Fraga et al., 2005). HDACs are responsible for the removal of acetylation 
marks and are frequently mutated (Ropero et al., 2006) or overexpressed (Zhu et al., 2004) in 
several tumor types. For example, SirT1, a HDAC, is upregulated in various cancer types and 
was shown to interact with DNMT1, thus influencing DNA methylation patterns (Espada et 
al., 2007). Noonan and colleagues have demonstrated that HDAC expression can be regulated 
by miRNAs. Interestingly, miR-449a is downregulated in prostate cancer tissues compared to 
normal control tissue (Noonan et al., 2009). The authors have identified HDAC1 as a direct 
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target of miR-449a, which represses HDAC1 expression in prostate tumor cells, thereby regu-
lating cell growth and survival (Noonan et al., 2009). Besides alterations in HDAC expression 
and function, the global imbalance in histone acetylation has been shown in other cancer 
types to be caused by mutations, deletions or translocations in HATs and HAT-related genes 
(Bryan et al., 2002; Moore et al., 2004) (Figure 5). 
 In addition to the global loss of H4K16ac, tumors cells endure a global loss of the repres-
sive mark H4K20me3 (Fraga et al., 2005) and a gain in the active mark H3K4me3 
(Hamamoto et al., 2004) and the repressive marks H3K9me (Ellinger et al., 2014; Kondo et 
al., 2007) and H3K27me3 (Vire et al., 2006). Like alterations in histone acetylation, 
thechanges in histone methylation patterns in cancer are mainly caused by aberrant expression 
of both, HMTs and HDMs (Chi et al., 2010). A recent study by Dalgliesh and co-workers has 
identified inactivating mutations in SETD2, a histone methyltransferase, and in the histone 
demethylases UTX and JARID1C in renal carcinomas (Dalgliesh et al., 2010). Inactivating 
mutations in UTX have been also reported in multiple myeloma and esophageal squamous 
cell carcinomas (van Haaften et al., 2009). Remarkably, the histone methyltransferase EZH2 
has been demonstrated to induce extensive gene silencing and its overexpression has been 
linked to progression of multiple solid tumors, including melanoma, breast, bladder and pros-
tate cancer (Bachmann et al., 2006; Kleer et al., 2003; Varambally et al., 2002; Weikert et al., 
2005). This process also involves widespread elevated levels of H3K27me3, the mark depos-
ited by EZH2. Interestingly, upregulation of the lincRNA HOTAIR has been demonstrated to 
contribute to cancer metastasis and poor survival in breast and esophageal squamous cell car-
cinoma by retargeting EZH2 leading to alterations in the H3K27me3 landscape (Chen et al., 
2013; Gupta et al., 2010). Furthermore, upregulation of EZH2 in many cancer types has been 
shown to depend on the genomic loss of miR-101 (Varambally et al., 2008). Nevertheless, 
several studies have reported inactivating mutations in different myeloid malignancies, pro-
posing EZH2 to act as a tumor suppressor protein (Ernst et al., 2010; Nikoloski et al., 2010). 
Clearly, this is contrary to the situation in solid tumors, where EZH2 functions as an onco-
gene. Therefore, it is assumed that changes in H3K27me3 levels (in both directions) are criti-
cal for cellular homeostasis and may are involved in tumor development (Bannister and 
Kouzarides, 2011). EZH2 overexpression and inactivating mutations in HDMs have been re-
ported to occur in many cancer types supporting an important role of the H3K27me3 mark in 
carcinogenesis. Besides EZH2, also SUZ12 has been found to be overexpressed in both colon 
and breast cancer (Kirmizis et al., 2003). 
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 Also other HMTs are deregulated in cancers. For example, NSD1 has been reported to un-
dergo epigenetic silencing by promoter CpG hypermethylation in neuroblastoma and glioma 
(Berdasco et al., 2009). For the MLL (mixed lineage leukemia) gene, which encodes a H3K4 
histone methyltransferase, more than different 50 translocations or partial tandem duplications 
on chromosome 11q13 have been discovered and found to be associated with poor survival in 
leukemia (Caligiuri et al., 1997; Dohner et al., 2002; Krivtsov and Armstrong, 2007; Ziemin-
van der Poel et al., 1991). Recently, DOT1L, the major H3K79 methyltransferase has been 
implicated in the development of MLL-rearranged leukemia, where MLL fusion oncoproteins 
result in inappropriate recruitment of DOT1L causing aberrant H3K79 and H3K4 methylation 
patterns (Dohner et al., 2002; Krivtsov and Armstrong, 2007; Krivtsov et al., 2008; Okada et 
al., 2005; Wang et al., 2009). 
 Upregulation of HDMs has been shown to occur in some cancers (Shi, 2007). For example 
the H3K4 and H3K9 demethylase LSD1 is overexpressed in prostate cancer, where it was 
shown to be involved in AR (androgen receptor)‐mediated transcription by acting as an H3K9 
demethylase (Kahl et al., 2006; Metzger et al., 2005). Moreover, the three tudor domain-
containing KDM4/JMJD2 (A, B and C) proteins have been reported to be overexpressed in 
lung, breast, colorectal and prostate cancer and in esophageal squamous carcinoma (Berry and 
Janknecht, 2013; Yang et al., 2000). 
 Alterations of histone modifications are not only linked to cellular identity but also to ge-
nomic instability and chromosome segregation defects, both prominent features of cancer 
cells. In this regard, it was shown that homozygous null mutant mice for PR-Set7, an 
H4K20me1 histone methyltransferase, die at an early embryonic state as a result of enormous 
DNA damage, cell cycle defects and improper chromosome condensation (Oda et al., 2009). 
H4K20me1 is read by L3MBTL1 via its malignant brain tumor (MBT) domain leading to lo-
cal chromatin compaction and transcriptional repression (Kalakonda et al., 2008; Trojer et al., 
2007; Trojer and Reinberg, 2008). H4K20me3 is enriched in pericentromeric heterochromatin 
(Schotta et al., 2004) and global changes in H4K20me3 levels have been implicated in carcin-
ogenesis. In this regard, Fraga and colleagues have reported a loss of H4K16ac and 
H4K20me3 in cancer cells in association with hypomethylation of DNA repetitive sequences, 
a hallmark that is frequently observed in human cancers (Fraga et al., 2005). Interestingly, 
using a mouse model of multistage skin carcinogenesis, Fraga and co-workers have demon-
strated that these changes in histone modification patterns occur early and accumulate during 
the tumorigenic process (Fraga et al., 2004) supporting an intimate link of aberrant histone 
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modification profiles with cancer progression. Another histone methyltransferase SUV39, re-
sponsible for H3K9 methylation, is also required for genomic stability. Suv39h-deficient mice 
display reduced H3K9me2/3 levels, impaired viability and chromosomal instabilities associ-
ated with an increased risk of tumor development (Peters et al., 2001). 
 
1.2.2 DNA methylation and cancer 
Aberrant DNA methylation is a hallmark of cancer cells (Baylin and Jones, 2011; Esteller, 
2007a). The cancer epigenome is characterized by a loss of global methylation (Goelz et al., 
1985) along with a gain of methylation at the promoters of selected CpG islands (CGIs) of 
tumor suppressor genes (Baylin et al., 2001). Global hypomethylation is predominantly found 
at repetitive sequences and is linked to chromosomal instability, translocations, gene disrup-
tion and reactivation of endoparasitic sequences (Gaudet et al., 2003; Goelz et al., 1985). For 
example L1, a LINE family member, has been shown to be hypomethylated in a variety of 
cancers such as breast, lung, bladder and liver tumors (Wilson et al., 2007). Hypomethylation 
at specific promoters is thought to be responsible for the aberrant expression of oncogenes 
and the induction of loss of imprinting (LOI) in some regions (Portela and Esteller, 2010). For 
example, the tumor suppressor MASPIN (also known as SERPINB5) is hypermethylated in 
breast and prostate epithelial cells (Futscher et al., 2004) and seems to be hypomethylated in 
other cancers. MASPIN hypomethylation and its expression have been demonstrated to in-
crease with the dedifferentiation of some cancer cells (Bettstetter et al., 2005; Futscher et al., 
2002). Other well-studied examples of hypomethylated genes in cancer include SNCG in 
breast and ovarian cancer, S100P in pancreatic cancer and MAGE and DPP6 in melanomas 
(Irizarry et al., 2009; Portela and Esteller, 2010; Wilson et al., 2007). The most frequently ob-
served LOI event based on hypomethylation is the insulin-like growth factor 2 (IGF2) that 
has been reported in several tumors such as breast, liver, lung and colon cancer (Ito et al., 
2008). 
 In contrast to global DNA hypomethylation, hypermethylation is found at particular CGIs. 
Transcriptional silencing due to promoter hypermethylation occurs early in tumor progression 
and mediates abnormalities in important cellular pathways such as loss of cell cycle control, 
altered receptor function, disruption of cell-cell/cell-substratum interaction, inactivation of 
signal transduction pathways, loss of apoptotic signals and genetic instability (Baylin et al., 
2001) (see 1.2.5). It has been proposed that these hypermethylated promoters constitute a new 
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generation of biomarkers which possess diagnostic and prognostic features in the clinic (Kelly 
et al., 2010). Aberrant CGI methylation in tumors was first described almost three decades 
ago (Baylin et al., 1986). Later, as more and more genes affected by this process were identi-
fied, it was observed that in some tumors the consistent increase in methylation occurs at par-
ticular groups of genes. The methylation of two separate genes was shown to be correlated in 
a given tumor type. These multiple concordant methylation evens was named CpG island 
methylator phenotype (CIMP) and was first described in colon cancer (Toyota et al., 1999) 
(see 1.2.6). 
 CGIs of promoter regions have been in the focus of most studies but recent findings pro-
pose that most of the aberrant DNA methylation in cancer occurs in CpG island shores, for 
example in HOXA2 and GATA2 (Portela and Esteller, 2010). About half of the changes in 
CpG island shores are assumed to occur at regions that become hypermethylated during nor-
mal tissue differentiation (Portela and Esteller, 2010), for example TGFB1 and PAX5 (Doi et 
al., 2009; Irizarry et al., 2009). Therefore, differential DNA methylation has been suggested 
to correlate with gene expression at CpG island shores like it does with CGI (Ji et al., 2010). 
 DNMTs have been reported to be upregulated in several cancers such colon (el-Deiry et 
al., 1991), prostate (Patra et al., 2002), breast (Girault et al., 2003) and liver cancer (Oh et al., 
2007) and in leukemia (Melki et al., 1998). Besides alterations in the expression levels of 
DNMTs also mutations have been found. For example, DNMT3A mutations have been re-
ported in leukemia (Ley et al., 2010) leading to either a reduction in catalytic activity and sub-
sequent activation of more than 800 genes including HOX genes and IDH1, or aberrant bind-
ing affinity of DNMT3A to histone H3 (Yan et al., 2011). In addition to leukemia, further 
mutations have been also reported in lung, ovarian, kidney, liver and uterus cancer (Plass et 
al., 2013). Recently, the gain-of-function mutation in the isocitrate dehydrogenase 1 (IDH1) 
Arg132His (R132H) (also equivalent mutations in IDH2) has been described to also exert a 
massive effect on chromatin structure in glioblastoma and leukemia by production of the on-
cometabolite 2-hydroxyglutarate (2-HG) (Xu et al., 2011). Several reports have demonstrated 
that 2-HG inhibits TET family hydroxylases and JmjC family of histone demethylases leading 
to DNA hypermethylation and an increase in H3K9me3, H3K27me3, H3K4me3 and 
H3K36me3 (Figueroa et al., 2010; Lu et al., 2012). Mutations in IDH1/2 have been also re-
ported in leukemia (Figueroa et al., 2010). 
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1.2.3 Chromatin remodeling and cancer 
Chromatin remodelers function in complexes in an ATP-dependent manner to disrupt the 
DNA-nucleosome interaction in order to move, replace or remove nucleosome from chroma-
tin (Hargreaves and Crabtree, 2011). All four classes of chromatin remodelers, SWI/SNF, 
chromodomain helicase DNA-binding proteins (CHDs), ISWI and INO80, have been reported 
to contribute to cancer progression (Portela and Esteller, 2010). Genome-wide sequencing of 
human cancers has revealed that genes involved in establishing chromatin structure are also 
frequently mutated (Shain and Pollack, 2013). Yet, the mechanisms by which mutations in 
chromatin remodeler complexes drive tumorigenesis remain unclear. Clearly, chromatin re-
modeler complexes act on large proportions of the genome. Therefore, it is assumed that mu-
tations in their components can cause serious aberrations in chromatin structure thereby influ-
encing cancer progression (Plass et al., 2013). Several chromatin modifiers have been pro-
posed to be tumor suppressors but mutations in these complexes might also lead to a change 
of function rather than to a loss of function (Wilson and Roberts, 2011). SWI/SNF chromatin 
remodelers play a central role during lineage specification and in the maintenance of pluripo-
tency by regulating and coordinating the gene expression program. Inactivating mutations in 
subunits of the SWI/SNF complexes including SNF5 (also known as SMARCB1), ARID1A, 
BAF180, BRM, and BRG1 are frequently found in various cancer types (Wilson and Roberts, 
2011). ARID1A has been found to be amongst genes showing the highest mutation rates 
across multiple cancers (Lawrence et al., 2014) and ARID1A is mutated in ~57% of ovarian 
clear cell carcinomas (Jones et al., 2010; Wiegand et al., 2010). Recently, Bitler and co-
workers have identified a synthetic lethality in ARID1A-mutated cancers upon EZH2 inhibi-
tion representing a novel treatment strategy in these cancers (Bitler et al., 2015). A bi-allelic 
inactivation of SNF5 has been identified to be the only recurrent mutation in malignant 
rhabdoid tumors, which usually have a low frequency of mutations (Versteege et al., 1998). 
These data demonstrate the importance of proper chromatin remodeling. It has been proposed 
that SWI/SNF complexes contribute to tumor suppression by influencing gene expression of 
key pathways, including Rb, p53, Polycomb, Sonic hedgehog, MYC, nuclear hormone recep-
tor signaling and stem cell programs (Shain and Pollack, 2013) but also by affecting overall 
chromatin structure and genome packaging for mitosis. Interestingly, CHD5, a member of the 
CHD family, has been found to gain DNA hypermethylation in the promoter region resulting 
in transcriptional silencing in colon and breast cancers and gliomas (Mulero-Navarro and 
Esteller, 2008). 
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 In addition to nucleosome positioning, histone variants have been linked to cancer. For 
example, in lung cancer, cells expressing macroH2A isoforms have been shown to undergo-
ing cellular senescence. Moreover, patients with elevated expression of histone macroH2A1.1 
and macroH2A2 have slower tumor proliferation rates and a better prognosis (Sporn et al., 
2009). 
 Recently, recurrent gain-of-function mutations in the histone H3 genes have been identi-
fied in pediatric glioblastoma with major implications on chromatin structure and gene ex-
pression (Schwartzentruber et al., 2012; Wu et al., 2012). Of particular interest are the muta-
tions found in the H3F3A gene, encoding the histone variant H3.3, with important conse-
quences for chromatin remodeling. These H3.3 mutations result in Lys27Met (K27M) and 
Gly34Arg or Gly34Val (G34R/V) substitutions leading to global changes in histone modifica-
tions, involving H3K27me3 and H3K36me3 (Sturm et al., 2012). The K27M mutation has 
been reported to inhibit EZH2 within PRC2, resulting in a prominent global loss in 
H3K27me3 and upregulation of PRC2-target genes. The other mutation G34R/V has been 
shown to induce a redistribution of H3K36me3 and might affect the distribution of its corre-
sponding enzyme SETD2, leading to upregulation of MYCN (Bjerke et al., 2013). Tumors 
carrying these mutations also display a DNA hypomethylation phenotype, suggesting a rela-
tionship between histone modifications and DNA methylation (Bender et al., 2013). 
 
1.2.4 Epigenetic therapies 
As epigenetic alterations are potentially reversible, unlike DNA mutations, the pharmacologi-
cal inhibition of oncogenically activated chromatin modifying enzymes or the modulation of 
other chromatin modifiers to ‘correct’ aberrant modifications may have important therapeutic 
implications in cancer as well as in other diseases with an altered epigenome. The identifica-
tion of downstream ‘driver pathways’ which are responsible for the oncogenic effects of these 
mutations may prove efficacious and provide opportunities for synthetic lethal strategies. For 
example, as described above, a synthetic lethality was identified in ARID1A-mutated ovarian 
cancers upon inhibition of EZH2 using the small-molecule inhibitor GSK126 (Bitler et al., 
2015). 
 In general, two classes of drugs can be distinguished, on the one hand drugs targeting epi-
genetic regulators (such as DMNTs and HDACs) and on the other hand drugs specifically 
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targeting mutations in epigenetic regulators (such as IDH1 R132H). The latter one may are 
less toxic but they can be only used in a subset of patients with that particular mutation. 
 So far, the US Food and Drug Administration (FDA) has approved four epigenetic drugs 
based on their considerable clinical benefit. These are the two DNMT inhibitors azacytidine 
and 5-aza-2´deoxycytidine (also known as Vidaza and Dacogen/Decitabin, respectively) and 
the two HDAC inhibitors SAHA and romidepsin (also known as Vorinostat and Istodax, re-
spectively). Inhibitors of DNA methylation are cytosine analogues, which after being incorpo-
rated into the DNA during replication, trap DNMT via covalent binding. Both inhibitors for 
DNMTs have been shown to induce significant response rates and a survival benefit in pa-
tients with acute myeloid leukemia (Kantarjian et al., 2012) and myelodysplastic syndrome 
(Fenaux, 2005; Lubbert et al., 2011). HDAC inhibitors promote the acetylation of histones 
and facilitate an open form of chromatin structure resulting in gene activation. In 2006, the 
first HDAC inhibitor Vorinostat has been approved by the FDA for treatment of patients with 
cutaneous T cell lymphoma (CTCL) (Kelly et al., 2005; O'Connor et al., 2006). Also the se-
cond HDAC inhibitor romidepsin was approved for CTCL. During the last years, second-
generation HDAC inhibitors have been developed to achieve a more selective targeting of 
particular HDACs (the family of HDACs comprises 18 members) (Arrowsmith et al., 2012). 
For example, in preliminary studies the potent HDAC inhibitor Panobinostat has proven effi-
cacy in CTCL (Ellis et al., 2008) and promising results in clinical trials have been reported in 
Hodgkins`s lymphoma and prostate cancer (Dickinson et al., 2009; Rathkopf et al., 2010). 
 Both classes of DNMT and HDAC inhibitors aim to reactivate genes which have under-
went epigenetic silencing in cancer. In preclinical studies it has been demonstrated that tran-
scriptional derepression is associated with chromatin remodeling and anti-tumor activity (both 
in vitro and in vivo). As depicted in Figure 6, epigenetic drugs induce several anti-tumor ef-
fects. The reactivation of hypermethylated genes by DNMT inhibitors has been shown to in-
hibit cell growth (e.g. by upregulation of the cell cycle regulator p16), increase chemosensi-
tivity (e.g. by upregulation of the repair gene MLH1) and increase cell adhesion (e.g. by up-
regulation of E-Cadherin) (Figure 6a). The potential activation of transposons and tumor an-
tigens might be beneficial as it could induce the interferon response and increase immunogen-
icity (Yoo and Jones, 2006) (Figure 6a). The inhibition of HDACs prevents hypomethylation 
of histones resulting in chromatin remodeling, transcriptional activation, and restoration of 
malignant cells to a more normal state (Yoo and Jones, 2006). Most HDAC inhibitors induce 
p21WAF1/CIP1 gene expression, which leads to the inhibition of complexes of cyclin D with 
1 Introduction 
__________________________________________________________________________________________ 
41 
CDK4 (cyclin D kinase-4) and promotes cell cycle arrest as well as differentiation (Rocchi et 
al., 2005) (Figure 6b). HDAC inhibitors have been found to cause an anti-angiogenic effect 
(Michaelis et al., 2004; Zgouras et al., 2004) and to promote apoptosis (Dai et al., 2005) (Fig-
ure 6b). Particularly for the treatment of solid cancers, it might be beneficial to combine both 
HDAC and DNMT inhibitors (Rudek et al., 2005) since the administration of DNA methyla-
tion inhibitors alone in solid tumors has not been successful to date (Yoo and Jones, 2006). 
 So far, targeting of histone acetyltransferases has proven to be difficult, therefore clinical 
studies have not been undertaken. However, some potent inhibitors have been identified for 
histone methyltransferases. For example, AZ505 targets the oncogenic protein SMYD2, 
which represses p53 and Rb (Ferguson et al., 2011). Potent inhibitors have been found to tar-
get DOT1L, such as EPZ004777 and EPZ-5676, which both show activity in MLL-fusion 
proteins causing aberrant DOT1L localization (Daigle et al., 2013; Daigle et al., 2011). In 
2012, EPZ-5676 has entered phase 1 clinical trials in patients with acute myeloid leukemia 
(AML) and acute lymphoblastic leukemia (ALL) (Basavapathruni et al., 2014). Furthermore, 
the highly selective EZH2 inhibitor GSK126 has been recently shown in vivo and in vitro to 
reduce global H3K27me3 levels and to reactive PRC2-target genes in lymphomas with acti-
vating EZH2 mutations (McCabe et al., 2012). 
 
a 
 
b 
 
Figure 6. Effects of DNMT and HDAC inhibitors in human cancer. a. DNMT inhibitors such as azacytidine 
induce genome-wide demethylation resulting in the reactivation of methylation-silenced genes. Upregulation of 
cell-cycle regulators such as p16 leads to inhibition of growth. Chemosensitivity is increased with the activation 
of repair genes such as MLH1, and cell adhesion can be increased due to E-cadherin reactivation. The potential 
activation of transposons might be beneficial, as it would increase interferon response. Activation of tumor 
antigens can lead to increased immunogenicity, which might be helpful when considering combining 
immunotherapy with epigenetic drugs. b. HDAC inhibitors prevent hypomethylation of histones resulting in 
chromatin remodeling, transcriptional activation, and restoration of malignant cells to a more normal state. 
Almost all HDAC inhibitors induce gene expression of p21WAF1/CIP1, which leads to inhibition of cyclin D-CDK4 
complexes and cell cycle arrest and differentiation. HDAC inhibitors are also known to have anti-angiogenic 
effects and to promote apoptosis. Many pathways are assumed to be involved in this process and promote 
growth inhibition, differentiation, apoptosis and anti-angiogenesis. IFN, interferon; CDK4, cyclin D kinase-4; 
MLH1, mutL homologue-1. From (Yoo and Jones, 2006). 
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 The pharmacological inhibition of epigenetic modifiers is not only restricted to inhibition 
of enzymatic activity and a novel concept aims to disrupt protein-protein interactions of epi-
genetic reader proteins. A prominent example is the targeting of the bromodomain and extra-
terminal (BET) family proteins of transcriptional regulators, which can recognize acetylated 
lysine residues via their bromodomain. Specific small-molecule inhibitors such as JQ1 and 
PFI-1 have been demonstrated to inhibit recruitment of BET proteins to chromatin and to be 
potent in both in vitro and in vivo models of solid tumors (Asangani et al., 2014; 
Filippakopoulos et al., 2010) and hematological malignancies. Importantly, inhibition of BET 
proteins suppresses transcription of MYC, which plays an essential role in progression of 
AML, MLL and Burkitt`s lymphoma (Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 
2011). 
 Many more epigenetic drugs are currently in preclinical or clinical trials (also in combina-
tion with other epigenetic drugs or with therapies such as immunotherapy) (Arrowsmith et al., 
2012; Plass et al., 2013). Thus, targeting the epigenome of cancer cells represents a new fron-
tier in drug discovery, which has an enormous potential for the development of future cancer 
therapeutics. 
 
1.2.5 Epigenetic silencing of tumor suppressor genes 
Disruption of gene function in cancer cells can occur through genetic alterations, by gene mu-
tation or deletion, or through epigenetic alterations that alter the heritable state of gene ex-
pression (Baylin et al., 2001). Epigenetic silencing of tumor suppressor genes is generally 
thought to involve DNA methylation, histone modifications, and the compaction of chromatin 
(Figure 7). The most studied epigenetic alteration in carcinogenesis is transcriptional silenc-
ing associated with a gain in DNA methylation (in a normally unmethylated gene promoter) 
and, recently, the establishment of repressive histone marks at site of tumor suppressor genes 
has been increasingly investigated in numerous studies. 
 Transcriptional silencing of tumor suppressor genes by CGI promoter hypermethylation 
plays a key role in the tumorigenic process and contributes to all of the hallmarks of cancer 
cells as a result of tumor suppressor inactivation (Hanahan and Weinberg, 2000). This process 
involves methyl-CpG-binding proteins and DNMTs, which are associated with HDACs and 
HMTs (Dobosy and Selker, 2001; Fuks, 2005; Wade, 2001; Wang et al., 2004b). The affected 
genes are involved in all cellular pathways and confer characteristic features to tumor cells 
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once they undergo transcriptional silencing. The list of hypermethylated genes in various tu-
mor types is constantly growing and this epigenetic aberration is now considered to be a 
common feature of human cancers (Esteller, 2007a). Genes with key roles in cancer biology 
such as the negative cell cycle regulators p16INK4a and Rb, and the DNA repair genes BRCA1 
and MHL1 have been shown to undergo silencing by DNA methylation in tumor cells (Egger 
et al., 2004; Esteller, 2005; Feinberg and Tycko, 2004; Herman and Baylin, 2003). Important-
ly, the pattern of CGI hypermethylation has been shown to vary with the cancer type 
(Costello et al., 2000; Esteller et al., 2001a; Paz et al., 2003). Each cancer shows a specific 
DNA hypermethylome, which almost completely defines that particular tumor type, similar 
than cytogenetic and cancer-specific genetic markers (Esteller, 2007b; Schuebel et al., 2007). 
Thus, these features have a significant value for diagnostic and prognostic usage in cancer 
treatment (Esteller, 2007a). 
 
 
Figure 7. Heritable gene silencing. The interplay between DNA methylation, histone modifications and nu-
cleosome remodeling contributes to gene silencing. Several epigenetic enzymes including DNMTs, HDACs 
and HMTs, as well as chromatin remodeler factors such as NURFs contribute to the establishment of a herita-
ble repressive state at genes leading to transcriptional silencing. The process of gene silencing is crucial for 
development and differentiation; however, aberrant silencing at tumor suppressor genes contributes to cancer 
development. DNMT, DNA methyltransferase; HDAC, histone deacetylase; HMT, histone methyltransferase; 
NURF, nucleosomal remodeling factor. From (Jones and Baylin, 2007). 
 
 The association of PcG proteins with cancer development was first shown by identifying 
BMI1 a proto-oncogene, which together with MYC promotes generation of B- and T-cell 
lymphomas (Haupt et al., 1991; van Lohuizen et al., 1991). It has been proposed that BMI1 
inhibits MYC-induced apoptosis through repression of the CDKN2A locus (Jacobs et al., 
1999a; Jacobs et al., 1999b). The tumor suppressor gene CDKN2A encodes two distinct pro-
teins, INK4A and ARF, both restricting cellular proliferation in response to aberrant mitogen-
ic signaling (Sparmann and van Lohuizen, 2006). The cyclin-dependent kinase inhibitor 
INK4A is responsible for the activation of the retinoblastoma (RB) pathway, whereas ARF 
induces p53 though inhibition of MDM2 (Sherr, 2001). The CDKN2A gene is frequently hit 
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by mutations, deletions and methylation-associated epigenetic silencing in a variety of human 
tumors (Lowe and Sherr, 2003) highlighting the importance of these pathways. 
 Hypermethylation of CGIs often affects promoters of miRNAs (Saito et al., 2006) leading 
to an overall downregulation of miRNAs in human cancers (Melo et al., 2009). It has been 
demonstrated that miRNAs have a tumor suppressor function. For example, repression of 
miR-124a by hypermethylation has been found to mediate CDK6 activation and phosphoryla-
tion of Rb (Lujambio et al., 2007). However, hypermethylation of miRNA and subsequent 
repression of miRNA expression has been not only described in cancer but also in metastasis 
development. Inactivation of miR-148, miR-34b/c and miR-9 by promoter hypermethylation 
has been shown to promote tumor dissemination from the primary tumor site (Lujambio et al., 
2008). 
 It is still poorly understood why some genes become hypermethylated in a given tumor 
type whereas others with similar function remain methylation-free in others. In this context, 
Keshet and colleagues have performed a genome-wide investigation of DNA methylation in 
prostate and colon cancer cells and have suggested that there might be a common sequence 
motif in promoters, that acquire CGI methylation (Keshet et al., 2006). Alternatively, the pre-
cise locations of de novo methylation in cancer may be determined by a pre-programmed tar-
geting mechanism (Cedar and Bergman, 2009). In respect thereof, genes targeted by tran-
scriptional repressor complexes, for example by PcG proteins, early in development might 
mark these genes, which are more prone to gain hypermethylation later in the tumor cells. In-
deed, several studies have demonstrated that a significant proportion of de novo methylated 
CGIs are target sites for PcG proteins such as EZH2. (Ohm et al., 2007; Schlesinger et al., 
2007; Widschwendter et al., 2007). Apart from that, aberrant methylation could also result 
from genetic alterations leading to selective targeting of the DNA methylation machinery. Fu-
sion proteins such as promyelocytic leukemia-retinoic acid receptor-α (PML-RARA) might 
lead to aberrant CGI methylation patterns in leukemia though recruitment of DNMTs and 
HDACs to several novel target genes (Di Croce et al., 2002). Another example is given by the 
oncogenic Myc protein that has been demonstrated to bind Dnmt3a and to associate with 
DNA methyltransferase activity in vivo (Brenner et al., 2005). Similar as suggested for genet-
ic mutations, it is also possible that hypermethylated genes and their subsequent inactivation 
confers a selective clonal advantage to tumor cells (Esteller, 2007a). Therefore, it might be 
that the selection for targeting and hypermethylation does not occur exclusively, and both 
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events presumably arise during generation and maintenance of hypermethylated CGIs at tu-
mor suppressor genes (Esteller, 2007a). 
 Similar to changes in histone modification patterns, which have been shown to arise early 
in carcinogenesis (Fraga et al., 2005), it has been demonstrated that also CGI hypermethyla-
tion of tumor suppressor genes occurs early in tumorigenesis. For example, CGI hypermeth-
ylation occurs in genes such as p16INK4a, p14ARF and MGMT in colorectal adenomas and aber-
rant methylation in MLH1 has been found in atypical endometrial hyperplasia (Esteller, 
2005). Furthermore, CGI hypermethylation has been observed to precede mutations in KRAS 
in small colorectal adenomas (Esteller and Herman, 2004) suggesting that that epigenetic 
changes might be crucial steps during the neoplastic transformation process (Esteller, 2007a). 
In this context, Baylin and Ohm have proposed that epigenetic changes might commit cancer 
cells to altered signal-transduction pathways during the early stages of tumor development 
(Baylin and Ohm, 2006). 
 It has been also observed that the number of genes acquiring promoter CGI hypermethyla-
tion increases during tumorigenic progression (Fraga et al., 2004; Gallagher et al., 2005), 
which might be meaningful in early detection screenings in cases of sporadic cancers but par-
ticularly in patients with high familial risk of cancer development (Esteller et al., 2001b). In 
support of that, epigenetic silencing of tumor suppressors via promoter CGI hypermethylation 
could provide a powerful tool for the prediction of tumor prognosis. For example, hypermeth-
ylation of the tumor suppressors such as DAPK (death-associated protein kinase), p16INK4a 
and EMP3 (epithelial membrane protein 3) have been correlated with tumor aggressiveness in 
lung, colorectal and brain cancers patients (Esteller, 2005). 
 The hypermethylation of promoter CGI sites in cancer cells is accompanied by specific 
histone marks including deacetylation of histone H3 and H4, loss of H3K4me3, and gain of 
H3K9me3 and H3K27me3 (Ballestar et al., 2003; Fahrner et al., 2002; Vire et al., 2006). A 
key link between histone modifications and DNA methylation was demonstrated by pioneer-
ing studies showing that 5mC could attract methyl-CpG-binding proteins and HDACs in 
methylated CGIs in the process of chromatin compaction and gene repression (Jones et al., 
1998; Nan et al., 1998). In addition to histone modifications and DNA methylation, nucleo-
some remodeling is also involved in the process of gene silencing at tumor suppressor genes 
(Figure 7). Zhang and co-workers have shown that MBD2 interacts with the nucleosomal 
remodeling complex (NuRD), thus directing the complex to methylated DNA (Zhang et al., 
1999). Another example is given by Brahma (Brm), the catalytic subunit of the SWI/SNF 
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chromatin-remodeling complex, which has been shown to associate with MeCP2 and to par-
ticipate in MeCP2-dependent transcriptional silencing (Harikrishnan et al., 2005). Lin and 
colleagues have found that changes in the nucleosomal occupancy contribute to the epigenetic 
silencing of the CGI in the MLH1 gene (Lin et al., 2007). The authors suggest that heritable 
changes in nucleosome occupancy enabled by DNA methylation may contribute to epigenetic 
silencing of tumor suppressor genes. Moreover, also histone modifications are involved in the 
chromatin-remodeling process. For example, NURF (nucleosome remodeling factor), a mem-
ber of the ISWI family of chromatin remodeling complexes, has been demonstrated to couple 
H3K4me3 with chromatin remodeling (Li et al., 2006; Wysocka et al., 2006). These findings 
highlight that all three processes of DNA methylation, histone modifications and nucleosome 
remodeling are intimately linked (Figure 7) and that alterations in these processes lead to the 
permanent silencing of cancer-relevant genes (Jones and Baylin, 2007). 
 
1.2.6 CpG island methylator phenotype 
In cancer cells CpG island promoters are commonly hypermethylated, and this methylation is 
associated with transcriptional repression and gain of histone repressive marks (Jones and 
Baylin, 2007). The changes in CpG island methylation in a given tumor can involve a group 
of loci and has been hypothesized to constitute a distinct phenotype. Toyota and co-workers 
reported methylation profiling data that indicated a dichotomous classification of human co-
lon carcinomas into frequent promoter methylation and infrequent methylation groups 
(Toyota et al., 1999). The authors have then proposed to term this observation a ‘CpG island 
methylator phenotype’ or ‘CIMP’ (Toyota et al., 1999). Although, the CIMP existence has 
been challenged (Yamashita et al., 2002), several studies have succeeded to show that a sub-
set of CpG islands are coordinately methylated in various tumors types. Weisenberger and 
colleagues have reported that CIMP-positive colorectal cancers represent a distinct subset, 
encompassing tumors that frequently have a BRAF mutation and display a mismatch repair 
deficiency as a consequence of CIMP-associated methylation of MLH1 (Weisenberger et al., 
2006). Remarkably, studies in gliomas, have identified that IDH1 mutations correlate with 
tumors displaying a CpG island methylator phenotype (Noushmehr et al., 2010). These find-
ings constitute an important concept that might also occur in other tumor types. Recently, 
Mack and colleagues have identified that poor-prognosis hindbrain ependymomas exhibit a 
CpG island methylator phenotype (Mack et al., 2014). Remarkably, many CIMP loci have 
1 Introduction 
__________________________________________________________________________________________ 
47 
been identified as targets of PcG proteins (Mack et al., 2014; Widschwendter et al., 2007), for 
example, transcriptional silencing at these loci in ependymomas has been found to largely 
overlap with PRC2 target sites and its catalyzed H3K27me3 mark (Mack et al., 2014). These 
findings have implications for cancer therapy, as CIMP-positive hindbrain ependymomas 
were responsive to clinical drugs that target either DNA or H3K27 methylation both in vitro 
and in vivo (Mack et al., 2014). 
 In addition to CIMP, some studies have reported that epigenetic inactivation is not limited 
to single genes but can also encompass large stretches of DNA across the genome during tu-
morigenesis which can become aberrantly methylated through long-range epigenetic silencing 
(LRES) (Coolen et al., 2010; Frigola et al., 2006; Hsu et al., 2010). The characteristics of 
LRES are an increase in CpG island hypermethylation and gain or reinforcement of the re-
pressive histone modifications H3K9me2 and H3K27me3 (Coolen et al., 2010). 
 
1.3 Prostate Cancer 
Prostate cancer is the most common male malignancy and one of the leading causes of death 
in western countries. Clinically advanced prostate cancer causes over 250,000 deaths world-
wide annually (Jemal et al., 2011). If detected at early stages, when still locally confined, 
prostate cancer is eradicated in 70-80% of the patients by radical prostatectomy (surgical ex-
cision of the prostate) or radiation therapy. However, around five years after primary treat-
ment, the remaining 20-30% of patients develop metastasis (Cooperberg et al., 2007). 
 An important tool in prostate cancer diagnosis is the measurement of the prostate-specific 
antigen (PSA). PSA, a kallikrein-related serine protease, is produced in normal prostate tis-
sues, but is released into the blood upon disruption of normal prostate architecture during tu-
morigenesis (Lilja et al., 2008). Patients with elevated PSA levels usually undergo biopsy to 
determine the presence of prostate cancer. After biopsy, histological grading is performed us-
ing the Gleason scoring system. The Gleason scoring classifies tumors from 1 to 5 (from most 
to least differentiated) based on the most abundant differentiation status by assigning a com-
bined score (the sum of the two most common patterns) (Epstein, 2010; Mellinger et al., 
1967). Patients with a Gleason score of less than 5 (low risk prostate cancer), 3+3 and 3+4 
(low-intermediate risk prostate cancer) and 4+3 (intermediate risk prostate cancer) are consid-
ered to have indolent tumors, which are not causing symptoms and are expected to grow 
slowly. Therefore, this group of patients is managed conservatively by ‘active surveillance’ 
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through monitoring of their PSA levels. Nonetheless, a small fraction of these tumors will 
progress rapidly and require immediate treatment (Albertsen et al., 2005; Eggener et al., 
2007). Therefore, a major clinical challenge is the current inability to distinguish indolent 
from aggressive tumors in patients displaying a low Gleason score in the biopsy (Sartor et al., 
2008). The lack of this prognostic information has led to an enormous ‘overtreatment’ of pa-
tients who would instead require only conservative treatment (Shen and Abate-Shen, 2010). 
Patients with a Gleason score of 4+4 or higher (high risk prostate cancer) are considered to 
have aggressive tumors and therefore undergo immediate treatment by surgery, radiation ther-
apy or hormonal therapy targeting the androgen receptor (AR) pathway depending of type, 
size and location of the tumor. 
 
 
Figure 8. Disease progression of human prostate cancer. Stages of tumor progression are depicted, together 
with molecular processes (red) and genes (blue), which are likely to significantly contribute at each stage. From 
(Shen and Abate-Shen, 2010). 
 
 Androgens are crucial for the development and function of the prostate gland and for the 
maintenance of prostate cancer cells, which arise from the secretory epithelium of the pros-
tate. Therefore, treatment of advanced prostate cancer is based on blocking or reducing the 
production of androgens or antagonizing the AR and its target genes (Chen et al., 2008). 
However, prostate cancer relapse can be managed efficiently by androgen-deprivation therapy 
(ADT) only for a limited time period by targeting the AR axis under which the majority of 
cancer cells die, producing a tumor remission and a reduction in circulating PSA levels 
(Denmeade and Isaacs, 2002). Thus far, these treatments are not curative, the most effective 
standard chemotherapies result only in a mean increase in survival time of two months 
(Petrylak et al., 2004; Tannock et al., 2004), and castration-resistance inevitably follows with-
in a period of months to years, resulting in relapse and metastasis. Prostate cancer metastatic 
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sites are lung, liver, pleura and bones, where osteoblastic lesions are formed (Bubendorf et al., 
2000; Logothetis and Lin, 2005). Hence, the second major challenge in prostate cancer man-
agement is the durable control of advanced prostate cancer and the understanding of pathways 
of castration-resistance and the identification of novel therapeutic approaches (Shen and 
Abate-Shen, 2010). 
 Prostate cancer is considered as a heterogeneous, multifocal disease as primary tumors 
often contain multiple independent histologic cancer foci, which are often genetically distinct 
(Shen and Abate-Shen, 2010). Remarkably, major tumor subtypes are not present on the his-
topathological level. Gene expression analyses of prostate cancer have not been able to strict-
ly define molecular signatures associated with distinct tumor subtypes that correlate with dis-
ease outcome (Lapointe et al., 2004; Singh et al., 2002; Tomlins et al., 2007b). Recently, ge-
nomic analyses have provided evidence for defined molecular subtypes (Palanisamy et al., 
2010; Taylor et al., 2010; Tomlins et al., 2008). For example, genomic profiling of prostate 
cancer has identified numerous recurrent DNA alterations that lead to the dysregulation of 
genes involved in prostate development, chromatin modification, cell cycle regulation, and 
androgen signaling (Baca and Garraway, 2012). Early in tumorigenesis, prostate cancer cells 
undergo chromosomal deletions resulting in the inactivation of tumor suppressor genes in-
cluding PTEN, TP53 and CDKN1B (Shen and Abate-Shen, 2010). Comparative genomic hy-
bridization arrays have identified a number of chromosomal alterations including gains at 8q 
and losses at 3p, 8p, 10q, 13q and 17p (Dong, 2001; Lapointe et al., 2007; Taylor et al., 
2010). Several key regulatory genes are located within these chromosomal regions and under-
go copy number alterations such as NKX3.1 at 8p21, MYC at 8q24 and PTEN at 10q23 (Shen 
and Abate-Shen, 2010). These events result in NKX3.1 downregulation, PTEN inactivation 
and MYC overexpression (Figure 8). Loss of PTEN is a frequent event in prostate cancer 
progression - up to 70% of late stage tumors exhibit loss of PTEN function or activation of the 
PI3K pathway (Taylor et al., 2010) (Figure 8). Both events result in enhanced cell prolifera-
tion, migration and survival (Stiles et al., 2004; Vivanco and Sawyers, 2002) but also lead to 
castration-resistant growth (Gao et al., 2006; Jiao et al., 2007; Wang et al., 2003). About half 
of prostatic adenocarcinomas overexpress an oncogenic ETS transcription factor gene, mostly 
ERG, due to a somatic fusion with a constitutively active or androgen-regulated promoter 
(Tomlins et al., 2007a; Tomlins et al., 2005). The most common rearrangement results in the 
generation of a TMPRSS2-ERG fusion gene (Figure 8). In this regard, Berger and colleagues 
have reported complex ‘chains’ of rearrangements in prostate cancer genomes that may arise 
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from the shuffling and re-ligation of broken DNA fragments to one another resulting in a 
novel configuration (Berger et al., 2011). These shuffling events may simultaneously deregu-
late numerous cancer-related genes. 
 Recent studies have performed exome sequencing of localized and castration-resistant 
prostate cancer and have discovered base pair mutations in genes such as SPOP, FOXA1 and 
KDM6A, which are implicated in deregulated cellular process during prostate carcinogenesis 
(Barbieri et al., 2012; Grasso et al., 2012; Kumar et al., 2011). However, compared to other 
cancers, the prostate cancer genome displays a low frequency of mutations (Barbieri et al., 
2012; Grasso et al., 2012; Kumar et al., 2011). Thus, the perturbation of epigenetic pathways 
is likely to essentially contribute to the tumorigenic process (see 1.3.1). 
 In order to develop more effective therapies, a concerted effort is underway to characterize 
and target the critical cell population resistant to conventional treatment regimens, particularly 
upon AR withdrawal. Unfortunately, the identification of such cells has been hampered by the 
fact that, unlike other cancer types, prostate cancer has proven remarkably resilient to classifi-
cation into molecular subtypes associated with distinct disease outcomes (Taylor et al., 2010). 
Up to now, available molecular biomarkers do not provide greater prognostic significance 
than the usage of the Gleason score system (True et al., 2006). In addition, an inherent lack of 
understanding of the biological processes that distinguish indolence from aggressiveness is a 
considerable limitation for the identification of early prognostic biomarkers, which could aid 
in preoperative therapy decision making for low and intermediate risk cases, and the identifi-
cation of therapeutic targets. 
 Tumor cells may be divided into well-differentiated mature or immature precursor cells 
according to different sources. The latter are considered to be cancer stem cells (CSCs) (Dean 
et al., 2005). They possess unlimited proliferative differentiation potential, self-renewal, po-
tential tumorigenic capacity and permanency (Collins et al., 2005). Importantly, CSCs where 
shown to be resistant to conventional treatment regimens, particularly chemotherapy 
(Abdullah and Chow, 2013) and radiotherapy (Rich, 2007). Prostate cancer stem cells are an 
enticing explanation for cancer relapse, metastasis formation, therapy failure, and, thus are the 
object in current cancer research. However, the molecular pathways regulating generation and 
propagation of stem-like prostate cancer cells are poorly understood. The population of pros-
tate cancer stem cells may constitute an important target for therapeutic intervention in ag-
gressive prostate cancer. 
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1.3.1 Epigenetics in prostate cancer 
Since prostate cancer is characterized by a low frequency of mutations (Grasso et al., 2012), 
aberrant gene activity contributing to prostate cancer is likely based on alterations in gene ex-
pression levels, which can be driven by copy number alterations and/or translocations (such 
as PTEN, TP53 loss and ERG fusions) or by alterations in transcriptional or post-
transcriptional regulation. In addition, recent studies provide strong evidence that alterations 
in epigenetic pathways play an important role in prostate cancer initation and progression. 
DNA methylation and histone modifications, have been demonstrated to play critical roles in 
prostate cancer growth and metastasis (Albany et al., 2011). The best-studied epigenetic alter-
ation in prostate cancer is aberrant DNA methylation (hypo- and hypermethylation) leading to 
genomic instability and inappropriate gene expression patterns. Hypermethylation frequently 
silences DNA repair genes (GSTP1, MGMT), hormone-receptor genes (AR, ESR), cell adhe-
sion genes (CDH1, CD44), cell cycle control genes (CCND2, CDKN1B, SFN), apoptotic 
genes (PYCARD, RPRM, GLIPR1) and the well-characterized tumor suppressor genes APC, 
RARB and RASSF1 (Jeronimo et al., 2004; Kang et al., 2004; Maruyama et al., 2002; Sasaki 
et al., 2002; Yegnasubramanian et al., 2004). For example, GSTP1, encoding the intracellular 
detoxification enzyme glutathione S-transferase P, has been shown to undergo promoter hy-
permethylation in early tumorigenesis (Brooks et al., 1998; Kang et al., 2004; Perry et al., 
2007). Hypermethylation and subsequent silencing of GSTP1 was detected in >90% of pros-
tate tumors and in about 75% of preinvasive high-grade PIN (Brooks et al., 1998; Kang et al., 
2004; Lee et al., 1994). Loss of GSTP1 is thought to sensitize cells to DNA damage by elec-
trophilic compounds (Jeronimo et al., 2004; Yegnasubramanian et al., 2004). 
 Genome-wide hypomethylation is found in both primary tumors but to a higher extend in 
metastatic prostate cancer (Brothman et al., 2005; Yegnasubramanian et al., 2008). It has been 
demonstrated that global hypomethylation is associated with increased tumor stage, Gleason 
grade ≥ 7 and hypermethylation of particular loci, such as GSTP1, RARB, APC, PYCARD, 
PTGS2, ABCB1 and RASSF1 (Florl et al., 2004; Kang et al., 2004). 
 Specific histone modification patterns were identified to be altered in prostate cancer and 
may serve as prognostic markers of the disease. Seligson and colleagues have reported a 
marked reduction of H3K4me1, H3K9me2, H3K9me3 and H3 and H4 acetylation in prostate 
cancer when compared to normal prostate tissue (Seligson et al., 2005). This histone modifi-
cation pattern was shown be predictive of clinical outcome independently of tumor stage, pre-
operative PSA levels, and capsule invasion (Seligson et al., 2005). Another study has reported 
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a substantial increase of H3K4me1, H3K4me2 and H3K4me3 in tissue of patients with castra-
tion-resistant prostate cancer (Ellinger et al., 2010). 
 Gene expression levels of epigenetic regulators are frequently altered in cancer (see 1.2). 
Overexpression of histone-modifying enzymes have been linked to prostate cancer progres-
sion and many of which are reported to be independent prognostic markers. The lysine-
specific demethylase KDM1A (also known as LSD1) interacts with the AR and promotes 
AR-dependent transcription of target genes through demethylation of H3K9me1 and 
H3K9me2 (Metzger et al., 2005). Overexpression of the AR coactivators KDM1A and four 
and a half LIM domain protein 2 (FHL2) have been demonstrated to correlate with an in-
creased risk of cancer relapse after radial prostatectomy (Kahl et al., 2006). UHRF1, which 
together with PCNA recruits DNMT1 to replication foci, has been reported to be involved in 
epigenetic silencing of tumor suppressor genes (Babbio et al., 2012). UHRF1 overexpression 
has been associated with reduced survival rates in prostate cancer (Babbio et al., 2012). As 
mentioned earlier, a prominent example is EZH2 that is frequently amplified (Saramaki et al., 
2006) and overexpressed in prostate cancer with a moderate increase in localized tumors and 
higher expression in metastatic prostate cancers (Bachmann et al., 2006; Varambally et al., 
2002; Xiao, 2011). Strong expression of EZH2 is associated with increased tumor cell prolif-
eration and aggressive tumors, and clinically localized prostate cancer tumors with high 
EZH2 levels are associated with a poorer prognosis (Bachmann et al., 2006; Varambally et 
al., 2002). EZH2 target genes in prostate cancer include genes that are associated with metas-
tasis such as E-Cadherin (Cao et al., 2008) and DAB2IP (Chen et al., 2005). Loss of these 
genes promotes metastasis formation through activation of NF-κB and Ras pathways (Min et 
al., 2010). 
 Another example of aberrant expression of an epigenetic modifier in prostate cancer is 
given by the SWI/SNF ATPase BRM, whose expression, both on mRNA and protein levels, 
has been found downregulated in prostate cancer compared to non-neoplastic tissue (Shen et 
al., 2008a). 
 Expression profiling studies in prostate cancer has unveiled a widespread dysregulation of 
miRNAs contributing to important clinical and pathological features, for example extrapros-
tatic extension (Ambs et al., 2008; Ozen et al., 2008). Mounting evidence suggests that    
miRNAs have key roles in the tumorigenic process by modulating the cancer epigenome for 
example by posttranslational gene silencing of components of the DNA methylation machin-
ery (DNMTs), histone-modifying enzymes (HDACs, HATs, HMTs) or nucleosome remodel-
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ing factors (NURFs) (Perry et al., 2010). For example, miR-101 has been identified to nega-
tively regulate EZH2. During prostate tumor progression miR-101 levels decrease due to so-
matic loss of one or both of the two genomic loci encoding miR-101 resulting in the upregula-
tion of EZH2 (Varambally et al., 2008). Expression of miR-101 was significantly decreased 
in metastatic prostate cancer compared to that in clinically localized disease or benign adja-
cent prostate tissue and genomic loss of miRNA-101 was found in about one-third of tumors 
(Varambally et al., 2008). Downregulation of miR-101 has been also reported in other cancers 
including breast, ovarian, lung and colorectal cancers (Iorio et al., 2005; Schepeler et al., 
2008; Varambally et al., 2008; Yanaihara et al., 2006) suggesting that miR-101 might be part 
of a solid tumor signature. In addition, miRNAs with tumor suppressor functions can be sub-
ject to promoter hypermethylation, which is now considered as a common hallmark of human 
cancers including prostate cancer. 
 
1.4 The epigenetic regulator TIP5 
TIP5 is an epigenetic factor identified as a transcription termination factor 1 (TTF1) interact-
ing protein in a yeast-two hybrid screen (Strohner et al., 2001). The novel gene was named 
TIP5 (TTF1-interacting protein 5), also known as BAZ2A, and encodes a 205 kDa protein. 
Together with the ATPase SNF2h, the mammalian homolog of ISWI, TIP5 forms a macromo-
lecular complex. This novel chromatin remodeling complex was termed NoRC (nucleolar re-
modeling complex) and induces nucleosome sliding in an ATP- and histone 4 tail-dependent 
manner (Strohner et al., 2001). NoRC is responsible for the establishment of heterochromatic 
structures at the rDNA locus after cell division (Figure 9) (Guetg et al., 2010; Li et al., 2005; 
Santoro and Grummt, 2005; Santoro et al., 2002; Zhou et al., 2002). TIP5 contains several 
domains including a TAM/MBD domain, several AT-hook domains, a DDT domain, a BAZ1 
and a BAZ2 motif, a WAKZ motif, a bromodomain, and a PHD finger (Strohner et al., 2001). 
In order to establish the heterochromatic structure of the rDNA locus, TIP5 recruits several 
histone-modifying enzymes (HMTs, HDACs, PARP1/ARTD1), DNMTs and non-coding 
RNAs (pRNA) to the rDNA promoter (Guetg et al., 2010; Guetg and Santoro, 2012; Guetg et 
al., 2012; Mayer et al., 2006; Santoro and Grummt, 2005; Santoro et al., 2002). 
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Figure 9. Active and silent ribosomal RNA genes. Association of TIP5 and its interacting factors (chromatin 
enzymes and non-coding RNA) with silent rRNA genes. In contrast, active rRNA genes are bound by Polymer-
ase I (Pol I) and the Pol I transcription factor UBF. 
 
 Recently, TIP5 has been implicated in the epigenetic silencing of other genes than rRNA 
(ribosomal RNA) genes. A screen aimed to discover factors (RESEs) required for Ras-
mediated epigenetic silencing of the pro-apoptotic Fas gene in K-ras-transformed NIH3T3 
cells, identified several polycomb proteins, and proteins involved in chromatin modification 
and chromatin remodeling, including EZH2 and TIP5 (Gazin et al., 2007). This study has 
shown that knockdown of TIP5 or EZH2 in K-ras-transformed NIH3T3 cells impairs DNA 
methylation of the Fas gene promoter and inhibits anchorage-independent growth of trans-
formed cells and tumor growth in nude mice. Interestingly, K-ras-transformed NIH3T3 cells 
displayed upregulated TIP5 mRNA expression levels when compared to NIH3T3 cells (Gazin 
et al., 2007). The positive correlation between TIP5 levels and cancer has also been suggested 
by several other studies. For example, TIP5 was proposed as an eventual biomarker for early 
diagnosis of osteosarcoma, since the expression levels of TIP5 were higher in three osteosar-
coma cell lines (U2OS, MG-63, Saos-2) than in the osteoblastic cell line hFOB1.19 (Li et al., 
2009). Furthermore, TIP5 was found abundantly expressed in ovarian cancer cell lines includ-
ing OVCAR3, A2780, ES2, and MPSC1, whereas its expression levels were relatively low in 
the OSE4 cell line, which was derived from normal ovarian surface epithelium (Sheu et al., 
2008). Recently, a study by Leite and co-workers have suggested a role for miR-let7c, miR-
100, and miR-218 in prostate cancer since they were less expressed in metastatic prostate 
cancer (Leite et al., 2011). The authors propose a possible involvement of these miRNAs in 
the metastasation of prostate cancer though controlling the expression of RAS, c-Myc, Lam-
inin-5-β3, THAP2, SMARCA5, and TIP5. Finally, a putative TIP5 deregulation has been re-
ported in a pediatric case of pre-B acute lymphoblastic leukemia (ALL) in which a cryptic 
rearrangement between 12p13 and 12q13 generated a fusion of ETV6 with an intronic se-
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quence of TIP5 (Panagopoulos et al., 2006). Taken together, these studies suggest that TIP5 
might play a role in tumor initiation and progression in various cancer types. 
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2 Aim of the work 
As prostate cancer is characterized by a low frequency of somatic mutations, disruption of 
epigenetic pathways is likely to have an important role in the disease. Aberrant DNA meth-
ylation patterns are universally found in prostate cancer and are known to frequently affect 
genes involved in cancer-related processes. The aim of this work was to identify alterations to 
epigenetic regulators that contribute to poor prognosis in prostate cancer. For this purpose we 
initially analyzed expression profiles of prostate tumors and determined that the expression of 
the epigenetic regulator TIP5 is upregulated in prostate cancer. 
 
In this work we aimed to determine the role of TIP5 in prostate cancer by: 
1. Analyzing the function of TIP5 in cancer-specific properties such as cell migration, inva-
sion and stem cell-like features (self-renewal). 
2. Analyzing the molecular mechanisms of epigenetic silencing mediated by TIP5 in meta-
static prostate cancer cells. 
3. Identifying genes regulated by TIP5 in metastatic prostate cancer cells and the associated 
biological pathways. 
4. Investigating the suitability of TIP5 as a potential early biomarker in prostate cancer. 
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4 Discussion 
Alterations involving epigenetic regulators are now recognized as key events governing the 
tumor cell phenotype by affecting expression of genes critical to cancer. This work has identi-
fied a novel aberrant role for TIP5, an epigenetic regulator that was so far exclusively impli-
cated in the epigenetic repression of rRNA genes. Elevated expression of TIP5 correlates with 
metastatic and advanced prostate cancer and serves as an independent predictor of PSA recur-
rence. This work has determined that TIP5 directly regulates a host of non-rRNA genes and 
interacts with EZH2 to maintain aberrant repression directly at the promoters of genes recur-
rently silenced in prostate cancer and other cancer metastasis. Finally, this study has shown 
that TIP5 overexpression is tightly associated with a tumor subtype displaying dramatic ge-
nome-wide hypermethylation. Thus, TIP5 is implicated in aberrant epigenetic profiles and 
gene silencing characterizing aggressive prostate cancer, and serves as a useful marker to elu-
cidate and predict metastatic potential in prostate cancer. 
 This work has demonstrated that TIP5 is upregulated alongside EZH2 in prostate cancer. 
TIP5 and EZH2 physically interact with each other and cooperate to maintain silencing in 
prostate cancer cells at genes aberrantly repressed in metastatic tumors. Although TIP5 regu-
lates the epigenetic state of rRNA genes in PC3 cells as in non-malignant cells, in cancer cells 
its function appears to go beyond the epigenetic control of the rDNA locus. Depletion of TIP5 
in non-malignant cells induces loss of rDNA silencing with consequent upregulation of rRNA 
transcription and proliferation (this work and (Guetg et al., 2010; Santoro et al., 2009)) 
whereas the lack of TIP5 in prostate cancer cells reduces cell proliferation and viability, de-
lays cell cycle progression, and impairs malignant-specific features of PC3 cells such as cell 
mobility/invasion and self-renewal. The distinction of TIP5 function is further supported by 
the strong divergence in processes related to TIP5-regulated genes between non-cancer and 
prostate cancer cells. The switch of TIP5 function and its key role in prostate cancer is also 
underscored by the substantial overlap of TIP5- and EZH2-regulated genes in PC3 cells that 
share common biological processes, including pathways involved in extracellular matrix 
structure organization and biogenesis, and collagen synthesis known to be important for pros-
tate cancer metastasis (Hall, 2008; Banyard, 2007). Likewise, TIP5-high expressing tumors 
display hypermethylation of genes involved in these key pathways. In contrast, genes regulat-
ed by TIP5 and EZH2 in RWPE1 cells did not show any relevant common biological process 
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underscoring a functional TIP5/EZH2 cooperation, which is specific for prostate cancer cells. 
 Many EZH2 target genes in cancer are also EZH2 targets in embryonic stem cells (Yu et 
al., 2007) suggesting a strong association between PRC2 function in cancer and stem cells, 
which represent dedifferentiated and proliferative cell states. Hence, overexpression of EZH2 
might cause a normal cell to dedifferentiate back to a stem cell–like state by epigenetically 
repressing cell fate-regulating and tumor suppressor genes resulting in tumor development 
(Jones and Baylin, 2007; Kondo et al., 2008; Sparmann and van Lohuizen, 2006). 
 Why does TIP5 have an oncogenic activity in prostate cancer? EZH2 upregulation can be 
detected in the vast majority of all tumors, whereas TIP5 upregulation is specific to some 
cancers and biased towards a more aggressive prostate cancer disease. These data support the 
possibility that TIP5 upregulation in combination with EZH2 causes additional gene silencing 
distinct from the silenced gene signature, which would be achieved separately, and this coop-
eration endows the tumor cells with an additionally aggressive phenotype. Alternatively, ele-
vated levels of TIP5 might favor the recruitment to specific gene loci that would otherwise 
not be associated with TIP5 and, consequently, not be repressed. Future studies will decipher 
the nature of TIP5-binding sites in the genome of prostate cancer cells and the molecular fea-
tures that dictate the recruitment. 
 The data of this work have shown that the upregulation of TIP5 is further associated with 
DNA hypermethylation in tumors which likely strengthens and/or stabilizes gene silencing. 
Remarkably, TIP5 was previously reported to establish epigenetic silencing at rRNA genes 
through recruitment of DNMTs (Guetg et al., 2012; Santoro et al., 2002), raising the possibil-
ity that similar silencing mechanisms might take place at non-rRNA genes in cancer. This is 
also supported by the observation that 35% (352) of genes upregulated upon TIP5 depletion 
in PC3 cells have elevated DNA methylation in TIP5-high expressing tumors. Although 
EZH2-mediated recruitment of DNMTs inducing de novo methylation in cancer was reported 
in an experimental model (Vire et al., 2006), the relation between H3K27me3 and DNA 
methylation remains to be clearly defined. Several studies in cancer cells have observed that 
many hypermethylated CpG islands actually contain low levels of H3K27me3 (Gal-Yam et 
al., 2008; Kondo et al., 2008) and knockdown of EZH2 did not alter DNA methylation pro-
files of candidate CpG islands (McGarvey et al., 2007). Although our analysis in tumors does 
not allow for a direct measurement of H3K27me3 and DNA methylation co-occupancy, the 
presence of a large portion of Polycomb group sites among hypermethylated genes in TIP5-
high tumors supports a functional crosstalk between TIP5, EZH2 and DNA methylation. Re-
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markably, among hypermethylated genes in TIP5-high tumors, 27 genes were upregulated by 
TIP5 and EZH2 depletion in PC3 cells and 82 by EZH2 alone. 
 Lethality in prostate cancer is linked to the evolution of a metastatic phenotype. PSA re-
currence following radical prostatectomy reveals that tumor cells have gained the ability to 
invade the surrounding local tissue and/or metastasize prior to surgery. This work demon-
strates a key role for TIP5 in the growth and invasiveness of metastatic prostate cancer cells 
and in the regulation of genes related to metastatic features. Our results suggest that high 
TIP5 levels in the primary tumor indicate a higher probability of metastasis, linking molecular 
findings with recurrence in clinical samples. TIP5 may be involved in endowing cells with 
these abilities and could represent a promising therapeutic target for metastatic prostate can-
cer. An increasing number of epigenetic regulatory genes, including members of the class of 
bromodomain-containing proteins, are currently found to be dysregulated across many cancer 
types (Dawson et al., 2012). These genes represent novel targets of a new generation of poten-
tial cancer therapeutics. Accordingly, the fact that TIP5 contains a bromodomain previously 
shown to be important for its silencing function at the rDNA locus (Zhou and Grummt, 2005) 
might open the possibility to develop compounds to inactivate TIP5 function in cancer. 
 This study shows that TIP5 levels can serve as an independent prognostic marker of recur-
rence, especially in low/intermediate risk cases as assessed by Gleason score. Low expression 
of FGFR1 and CDKN1A together with PMP22 has recently been proposed as a prognostic 
indicator for low Gleason score prostate tumors that failed surveillance (Irshad et al., 2013). 
Remarkably, this work has identified FGFR1 and CDKN1A as genes upregulated upon 
knockdown of TIP5 and EZH2 in PC3 cells, underscoring the potential role of TIP5 in epige-
netic alterations contributing to the aggressive prostate cancer phenotype. Intermediate risk 
cases are a patient sub-cohort where most uncertainty exists to balance between active sur-
veillance or immediate definite therapy in order to avoid overtreatment. Screening of TIP5 
levels in biopsies may be a valuable biomarker to distinguish prostate cancer that possesses 
the potential for disease progression, aiding in therapy decision-making for this important pa-
tient subgroup. 
 240 
5 References 
__________________________________________________________________________________________ 
241 
5 References 
 
Abdullah, L. N., and Chow, E. K. (2013). Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 
2, 3. 
Albany, C., Alva, A. S., Aparicio, A. M., Singal, R., Yellapragada, S., Sonpavde, G., and Hahn, N. M. (2011). 
Epigenetics in prostate cancer. Prostate cancer 2011, 580318. 
Albertsen, P. C., Hanley, J. A., and Fine, J. (2005). 20-year outcomes following conservative management of 
clinically localized prostate cancer. JAMA 293, 2095-2101. 
Allfrey, V. G., Faulkner, R., and Mirsky, A. E. (1964). Acetylation and Methylation of Histones and Their 
Possible Role in the Regulation of Rna Synthesis. Proc Natl Acad Sci U S A 51, 786-794. 
Ambs, S., Prueitt, R. L., Yi, M., Hudson, R. S., Howe, T. M., Petrocca, F., Wallace, T. A., Liu, C. G., Volinia, 
S., Calin, G. A., et al. (2008). Genomic profiling of microRNA and messenger RNA reveals deregulated 
microRNA expression in prostate cancer. Cancer Res 68, 6162-6170. 
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., and Schapira, M. (2012). Epigenetic protein families: a new 
frontier for drug discovery. Nature reviews Drug discovery 11, 384-400. 
Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, 
K., Dhanireddy, S., Engelke, C., et al. (2014). Therapeutic targeting of BET bromodomain proteins in castration-
resistant prostate cancer. Nature 510, 278-282. 
Babbio, F., Pistore, C., Curti, L., Castiglioni, I., Kunderfranco, P., Brino, L., Oudet, P., Seiler, R., Thalman, G. 
N., Roggero, E., et al. (2012). The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in 
prostate cancer progression. Oncogene 31, 4878-4887. 
Baca, S. C., and Garraway, L. A. (2012). The genomic landscape of prostate cancer. Frontiers in endocrinology 
3, 69. 
Bachmann, I. M., Halvorsen, O. J., Collett, K., Stefansson, I. M., Straume, O., Haukaas, S. A., Salvesen, H. B., 
Otte, A. P., and Akslen, L. A. (2006). EZH2 expression is associated with high proliferation rate and aggressive 
tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24, 
268-273. 
Ball, P. (2003). Portrait of a molecule. Nature 421, 421-422. 
Ballestar, E., Paz, M. F., Valle, L., Wei, S., Fraga, M. F., Espada, J., Cigudosa, J. C., Huang, T. H., and Esteller, 
M. (2003). Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. Embo J 
22, 6335-6345. 
Bannister, A. J., and Kouzarides, T. (2011). Regulation of chromatin by histone modifications. Cell research 21, 
381-395. 
Barbieri, C. E., Baca, S. C., Lawrence, M. S., Demichelis, F., Blattner, M., Theurillat, J. P., White, T. A., 
Stojanov, P., Van Allen, E., Stransky, N., et al. (2012). Exome sequencing identifies recurrent SPOP, FOXA1 
and MED12 mutations in prostate cancer. Nat Genet 44, 685-689. 
Barski, A., Cuddapah, S., Cui, K., Roh, T. Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., and Zhao, K. 
(2007). High-resolution profiling of histone methylations in the human genome. Cell 129, 823-837. 
5 References 
__________________________________________________________________________________________ 
242 
Bartke, T., Vermeulen, M., Xhemalce, B., Robson, S. C., Mann, M., and Kouzarides, T. (2010). Nucleosome-
interacting proteins regulated by DNA and histone methylation. Cell 143, 470-484. 
Basavapathruni, A., Olhava, E. J., Daigle, S. R., Therkelsen, C. A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., 
Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2014). Nonclinical pharmacokinetics and metabolism of EPZ-
5676, a novel DOT1L histone methyltransferase inhibitor. Biopharmaceutics & drug disposition 35, 237-252. 
Basnet, H., Su, X. B., Tan, Y., Meisenhelder, J., Merkurjev, D., Ohgi, K. A., Hunter, T., Pillus, L., and 
Rosenfeld, M. G. (2014). Tyrosine phosphorylation of histone H2A by CK2 regulates transcriptional elongation. 
Nature 516, 267-271. 
Baylin, S. B., Esteller, M., Rountree, M. R., Bachman, K. E., Schuebel, K., and Herman, J. G. (2001). Aberrant 
patterns of DNA methylation, chromatin formation and gene expression in cancer. Human molecular genetics 
10, 687-692. 
Baylin, S. B., Hoppener, J. W., de Bustros, A., Steenbergh, P. H., Lips, C. J., and Nelkin, B. D. (1986). DNA 
methylation patterns of the calcitonin gene in human lung cancers and lymphomas. Cancer Res 46, 2917-2922. 
Baylin, S. B., and Jones, P. A. (2011). A decade of exploring the cancer epigenome - biological and translational 
implications. Nat Rev Cancer 11, 726-734. 
Baylin, S. B., and Ohm, J. E. (2006). Epigenetic gene silencing in cancer - a mechanism for early oncogenic 
pathway addiction? Nat Rev Cancer 6, 107-116. 
Bell, O., Tiwari, V. K., Thoma, N. H., and Schubeler, D. (2011). Determinants and dynamics of genome 
accessibility. Nature reviews Genetics 12, 554-564. 
Bender, S., Tang, Y., Lindroth, A. M., Hovestadt, V., Jones, D. T., Kool, M., Zapatka, M., Northcott, P. A., 
Sturm, D., Wang, W., et al. (2013). Reduced H3K27me3 and DNA hypomethylation are major drivers of gene 
expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660-672. 
Berdasco, M., Ropero, S., Setien, F., Fraga, M. F., Lapunzina, P., Losson, R., Alaminos, M., Cheung, N. K., 
Rahman, N., and Esteller, M. (2009). Epigenetic inactivation of the Sotos overgrowth syndrome gene histone 
methyltransferase NSD1 in human neuroblastoma and glioma. Proc Natl Acad Sci U S A 106, 21830-21835. 
Berger, M. F., Lawrence, M. S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A. Y., Sboner, A., 
Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011). The genomic complexity of primary human prostate 
cancer. Nature 470, 214-220. 
Bernardi, R., and Pandolfi, P. P. (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear 
bodies. Nature reviews Molecular cell biology 8, 1006-1016. 
Bernstein, E., and Allis, C. D. (2005). RNA meets chromatin. Genes & development 19, 1635-1655. 
Bernstein, E., Duncan, E. M., Masui, O., Gil, J., Heard, E., and Allis, C. D. (2006). Mouse polycomb proteins 
bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell 
Biol 26, 2560-2569. 
Berry, W. L., and Janknecht, R. (2013). KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer 
cells. Cancer Res 73, 2936-2942. 
Bestor, T. H., and Bourc'his, D. (2004). Transposon silencing and imprint establishment in mammalian germ 
cells. Cold Spring Harbor symposia on quantitative biology 69, 381-387. 
Bettstetter, M., Woenckhaus, M., Wild, P. J., Rummele, P., Blaszyk, H., Hartmann, A., Hofstadter, F., and 
Dietmaier, W. (2005). Elevated nuclear maspin expression is associated with microsatellite instability and high 
tumour grade in colorectal cancer. The Journal of pathology 205, 606-614. 
5 References 
__________________________________________________________________________________________ 
243 
Bird, A. P., and Wolffe, A. P. (1999). Methylation-induced repression--belts, braces, and chromatin. Cell 99, 
451-454. 
Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih 
Ie, M., Conejo-Garcia, J. R., et al. (2015). Synthetic lethality by targeting EZH2 methyltransferase activity in 
ARID1A-mutated cancers. Nat Med 21, 231-238. 
Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. 
R., Vinci, M., et al. (2013). Histone H3.3. mutations drive pediatric glioblastoma through upregulation of 
MYCN. Cancer discovery 3, 512-519. 
Bracken, A. P., and Helin, K. (2009). Polycomb group proteins: navigators of lineage pathways led astray in 
cancer. Nat Rev Cancer 9, 773-784. 
Brenner, C., Deplus, R., Didelot, C., Loriot, A., Vire, E., De Smet, C., Gutierrez, A., Danovi, D., Bernard, D., 
Boon, T., et al. (2005). Myc represses transcription through recruitment of DNA methyltransferase corepressor. 
Embo J 24, 336-346. 
Brooks, J. D., Weinstein, M., Lin, X., Sun, Y., Pin, S. S., Bova, G. S., Epstein, J. I., Isaacs, W. B., and Nelson, 
W. G. (1998). CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer 
epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, 
cosponsored by the American Society of Preventive Oncology 7, 531-536. 
Brothman, A. R., Swanson, G., Maxwell, T. M., Cui, J., Murphy, K. J., Herrick, J., Speights, V. O., Isaac, J., and 
Rohr, L. R. (2005). Global hypomethylation is common in prostate cancer cells: a quantitative predictor for 
clinical outcome? Cancer Genet Cytogenet 156, 31-36. 
Bryan, E. J., Jokubaitis, V. J., Chamberlain, N. L., Baxter, S. W., Dawson, E., Choong, D. Y., and Campbell, I. 
G. (2002). Mutation analysis of EP300 in colon, breast and ovarian carcinomas. International journal of cancer 
Journal international du cancer 102, 137-141. 
Bubendorf, L., Schopfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., Gasser, T. C., and Mihatsch, M. J. 
(2000). Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Human pathology 31, 578-
583. 
Cai, Y., Jin, J., Yao, T., Gottschalk, A. J., Swanson, S. K., Wu, S., Shi, Y., Washburn, M. P., Florens, L., 
Conaway, R. C., and Conaway, J. W. (2007). YY1 functions with INO80 to activate transcription. Nature 
structural & molecular biology 14, 872-874. 
Caligiuri, M. A., Strout, M. P., Oberkircher, A. R., Yu, F., de la Chapelle, A., and Bloomfield, C. D. (1997). The 
partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is 
restricted to one chromosome. Proc Natl Acad Sci U S A 94, 3899-3902. 
Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H., Mani, R. S., Tomlins, S. A., Mehra, R., Laxman, B., Cao, X., 
Kleer, C. G., et al. (2008). Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 
27, 7274-7284. 
Cao, R., Tsukada, Y., and Zhang, Y. (2005). Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene 
silencing. Mol Cell 20, 845-854. 
Cao, R., and Zhang, Y. (2004). SUZ12 is required for both the histone methyltransferase activity and the 
silencing function of the EED-EZH2 complex. Mol Cell 15, 57-67. 
Carapeti, M., Aguiar, R. C., Goldman, J. M., and Cross, N. C. (1998). A novel fusion between MOZ and the 
nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91, 3127-3133. 
Caretti, G., Di Padova, M., Micales, B., Lyons, G. E., and Sartorelli, V. (2004). The Polycomb Ezh2 
methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes & development 
18, 2627-2638. 
5 References 
__________________________________________________________________________________________ 
244 
Cedar, H., and Bergman, Y. (2009). Linking DNA methylation and histone modification: patterns and 
paradigms. Nature reviews Genetics 10, 295-304. 
Chen, F. J., Sun, M., Li, S. Q., Wu, Q. Q., Ji, L., Liu, Z. L., Zhou, G. Z., Cao, G., Jin, L., Xie, H. W., et al. 
(2013). Upregulation of the long non-coding RNA HOTAIR promotes esophageal squamous cell carcinoma 
metastasis and poor prognosis. Mol Carcinog 52, 908-915. 
Chen, H., Tu, S. W., and Hsieh, J. T. (2005). Down-regulation of human DAB2IP gene expression mediated by 
polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 280, 22437-22444. 
Chen, Y., Sawyers, C. L., and Scher, H. I. (2008). Targeting the androgen receptor pathway in prostate cancer. 
Current opinion in pharmacology 8, 440-448. 
Chi, P., Allis, C. D., and Wang, G. G. (2010). Covalent histone modifications--miswritten, misinterpreted and 
mis-erased in human cancers. Nat Rev Cancer 10, 457-469. 
Cimmino, L., Abdel-Wahab, O., Levine, R. L., and Aifantis, I. (2011). TET family proteins and their role in 
stem cell differentiation and transformation. Cell stem cell 9, 193-204. 
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., and Maitland, N. J. (2005). Prospective identification of 
tumorigenic prostate cancer stem cells. Cancer Res 65, 10946-10951. 
Coolen, M. W., Stirzaker, C., Song, J. Z., Statham, A. L., Kassir, Z., Moreno, C. S., Young, A. N., Varma, V., 
Speed, T. P., Cowley, M., et al. (2010). Consolidation of the cancer genome into domains of repressive 
chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nature cell biology 12, 
235-246. 
Cooperberg, M. R., Broering, J. M., Kantoff, P. W., and Carroll, P. R. (2007). Contemporary trends in low risk 
prostate cancer: risk assessment and treatment. The Journal of urology 178, S14-19. 
Cortazar, D., Kunz, C., Selfridge, J., Lettieri, T., Saito, Y., MacDougall, E., Wirz, A., Schuermann, D., Jacobs, 
A. L., Siegrist, F., et al. (2011). Embryonic lethal phenotype reveals a function of TDG in maintaining 
epigenetic stability. Nature 470, 419-423. 
Cortellino, S., Xu, J., Sannai, M., Moore, R., Caretti, E., Cigliano, A., Le Coz, M., Devarajan, K., Wessels, A., 
Soprano, D., et al. (2011). Thymine DNA glycosylase is essential for active DNA demethylation by linked 
deamination-base excision repair. Cell 146, 67-79. 
Costello, J. F., Fruhwald, M. C., Smiraglia, D. J., Rush, L. J., Robertson, G. P., Gao, X., Wright, F. A., 
Feramisco, J. D., Peltomaki, P., Lang, J. C., et al. (2000). Aberrant CpG-island methylation has non-random and 
tumour-type-specific patterns. Nat Genet 24, 132-138. 
Creyghton, M. P., Markoulaki, S., Levine, S. S., Hanna, J., Lodato, M. A., Sha, K., Young, R. A., Jaenisch, R., 
and Boyer, L. A. (2008). H2AZ is enriched at polycomb complex target genes in ES cells and is necessary for 
lineage commitment. Cell 135, 649-661. 
Dai, Y., Rahmani, M., Dent, P., and Grant, S. (2005). Blockade of histone deacetylase inhibitor-induced 
RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process 
mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation. Mol Cell Biol 
25, 5429-5444. 
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., 
Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion 
leukemia. Blood 122, 1017-1025. 
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, 
M. P., Smith, J. J., Xiao, Y., et al. (2011). Selective killing of mixed lineage leukemia cells by a potent small-
molecule DOT1L inhibitor. Cancer Cell 20, 53-65. 
5 References 
__________________________________________________________________________________________ 
245 
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., 
Latimer, C., et al. (2010). Systematic sequencing of renal carcinoma reveals inactivation of histone modifying 
genes. Nature 463, 360-363. 
Dawson, M. A., Bannister, A. J., Gottgens, B., Foster, S. D., Bartke, T., Green, A. R., and Kouzarides, T. (2009). 
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 461, 819-822. 
Dawson, M. A., Kouzarides, T., and Huntly, B. J. (2012). Targeting epigenetic readers in cancer. N Engl J Med 
367, 647-657. 
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W. I., Robson, S. C., 
Chung, C. W., Hopf, C., Savitski, M. M., et al. (2011). Inhibition of BET recruitment to chromatin as an 
effective treatment for MLL-fusion leukaemia. Nature 478, 529-533. 
Dean, M., Fojo, T., and Bates, S. (2005). Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284. 
Deaton, A. M., and Bird, A. (2011). CpG islands and the regulation of transcription. Genes & development 25, 
1010-1022. 
Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., 
Paranal, R. M., Qi, J., et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 
146, 904-917. 
Denisenko, O., Shnyreva, M., Suzuki, H., and Bomsztyk, K. (1998). Point mutations in the WD40 domain of 
Eed block its interaction with Ezh2. Mol Cell Biol 18, 5634-5642. 
Denmeade, S. R., and Isaacs, J. T. (2002). A history of prostate cancer treatment. Nat Rev Cancer 2, 389-396. 
Di Croce, L., Raker, V. A., Corsaro, M., Fazi, F., Fanelli, M., Faretta, M., Fuks, F., Lo Coco, F., Kouzarides, T., 
Nervi, C., et al. (2002). Methyltransferase recruitment and DNA hypermethylation of target promoters by an 
oncogenic transcription factor. Science 295, 1079-1082. 
Dickinson, M., Ritchie, D., DeAngelo, D. J., Spencer, A., Ottmann, O. G., Fischer, T., Bhalla, K. N., Liu, A., 
Parker, K., Scott, J. W., et al. (2009). Preliminary evidence of disease response to the pan deacetylase inhibitor 
panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 147, 97-101. 
Dobosy, J. R., and Selker, E. U. (2001). Emerging connections between DNA methylation and histone 
acetylation. Cell Mol Life Sci 58, 721-727. 
Dohner, K., Tobis, K., Ulrich, R., Frohling, S., Benner, A., Schlenk, R. F., and Dohner, H. (2002). Prognostic 
significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute 
myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin 
Oncol 20, 3254-3261. 
Doi, A., Park, I. H., Wen, B., Murakami, P., Aryee, M. J., Irizarry, R., Herb, B., Ladd-Acosta, C., Rho, J., 
Loewer, S., et al. (2009). Differential methylation of tissue- and cancer-specific CpG island shores distinguishes 
human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet 41, 1350-1353. 
Dong, J. T. (2001). Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer metastasis 
reviews 20, 173-193. 
Donohoe, M. E., Zhang, X., McGinnis, L., Biggers, J., Li, E., and Shi, Y. (1999). Targeted disruption of mouse 
Yin Yang 1 transcription factor results in peri-implantation lethality. Mol Cell Biol 19, 7237-7244. 
Duncan, I. M. (1982). Polycomblike: a gene that appears to be required for the normal expression of the bithorax 
and antennapedia gene complexes of Drosophila melanogaster. Genetics 102, 49-70. 
5 References 
__________________________________________________________________________________________ 
246 
Eggener, S. E., Scardino, P. T., Carroll, P. R., Zelefsky, M. J., Sartor, O., Hricak, H., Wheeler, T. M., Fine, S. 
W., Trachtenberg, J., Rubin, M. A., et al. (2007). Focal therapy for localized prostate cancer: a critical appraisal 
of rationale and modalities. The Journal of urology 178, 2260-2267. 
Egger, G., Liang, G., Aparicio, A., and Jones, P. A. (2004). Epigenetics in human disease and prospects for 
epigenetic therapy. Nature 429, 457-463. 
el-Deiry, W. S., Nelkin, B. D., Celano, P., Yen, R. W., Falco, J. P., Hamilton, S. R., and Baylin, S. B. (1991). 
High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages 
of colon cancer. Proc Natl Acad Sci U S A 88, 3470-3474. 
Ellinger, J., Bachmann, A., Goke, F., Behbahani, T. E., Baumann, C., Heukamp, L. C., Rogenhofer, S., and 
Muller, S. C. (2014). Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer. 
Urologia internationalis 93, 113-118. 
Ellinger, J., Kahl, P., von der Gathen, J., Rogenhofer, S., Heukamp, L. C., Gutgemann, I., Walter, B., Hofstadter, 
F., Buttner, R., Muller, S. C., et al. (2010). Global levels of histone modifications predict prostate cancer 
recurrence. Prostate 70, 61-69. 
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, 
H., Ryan, G., et al. (2008). Histone deacetylase inhibitor panobinostat induces clinical responses with associated 
alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14, 4500-4510. 
Epstein, J. I. (2010). An update of the Gleason grading system. The Journal of urology 183, 433-440. 
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. 
M., Reiter, A., et al. (2010). Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid 
disorders. Nat Genet 42, 722-726. 
Eskeland, R., Leeb, M., Grimes, G. R., Kress, C., Boyle, S., Sproul, D., Gilbert, N., Fan, Y., Skoultchi, A. I., 
Wutz, A., and Bickmore, W. A. (2010). Ring1B compacts chromatin structure and represses gene expression 
independent of histone ubiquitination. Mol Cell 38, 452-464. 
Espada, J., Ballestar, E., Santoro, R., Fraga, M. F., Villar-Garea, A., Nemeth, A., Lopez-Serra, L., Ropero, S., 
Aranda, A., Orozco, H., et al. (2007). Epigenetic disruption of ribosomal RNA genes and nucleolar architecture 
in DNA methyltransferase 1 (Dnmt1) deficient cells. Nucleic acids research 35, 2191-2198. 
Esteller, M. (2005). Aberrant DNA methylation as a cancer-inducing mechanism. Annual review of 
pharmacology and toxicology 45, 629-656. 
Esteller, M. (2007a). Cancer epigenomics: DNA methylomes and histone-modification maps. Nature reviews 
Genetics 8, 286-298. 
Esteller, M. (2007b). Epigenetic gene silencing in cancer: the DNA hypermethylome. Human molecular genetics 
16 Spec No 1, R50-59. 
Esteller, M., Corn, P. G., Baylin, S. B., and Herman, J. G. (2001a). A gene hypermethylation profile of human 
cancer. Cancer Res 61, 3225-3229. 
Esteller, M., Fraga, M. F., Guo, M., Garcia-Foncillas, J., Hedenfalk, I., Godwin, A. K., Trojan, J., Vaurs-
Barriere, C., Bignon, Y. J., Ramus, S., et al. (2001b). DNA methylation patterns in hereditary human cancers 
mimic sporadic tumorigenesis. Human molecular genetics 10, 3001-3007. 
Esteller, M., and Herman, J. G. (2004). Generating mutations but providing chemosensitivity: the role of O6-
methylguanine DNA methyltransferase in human cancer. Oncogene 23, 1-8. 
Fahrner, J. A., Eguchi, S., Herman, J. G., and Baylin, S. B. (2002). Dependence of histone modifications and 
gene expression on DNA hypermethylation in cancer. Cancer Res 62, 7213-7218. 
5 References 
__________________________________________________________________________________________ 
247 
Faust, C., Schumacher, A., Holdener, B., and Magnuson, T. (1995). The eed mutation disrupts anterior 
mesoderm production in mice. Development 121, 273-285. 
Feinberg, A. P., and Tycko, B. (2004). The history of cancer epigenetics. Nat Rev Cancer 4, 143-153. 
Felsenfeld, G., and Groudine, M. (2003). Controlling the double helix. Nature 421, 448-453. 
Fenaux, P. (2005). Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nature clinical practice 
Oncology 2 Suppl 1, S36-44. 
Feng, S., Jacobsen, S. E., and Reik, W. (2010). Epigenetic reprogramming in plant and animal development. 
Science 330, 622-627. 
Ferguson, A. D., Larsen, N. A., Howard, T., Pollard, H., Green, I., Grande, C., Cheung, T., Garcia-Arenas, R., 
Cowen, S., Wu, J., et al. (2011). Structural basis of substrate methylation and inhibition of SMYD2. Structure 
19, 1262-1273. 
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, 
A., Fernandez, H. F., et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, 
disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567. 
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, 
T. T., Felletar, I., et al. (2010). Selective inhibition of BET bromodomains. Nature 468, 1067-1073. 
Florl, A. R., Steinhoff, C., Muller, M., Seifert, H. H., Hader, C., Engers, R., Ackermann, R., and Schulz, W. A. 
(2004). Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. 
British journal of cancer 91, 985-994. 
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., 
Ropero, S., Petrie, K., et al. (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a 
common hallmark of human cancer. Nat Genet 37, 391-400. 
Fraga, M. F., Herranz, M., Espada, J., Ballestar, E., Paz, M. F., Ropero, S., Erkek, E., Bozdogan, O., Peinado, 
H., Niveleau, A., et al. (2004). A mouse skin multistage carcinogenesis model reflects the aberrant DNA 
methylation patterns of human tumors. Cancer Res 64, 5527-5534. 
Friedman, J. M., Liang, G., Liu, C. C., Wolff, E. M., Tsai, Y. C., Ye, W., Zhou, X., and Jones, P. A. (2009). The 
putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group 
protein EZH2. Cancer Res 69, 2623-2629. 
Frigola, J., Song, J., Stirzaker, C., Hinshelwood, R. A., Peinado, M. A., and Clark, S. J. (2006). Epigenetic 
remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat 
Genet 38, 540-549. 
Fuks, F. (2005). DNA methylation and histone modifications: teaming up to silence genes. Curr Opin Genet Dev 
15, 490-495. 
Futscher, B. W., O'Meara, M. M., Kim, C. J., Rennels, M. A., Lu, D., Gruman, L. M., Seftor, R. E., Hendrix, M. 
J., and Domann, F. E. (2004). Aberrant methylation of the maspin promoter is an early event in human breast 
cancer. Neoplasia 6, 380-389. 
Futscher, B. W., Oshiro, M. M., Wozniak, R. J., Holtan, N., Hanigan, C. L., Duan, H., and Domann, F. E. 
(2002). Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 31, 175-179. 
Gal-Yam, E. N., Egger, G., Iniguez, L., Holster, H., Einarsson, S., Zhang, X., Lin, J. C., Liang, G., Jones, P. A., 
and Tanay, A. (2008). Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 
prostate cancer cell line. Proc Natl Acad Sci U S A 105, 12979-12984. 
5 References 
__________________________________________________________________________________________ 
248 
Gallagher, W. M., Bergin, O. E., Rafferty, M., Kelly, Z. D., Nolan, I. M., Fox, E. J., Culhane, A. C., McArdle, 
L., Fraga, M. F., Hughes, L., et al. (2005). Multiple markers for melanoma progression regulated by DNA 
methylation: insights from transcriptomic studies. Carcinogenesis 26, 1856-1867. 
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., and Abate-Shen, C. (2006). Emergence of 
androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res 66, 
7929-7933. 
Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., Leonhardt, H., and 
Jaenisch, R. (2003). Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492. 
Gazin, C., Wajapeyee, N., Gobeil, S., Virbasius, C. M., and Green, M. R. (2007). An elaborate pathway required 
for Ras-mediated epigenetic silencing. Nature 449, 1073-1077. 
Girault, I., Tozlu, S., Lidereau, R., and Bieche, I. (2003). Expression analysis of DNA methyltransferases 1, 3A, 
and 3B in sporadic breast carcinomas. Clin Cancer Res 9, 4415-4422. 
Goelz, S. E., Vogelstein, B., Hamilton, S. R., and Feinberg, A. P. (1985). Hypomethylation of DNA from benign 
and malignant human colon neoplasms. Science 228, 187-190. 
Goll, M. G., and Bestor, T. H. (2005). Eukaryotic cytosine methyltransferases. Annual review of biochemistry 
74, 481-514. 
Gordon, S., Akopyan, G., Garban, H., and Bonavida, B. (2006). Transcription factor YY1: structure, function, 
and therapeutic implications in cancer biology. Oncogene 25, 1125-1142. 
Grasso, C. S., Wu, Y. M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., 
Lonigro, R. J., Brenner, J. C., et al. (2012). The mutational landscape of lethal castration-resistant prostate 
cancer. Nature 487, 239-243. 
Guetg, C., Lienemann, P., Sirri, V., Grummt, I., Hernandez-Verdun, D., Hottiger, M. O., Fussenegger, M., and 
Santoro, R. (2010). The NoRC complex mediates the heterochromatin formation and stability of silent rRNA 
genes and centromeric repeats. Embo J 29, 2135-2146. 
Guetg, C., and Santoro, R. (2012). Noncoding RNAs link PARP1 to heterochromatin. Cell Cycle 11, 2217-2218. 
Guetg, C., Scheifele, F., Rosenthal, F., Hottiger, M. O., and Santoro, R. (2012). Inheritance of silent rDNA 
chromatin is mediated by PARP1 via noncoding RNA. Mol Cell 45, 790-800. 
Gupta, R. A., Shah, N., Wang, K. C., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M. C., Hung, T., Argani, P., 
Rinn, J. L., et al. (2010). Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer 
metastasis. Nature 464, 1071-1076. 
Hackett, J. A., Zylicz, J. J., and Surani, M. A. (2012). Parallel mechanisms of epigenetic reprogramming in the 
germline. Trends in genetics : TIG 28, 164-174. 
Hall, T. M. (2005). Multiple modes of RNA recognition by zinc finger proteins. Current opinion in structural 
biology 15, 367-373. 
Hamamoto, R., Furukawa, Y., Morita, M., Iimura, Y., Silva, F. P., Li, M., Yagyu, R., and Nakamura, Y. (2004). 
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature cell biology 6, 
731-740. 
Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hargreaves, D. C., and Crabtree, G. R. (2011). ATP-dependent chromatin remodeling: genetics, genomics and 
mechanisms. Cell research 21, 396-420. 
5 References 
__________________________________________________________________________________________ 
249 
Harikrishnan, K. N., Chow, M. Z., Baker, E. K., Pal, S., Bassal, S., Brasacchio, D., Wang, L., Craig, J. M., 
Jones, P. L., Sif, S., and El-Osta, A. (2005). Brahma links the SWI/SNF chromatin-remodeling complex with 
MeCP2-dependent transcriptional silencing. Nat Genet 37, 254-264. 
Haupt, Y., Alexander, W. S., Barri, G., Klinken, S. P., and Adams, J. M. (1991). Novel zinc finger gene 
implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 
65, 753-763. 
He, G., Wang, Q., Zhou, Y., Wu, X., Wang, L., Duru, N., Kong, X., Zhang, P., Wan, B., Sui, L., et al. (2011a). 
YY1 is a novel potential therapeutic target for the treatment of HPV infection-induced cervical cancer by arsenic 
trioxide. International journal of gynecological cancer : official journal of the International Gynecological 
Cancer Society 21, 1097-1104. 
He, Y. F., Li, B. Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011b). Tet-
mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303-
1307. 
Hennig, L., and Derkacheva, M. (2009). Diversity of Polycomb group complexes in plants: same rules, different 
players? Trends in genetics : TIG 25, 414-423. 
Herman, J. G., and Baylin, S. B. (2003). Gene silencing in cancer in association with promoter 
hypermethylation. The New England journal of medicine 349, 2042-2054. 
Hsu, P. Y., Hsu, H. K., Singer, G. A., Yan, P. S., Rodriguez, B. A., Liu, J. C., Weng, Y. I., Deatherage, D. E., 
Chen, Z., Pereira, J. S., et al. (2010). Estrogen-mediated epigenetic repression of large chromosomal regions 
through DNA looping. Genome research 20, 733-744. 
Huntly, B. J., Shigematsu, H., Deguchi, K., Lee, B. H., Mizuno, S., Duclos, N., Rowan, R., Amaral, S., Curley, 
D., Williams, I. R., et al. (2004). MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to 
committed murine hematopoietic progenitors. Cancer Cell 6, 587-596. 
Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., 
Campiglio, M., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65, 
7065-7070. 
Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., Cui, H., Gabo, K., Rongione, M., 
Webster, M., et al. (2009). The human colon cancer methylome shows similar hypo- and hypermethylation at 
conserved tissue-specific CpG island shores. Nat Genet 41, 178-186. 
Irshad, S., Bansal, M., Castillo-Martin, M., Zheng, T., Aytes, A., Wenske, S., Le Magnen, C., Guarnieri, P., 
Sumazin, P., Benson, M. C., et al. (2013). A molecular signature predictive of indolent prostate cancer. Sci 
Transl Med 5, 202ra122. 
Issa, J. P. (2004). CpG island methylator phenotype in cancer. Nat Rev Cancer 4, 988-993. 
Ito, S., D'Alessio, A. C., Taranova, O. V., Hong, K., Sowers, L. C., and Zhang, Y. (2010). Role of Tet proteins in 
5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129-1133. 
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., and Zhang, Y. (2011). Tet proteins 
can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 1300-1303. 
Ito, Y., Koessler, T., Ibrahim, A. E., Rai, S., Vowler, S. L., Abu-Amero, S., Silva, A. L., Maia, A. T., 
Huddleston, J. E., Uribe-Lewis, S., et al. (2008). Somatically acquired hypomethylation of IGF2 in breast and 
colorectal cancer. Human molecular genetics 17, 2633-2643. 
Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A., and van Lohuizen, M. (1999a). The oncogene and 
Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397, 
164-168. 
5 References 
__________________________________________________________________________________________ 
250 
Jacobs, J. J., Scheijen, B., Voncken, J. W., Kieboom, K., Berns, A., and van Lohuizen, M. (1999b). Bmi-1 
collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes & 
development 13, 2678-2690. 
Jaenisch, R., and Bird, A. (2003). Epigenetic regulation of gene expression: how the genome integrates intrinsic 
and environmental signals. Nat Genet 33 Suppl, 245-254. 
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA: a 
cancer journal for clinicians 61, 69-90. 
Jenkins, T. G., and Carrell, D. T. (2012). Dynamic alterations in the paternal epigenetic landscape following 
fertilization. Frontiers in genetics 3, 143. 
Jenuwein, T., and Allis, C. D. (2001). Translating the histone code. Science 293, 1074-1080. 
Jeon, Y., and Lee, J. T. (2011). YY1 tethers Xist RNA to the inactive X nucleation center. Cell 146, 119-133. 
Jeronimo, C., Henrique, R., Hoque, M. O., Mambo, E., Ribeiro, F. R., Varzim, G., Oliveira, J., Teixeira, M. R., 
Lopes, C., and Sidransky, D. (2004). A quantitative promoter methylation profile of prostate cancer. Clin Cancer 
Res 10, 8472-8478. 
Ji, H., Ehrlich, L. I., Seita, J., Murakami, P., Doi, A., Lindau, P., Lee, H., Aryee, M. J., Irizarry, R. A., Kim, K., 
et al. (2010). Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 
467, 338-342. 
Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., and Wu, H. (2007). Murine cell lines 
derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer 
development. Cancer Res 67, 6083-6091. 
Jones, P. A. (1999). The DNA methylation paradox. Trends in genetics : TIG 15, 34-37. 
Jones, P. A., and Baylin, S. B. (2007). The epigenomics of cancer. Cell 128, 683-692. 
Jones, P. L., Veenstra, G. J., Wade, P. A., Vermaak, D., Kass, S. U., Landsberger, N., Strouboulis, J., and 
Wolffe, A. P. (1998). Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat 
Genet 19, 187-191. 
Jones, S., Wang, T. L., Shih Ie, M., Mao, T. L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Jr., 
Vogelstein, B., et al. (2010). Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell 
carcinoma. Science 330, 228-231. 
Jürgens, G. (1985). A group of genes controlling the spatial expression of the bithorax complex in Drosophila. 
Nature 316, 153 - 155. 
Kahl, P., Gullotti, L., Heukamp, L. C., Wolf, S., Friedrichs, N., Vorreuther, R., Solleder, G., Bastian, P. J., 
Ellinger, J., Metzger, E., et al. (2006). Androgen receptor coactivators lysine-specific histone demethylase 1 and 
four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 66, 11341-11347. 
Kalakonda, N., Fischle, W., Boccuni, P., Gurvich, N., Hoya-Arias, R., Zhao, X., Miyata, Y., Macgrogan, D., 
Zhang, J., Sims, J. K., et al. (2008). Histone H4 lysine 20 monomethylation promotes transcriptional repression 
by L3MBTL1. Oncogene 27, 4293-4304. 
Kaneda, M., Okano, M., Hata, K., Sado, T., Tsujimoto, N., Li, E., and Sasaki, H. (2004). Essential role for de 
novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature 429, 900-903. 
Kang, G. H., Lee, S., Lee, H. J., and Hwang, K. S. (2004). Aberrant CpG island hypermethylation of multiple 
genes in prostate cancer and prostatic intraepithelial neoplasia. The Journal of pathology 202, 233-240. 
5 References 
__________________________________________________________________________________________ 
251 
Kangaspeska, S., Stride, B., Metivier, R., Polycarpou-Schwarz, M., Ibberson, D., Carmouche, R. P., Benes, V., 
Gannon, F., and Reid, G. (2008). Transient cyclical methylation of promoter DNA. Nature 452, 112-115. 
Kanhere, A., Viiri, K., Araujo, C. C., Rasaiyaah, J., Bouwman, R. D., Whyte, W. A., Pereira, C. F., Brookes, E., 
Walker, K., Bell, G. W., et al. (2010). Short RNAs are transcribed from repressed polycomb target genes and 
interact with polycomb repressive complex-2. Mol Cell 38, 675-688. 
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J. P., Chou, 
W. C., Buckstein, R., Cermak, J., et al. (2012). Multicenter, randomized, open-label, phase III trial of decitabine 
versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of 
older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30, 2670-2677. 
Kelly, T. K., De Carvalho, D. D., and Jones, P. A. (2010). Epigenetic modifications as therapeutic targets. 
Nature biotechnology 28, 1069-1078. 
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., 
Tong, W., Secrist, J. P., Schwartz, L., et al. (2005). Phase I study of an oral histone deacetylase inhibitor, 
suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23, 3923-3931. 
Keshet, I., Schlesinger, Y., Farkash, S., Rand, E., Hecht, M., Segal, E., Pikarski, E., Young, R. A., Niveleau, A., 
Cedar, H., and Simon, I. (2006). Evidence for an instructive mechanism of de novo methylation in cancer cells. 
Nat Genet 38, 149-153. 
Kim, H., Kang, K., and Kim, J. (2009). AEBP2 as a potential targeting protein for Polycomb Repression 
Complex PRC2. Nucleic acids research 37, 2940-2950. 
Kirmizis, A., Bartley, S. M., and Farnham, P. J. (2003). Identification of the polycomb group protein SU(Z)12 as 
a potential molecular target for human cancer therapy. Molecular cancer therapeutics 2, 113-121. 
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G., Otte, A. P., 
Hayes, D. F., et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation 
of breast epithelial cells. Proc Natl Acad Sci U S A 100, 11606-11611. 
Kohli, R. M., and Zhang, Y. (2013). TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502, 
472-479. 
Kondo, Y., Shen, L., Cheng, A. S., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, K., 
Kwabi-Addo, B., et al. (2008). Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of 
promoter DNA methylation. Nat Genet 40, 741-750. 
Kondo, Y., Shen, L., Suzuki, S., Kurokawa, T., Masuko, K., Tanaka, Y., Kato, H., Mizuno, Y., Yokoe, M., 
Sugauchi, F., et al. (2007). Alterations of DNA methylation and histone modifications contribute to gene 
silencing in hepatocellular carcinomas. Hepatology research : the official journal of the Japan Society of 
Hepatology 37, 974-983. 
Kornberg, R. D. (1974). Chromatin structure: a repeating unit of histones and DNA. Science 184, 868-871. 
Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693-705. 
Kriaucionis, S., and Heintz, N. (2009). The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje 
neurons and the brain. Science 324, 929-930. 
Krivtsov, A. V., and Armstrong, S. A. (2007). MLL translocations, histone modifications and leukaemia stem-
cell development. Nat Rev Cancer 7, 823-833. 
Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., Xia, X., Jesneck, J., Bracken, A. 
P., Silverman, L. B., et al. (2008). H3K79 methylation profiles define murine and human MLL-AF4 leukemias. 
Cancer Cell 14, 355-368. 
5 References 
__________________________________________________________________________________________ 
252 
Ku, M., Koche, R. P., Rheinbay, E., Mendenhall, E. M., Endoh, M., Mikkelsen, T. S., Presser, A., Nusbaum, C., 
Xie, X., Chi, A. S., et al. (2008). Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of 
bivalent domains. PLoS genetics 4, e1000242. 
Kumar, A., White, T. A., MacKenzie, A. P., Clegg, N., Lee, C., Dumpit, R. F., Coleman, I., Ng, S. B., Salipante, 
S. J., Rieder, M. J., et al. (2011). Exome sequencing identifies a spectrum of mutation frequencies in advanced 
and lethal prostate cancers. Proc Natl Acad Sci U S A 108, 17087-17092. 
Landeira, D., Sauer, S., Poot, R., Dvorkina, M., Mazzarella, L., Jorgensen, H. F., Pereira, C. F., Leleu, M., 
Piccolo, F. M., Spivakov, M., et al. (2010). Jarid2 is a PRC2 component in embryonic stem cells required for 
multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. 
Nature cell biology 12, 618-624. 
Lapointe, J., Li, C., Giacomini, C. P., Salari, K., Huang, S., Wang, P., Ferrari, M., Hernandez-Boussard, T., 
Brooks, J. D., and Pollack, J. R. (2007). Genomic profiling reveals alternative genetic pathways of prostate 
tumorigenesis. Cancer Res 67, 8504-8510. 
Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., Ferrari, M., Egevad, L., Rayford, 
W., Bergerheim, U., et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate 
cancer. Proc Natl Acad Sci U S A 101, 811-816. 
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., 
Gabriel, S. B., Lander, E. S., and Getz, G. (2014). Discovery and saturation analysis of cancer genes across 21 
tumour types. Nature 505, 495-501. 
Lee, T. I., Jenner, R. G., Boyer, L. A., Guenther, M. G., Levine, S. S., Kumar, R. M., Chevalier, B., Johnstone, 
S. E., Cole, M. F., Isono, K., et al. (2006). Control of developmental regulators by Polycomb in human 
embryonic stem cells. Cell 125, 301-313. 
Lee, W. H., Morton, R. A., Epstein, J. I., Brooks, J. D., Campbell, P. A., Bova, G. S., Hsieh, W. S., Isaacs, W. 
B., and Nelson, W. G. (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione S-
transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 91, 11733-11737. 
Leite, K. R., Sousa-Canavez, J. M., Reis, S. T., Tomiyama, A. H., Camara-Lopes, L. H., Sanudo, A., Antunes, 
A. A., and Srougi, M. (2011). Change in expression of miR-let7c, miR-100, and miR-218 from high grade 
localized prostate cancer to metastasis. Urol Oncol 29, 265-269. 
Lewis, E. B. (1978). A gene complex controlling segmentation in Drosophila. Nature 276, 565-570. 
Lewis, P. (1949). Pc: Polycomb. Drosophila Information Service 21. 
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., 
Baty, J., Welch, J., et al. (2010). DNMT3A mutations in acute myeloid leukemia. The New England journal of 
medicine 363, 2424-2433. 
Li, E., Bestor, T. H., and Jaenisch, R. (1992). Targeted mutation of the DNA methyltransferase gene results in 
embryonic lethality. Cell 69, 915-926. 
Li, G., Margueron, R., Ku, M., Chambon, P., Bernstein, B. E., and Reinberg, D. (2010). Jarid2 and PRC2, 
partners in regulating gene expression. Genes & development 24, 368-380. 
Li, G., Zhang, W., Zeng, H., Chen, L., Wang, W., Liu, J., Zhang, Z., and Cai, Z. (2009). An integrative multi-
platform analysis for discovering biomarkers of osteosarcoma. BMC Cancer 9, 150. 
Li, H., Ilin, S., Wang, W., Duncan, E. M., Wysocka, J., Allis, C. D., and Patel, D. J. (2006). Molecular basis for 
site-specific read-out of histone H3K4me3 by the BPTF PHD finger of NURF. Nature 442, 91-95. 
5 References 
__________________________________________________________________________________________ 
253 
Li, J., Santoro, R., Koberna, K., and Grummt, I. (2005). The chromatin remodeling complex NoRC controls 
replication timing of rRNA genes. Embo J 24, 120-127. 
Liang, J., Prouty, L., Williams, B. J., Dayton, M. A., and Blanchard, K. L. (1998). Acute mixed lineage leukemia 
with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood 92, 2118-2122. 
Lilja, H., Ulmert, D., and Vickers, A. J. (2008). Prostate-specific antigen and prostate cancer: prediction, 
detection and monitoring. Nat Rev Cancer 8, 268-278. 
Lin, J. C., Jeong, S., Liang, G., Takai, D., Fatemi, M., Tsai, Y. C., Egger, G., Gal-Yam, E. N., and Jones, P. A. 
(2007). Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 12, 
432-444. 
Logothetis, C. J., and Lin, S. H. (2005). Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 5, 21-
28. 
Lowe, S. W., and Sherr, C. J. (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet 
Dev 13, 77-83. 
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., 
Figueroa, M. E., Melnick, A., et al. (2012). IDH mutation impairs histone demethylation and results in a block to 
cell differentiation. Nature 483, 474-478. 
Lubbert, M., Suciu, S., Baila, L., Ruter, B. H., Platzbecker, U., Giagounidis, A., Selleslag, D., Labar, B., 
Germing, U., Salih, H. R., et al. (2011). Low-dose decitabine versus best supportive care in elderly patients with 
intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results 
of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia 
Group and the German MDS Study Group. J Clin Oncol 29, 1987-1996. 
Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F., and Richmond, T. J. (1997). Crystal structure of the 
nucleosome core particle at 2.8 A resolution. Nature 389, 251-260. 
Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sanchez-Cespedes, M., Blanco, D., Montuenga, L. M., 
Rossi, S., Nicoloso, M. S., Faller, W. J., et al. (2008). A microRNA DNA methylation signature for human 
cancer metastasis. Proc Natl Acad Sci U S A 105, 13556-13561. 
Lujambio, A., Ropero, S., Ballestar, E., Fraga, M. F., Cerrato, C., Setien, F., Casado, S., Suarez-Gauthier, A., 
Sanchez-Cespedes, M., Git, A., et al. (2007). Genetic unmasking of an epigenetically silenced microRNA in 
human cancer cells. Cancer Res 67, 1424-1429. 
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stutz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, 
K., et al. (2014). Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506, 445-
450. 
Malik, H. S., and Henikoff, S. (2003). Phylogenomics of the nucleosome. Nature structural biology 10, 882-891. 
Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C. L., Dynlacht, B. D., and Reinberg, D. 
(2008). Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 32, 503-518. 
Margueron, R., and Reinberg, D. (2011). The Polycomb complex PRC2 and its mark in life. Nature 469, 343-
349. 
Maruyama, R., Toyooka, S., Toyooka, K. O., Virmani, A. K., Zochbauer-Muller, S., Farinas, A. J., Minna, J. D., 
McConnell, J., Frenkel, E. P., and Gazdar, A. F. (2002). Aberrant promoter methylation profile of prostate 
cancers and its relationship to clinicopathological features. Clin Cancer Res 8, 514-519. 
5 References 
__________________________________________________________________________________________ 
254 
 
Marx, V. (2012). Epigenetics: Reading the second genomic code. Nature 491, 143-147. 
Mayer, C., Schmitz, K. M., Li, J., Grummt, I., and Santoro, R. (2006). Intergenic transcripts regulate the 
epigenetic state of rRNA genes. Mol Cell 22, 351-361. 
Mayer, W., Niveleau, A., Walter, J., Fundele, R., and Haaf, T. (2000). Demethylation of the zygotic paternal 
genome. Nature 403, 501-502. 
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., 
Della Pietra, A., 3rd, Diaz, E., et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-
activating mutations. Nature 492, 108-112. 
McCormack, M. P., and Rabbitts, T. H. (2004). Activation of the T-cell oncogene LMO2 after gene therapy for 
X-linked severe combined immunodeficiency. The New England journal of medicine 350, 913-922. 
McGarvey, K. M., Greene, E., Fahrner, J. A., Jenuwein, T., and Baylin, S. B. (2007). DNA methylation and 
complete transcriptional silencing of cancer genes persist after depletion of EZH2. Cancer research 67, 5097-
5102. 
Melki, J. R., Warnecke, P., Vincent, P. C., and Clark, S. J. (1998). Increased DNA methyltransferase expression 
in leukaemia. Leukemia 12, 311-316. 
Mellinger, G. T., Gleason, D., and Bailar, J., 3rd (1967). The histology and prognosis of prostatic cancer. The 
Journal of urology 97, 331-337. 
Melo, S. A., Ropero, S., Moutinho, C., Aaltonen, L. A., Yamamoto, H., Calin, G. A., Rossi, S., Fernandez, A. F., 
Carneiro, F., Oliveira, C., et al. (2009). A TARBP2 mutation in human cancer impairs microRNA processing 
and DICER1 function. Nat Genet 41, 365-370. 
Mertz, J. A., Conery, A. R., Bryant, B. M., Sandy, P., Balasubramanian, S., Mele, D. A., Bergeron, L., and Sims, 
R. J., 3rd (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U 
S A 108, 16669-16674. 
Metivier, R., Gallais, R., Tiffoche, C., Le Peron, C., Jurkowska, R. Z., Carmouche, R. P., Ibberson, D., Barath, 
P., Demay, F., Reid, G., et al. (2008). Cyclical DNA methylation of a transcriptionally active promoter. Nature 
452, 45-50. 
Metzger, E., Wissmann, M., Yin, N., Muller, J. M., Schneider, R., Peters, A. H., Gunther, T., Buettner, R., and 
Schule, R. (2005). LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent 
transcription. Nature 437, 436-439. 
Michaelis, M., Michaelis, U. R., Fleming, I., Suhan, T., Cinatl, J., Blaheta, R. A., Hoffmann, K., Kotchetkov, R., 
Busse, R., Nau, H., and Cinatl, J., Jr. (2004). Valproic acid inhibits angiogenesis in vitro and in vivo. Molecular 
pharmacology 65, 520-527. 
Mikkelsen, T. S., Ku, M., Jaffe, D. B., Issac, B., Lieberman, E., Giannoukos, G., Alvarez, P., Brockman, W., 
Kim, T. K., Koche, R. P., et al. (2007). Genome-wide maps of chromatin state in pluripotent and lineage-
committed cells. Nature 448, 553-560. 
Min, J., Zaslavsky, A., Fedele, G., McLaughlin, S. K., Reczek, E. E., De Raedt, T., Guney, I., Strochlic, D. E., 
Macconaill, L. E., Beroukhim, R., et al. (2010). An oncogene-tumor suppressor cascade drives metastatic 
prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 16, 286-294. 
Moore, S. D., Herrick, S. R., Ince, T. A., Kleinman, M. S., Dal Cin, P., Morton, C. C., and Quade, B. J. (2004). 
Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res 64, 5570-5577. 
5 References 
__________________________________________________________________________________________ 
255 
Mulero-Navarro, S., and Esteller, M. (2008). Chromatin remodeling factor CHD5 is silenced by promoter CpG 
island hypermethylation in human cancer. Epigenetics 3, 210-215. 
Musselman, C. A., Lalonde, M. E., Cote, J., and Kutateladze, T. G. (2012). Perceiving the epigenetic landscape 
through histone readers. Nature structural & molecular biology 19, 1218-1227. 
Nan, X., Ng, H. H., Johnson, C. A., Laherty, C. D., Turner, B. M., Eisenman, R. N., and Bird, A. (1998). 
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. 
Nature 393, 386-389. 
Nekrasov, M., Klymenko, T., Fraterman, S., Papp, B., Oktaba, K., Kocher, T., Cohen, A., Stunnenberg, H. G., 
Wilm, M., and Muller, J. (2007). Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at 
Polycomb target genes. Embo J 26, 4078-4088. 
Nikoloski, G., Langemeijer, S. M., Kuiper, R. P., Knops, R., Massop, M., Tonnissen, E. R., van der Heijden, A., 
Scheele, T. N., Vandenberghe, P., de Witte, T., et al. (2010). Somatic mutations of the histone methyltransferase 
gene EZH2 in myelodysplastic syndromes. Nat Genet 42, 665-667. 
Noonan, E. J., Place, R. F., Pookot, D., Basak, S., Whitson, J. M., Hirata, H., Giardina, C., and Dahiya, R. 
(2009). miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28, 1714-1724. 
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. 
E., Sulman, E. P., Bhat, K. P., et al. (2010). Identification of a CpG island methylator phenotype that defines a 
distinct subgroup of glioma. Cancer Cell 17, 510-522. 
O'Carroll, D., Erhardt, S., Pagani, M., Barton, S. C., Surani, M. A., and Jenuwein, T. (2001). The polycomb-
group gene Ezh2 is required for early mouse development. Mol Cell Biol 21, 4330-4336. 
O'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., 
Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006). Clinical experience with intravenous and oral 
formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with 
advanced hematologic malignancies. J Clin Oncol 24, 166-173. 
Oda, H., Okamoto, I., Murphy, N., Chu, J., Price, S. M., Shen, M. M., Torres-Padilla, M. E., Heard, E., and 
Reinberg, D. (2009). Monomethylation of histone H4-lysine 20 is involved in chromosome structure and 
stability and is essential for mouse development. Mol Cell Biol 29, 2278-2295. 
Oh, B. K., Kim, H., Park, H. J., Shim, Y. H., Choi, J., Park, C., and Park, Y. N. (2007). DNA methyltransferase 
expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. 
International journal of molecular medicine 20, 65-73. 
Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., 
Daniel, V. C., Yu, W., et al. (2007). A stem cell-like chromatin pattern may predispose tumor suppressor genes 
to DNA hypermethylation and heritable silencing. Nat Genet 39, 237-242. 
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., and Zhang, Y. (2005). hDOT1L 
links histone methylation to leukemogenesis. Cell 121, 167-178. 
Okano, M., Bell, D. W., Haber, D. A., and Li, E. (1999). DNA methyltransferases Dnmt3a and Dnmt3b are 
essential for de novo methylation and mammalian development. Cell 99, 247-257. 
Oswald, J., Engemann, S., Lane, N., Mayer, W., Olek, A., Fundele, R., Dean, W., Reik, W., and Walter, J. 
(2000). Active demethylation of the paternal genome in the mouse zygote. Current biology : CB 10, 475-478. 
Ozen, M., Creighton, C. J., Ozdemir, M., and Ittmann, M. (2008). Widespread deregulation of microRNA 
expression in human prostate cancer. Oncogene 27, 1788-1793. 
5 References 
__________________________________________________________________________________________ 
256 
Palacios, D., Mozzetta, C., Consalvi, S., Caretti, G., Saccone, V., Proserpio, V., Marquez, V. E., Valente, S., 
Mai, A., Forcales, S. V., et al. (2010). TNF/p38alpha/polycomb signaling to Pax7 locus in satellite cells links 
inflammation to the epigenetic control of muscle regeneration. Cell stem cell 7, 455-469. 
Palanisamy, N., Ateeq, B., Kalyana-Sundaram, S., Pflueger, D., Ramnarayanan, K., Shankar, S., Han, B., Cao, 
Q., Cao, X., Suleman, K., et al. (2010). Rearrangements of the RAF kinase pathway in prostate cancer, gastric 
cancer and melanoma. Nat Med 16, 793-798. 
Panagopoulos, I., Strombeck, B., Isaksson, M., Heldrup, J., Olofsson, T., and Johansson, B. (2006). Fusion of 
ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a 
cryptic chromosome 12 rearrangement. Br J Haematol 133, 270-275. 
Pandey, R. R., Mondal, T., Mohammad, F., Enroth, S., Redrup, L., Komorowski, J., Nagano, T., Mancini-
Dinardo, D., and Kanduri, C. (2008). Kcnq1ot1 antisense noncoding RNA mediates lineage-specific 
transcriptional silencing through chromatin-level regulation. Mol Cell 32, 232-246. 
Pasini, D., Bracken, A. P., Jensen, M. R., Lazzerini Denchi, E., and Helin, K. (2004). Suz12 is essential for 
mouse development and for EZH2 histone methyltransferase activity. Embo J 23, 4061-4071. 
Pasini, D., Cloos, P. A., Walfridsson, J., Olsson, L., Bukowski, J. P., Johansen, J. V., Bak, M., Tommerup, N., 
Rappsilber, J., and Helin, K. (2010). JARID2 regulates binding of the Polycomb repressive complex 2 to target 
genes in ES cells. Nature 464, 306-310. 
Patra, S. K., Patra, A., Zhao, H., and Dahiya, R. (2002). DNA methyltransferase and demethylase in human 
prostate cancer. Mol Carcinog 33, 163-171. 
Paz, M. F., Fraga, M. F., Avila, S., Guo, M., Pollan, M., Herman, J. G., and Esteller, M. (2003). A systematic 
profile of DNA methylation in human cancer cell lines. Cancer Res 63, 1114-1121. 
Peng, J. C., Valouev, A., Swigut, T., Zhang, J., Zhao, Y., Sidow, A., and Wysocka, J. (2009). Jarid2/Jumonji 
coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139, 1290-
1302. 
Perry, A. S., Loftus, B., Moroose, R., Lynch, T. H., Hollywood, D., Watson, R. W., Woodson, K., and Lawler, 
M. (2007). In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer. British journal 
of cancer 96, 1587-1594. 
Perry, A. S., Watson, R. W., Lawler, M., and Hollywood, D. (2010). The epigenome as a therapeutic target in 
prostate cancer. Nature reviews Urology 7, 668-680. 
Peters, A. H., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schofer, C., Weipoltshammer, K., Pagani, 
M., Lachner, M., Kohlmaier, A., et al. (2001). Loss of the Suv39h histone methyltransferases impairs 
mammalian heterochromatin and genome stability. Cell 107, 323-337. 
Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, 
D., Moinpour, C., Kohli, M., et al. (2004). Docetaxel and estramustine compared with mitoxantrone and 
prednisone for advanced refractory prostate cancer. The New England journal of medicine 351, 1513-1520. 
Plass, C., Pfister, S. M., Lindroth, A. M., Bogatyrova, O., Claus, R., and Lichter, P. (2013). Mutations in 
regulators of the epigenome and their connections to global chromatin patterns in cancer. Nature reviews 
Genetics 14, 765-780. 
Plath, K., Fang, J., Mlynarczyk-Evans, S. K., Cao, R., Worringer, K. A., Wang, H., de la Cruz, C. C., Otte, A. P., 
Panning, B., and Zhang, Y. (2003). Role of histone H3 lysine 27 methylation in X inactivation. Science 300, 
131-135. 
Portela, A., and Esteller, M. (2010). Epigenetic modifications and human disease. Nature biotechnology 28, 
1057-1068. 
5 References 
__________________________________________________________________________________________ 
257 
Rajasekhar, V. K., and Begemann, M. (2007). Concise review: roles of polycomb group proteins in development 
and disease: a stem cell perspective. Stem cells 25, 2498-2510. 
Rakyan, V. K., Down, T. A., Balding, D. J., and Beck, S. (2011). Epigenome-wide association studies for 
common human diseases. Nature reviews Genetics 12, 529-541. 
Ramsahoye, B. H., Biniszkiewicz, D., Lyko, F., Clark, V., Bird, A. P., and Jaenisch, R. (2000). Non-CpG 
methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl 
Acad Sci U S A 97, 5237-5242. 
Rathkopf, D., Wong, B. Y., Ross, R. W., Anand, A., Tanaka, E., Woo, M. M., Hu, J., Dzik-Jurasz, A., Yang, W., 
and Scher, H. I. (2010). A phase I study of oral panobinostat alone and in combination with docetaxel in patients 
with castration-resistant prostate cancer. Cancer chemotherapy and pharmacology 66, 181-189. 
Razin, S. V., Iarovaia, O. V., Sjakste, N., Sjakste, T., Bagdoniene, L., Rynditch, A. V., Eivazova, E. R., Lipinski, 
M., and Vassetzky, Y. S. (2007). Chromatin domains and regulation of transcription. Journal of molecular 
biology 369, 597-607. 
Rich, J. N. (2007). Cancer stem cells in radiation resistance. Cancer Res 67, 8980-8984. 
Riising, E. M., Comet, I., Leblanc, B., Wu, X., Johansen, J. V., and Helin, K. (2014). Gene silencing triggers 
polycomb repressive complex 2 recruitment to CpG islands genome wide. Mol Cell 55, 347-360. 
Ringrose, L., and Paro, R. (2004). Epigenetic regulation of cellular memory by the Polycomb and Trithorax 
group proteins. Annual review of genetics 38, 413-443. 
Ringrose, L., and Paro, R. (2007). Polycomb/Trithorax response elements and epigenetic memory of cell 
identity. Development 134, 223-232. 
Rinn, J. L., Kertesz, M., Wang, J. K., Squazzo, S. L., Xu, X., Brugmann, S. A., Goodnough, L. H., Helms, J. A., 
Farnham, P. J., Segal, E., and Chang, H. Y. (2007). Functional demarcation of active and silent chromatin 
domains in human HOX loci by noncoding RNAs. Cell 129, 1311-1323. 
Rocchi, P., Tonelli, R., Camerin, C., Purgato, S., Fronza, R., Bianucci, F., Guerra, F., Pession, A., and Ferreri, A. 
M. (2005). p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, 
tributyrin and sodium butyrate) in neuroblastoma cells. Oncology reports 13, 1139-1144. 
Ropero, S., Fraga, M. F., Ballestar, E., Hamelin, R., Yamamoto, H., Boix-Chornet, M., Caballero, R., Alaminos, 
M., Setien, F., Paz, M. F., et al. (2006). A truncating mutation of HDAC2 in human cancers confers resistance to 
histone deacetylase inhibition. Nat Genet 38, 566-569. 
Rudek, M. A., Zhao, M., He, P., Hartke, C., Gilbert, J., Gore, S. D., Carducci, M. A., and Baker, S. D. (2005). 
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or 
hematologic malignancies. J Clin Oncol 23, 3906-3911. 
Russo, V., Riggs, A., and Martienssen, R. (1996). Epigenetic mechanisms of gene regulation,  (Cold Spring 
Habor, NY: Cold Spring Habor Laboratory Press). 
Ryan, R. J., and Bernstein, B. E. (2012). Molecular biology. Genetic events that shape the cancer epigenome. 
Science 336, 1513-1514. 
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., and Jones, P. A. (2006). Specific 
activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs 
in human cancer cells. Cancer Cell 9, 435-443. 
Sakabe, K., Wang, Z., and Hart, G. W. (2010). Beta-N-acetylglucosamine (O-GlcNAc) is part of the histone 
code. Proc Natl Acad Sci U S A 107, 19915-19920. 
5 References 
__________________________________________________________________________________________ 
258 
Santoro, R., and Grummt, I. (2005). Epigenetic mechanism of rRNA gene silencing: temporal order of NoRC-
mediated histone modification, chromatin remodeling, and DNA methylation. Mol Cell Biol 25, 2539-2546. 
Santoro, R., Li, J., and Grummt, I. (2002). The nucleolar remodeling complex NoRC mediates heterochromatin 
formation and silencing of ribosomal gene transcription. Nat Genet 32, 393-396. 
Santoro, R., Lienemann, P., and Fussenegger, M. (2009). Epigenetic engineering of ribosomal RNA genes 
enhances protein production. PLoS One 4, e6653. 
Saramaki, O. R., Tammela, T. L., Martikainen, P. M., Vessella, R. L., and Visakorpi, T. (2006). The gene for 
polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes, 
chromosomes & cancer 45, 639-645. 
Sarma, K., Margueron, R., Ivanov, A., Pirrotta, V., and Reinberg, D. (2008). Ezh2 requires PHF1 to efficiently 
catalyze H3 lysine 27 trimethylation in vivo. Mol Cell Biol 28, 2718-2731. 
Sarma, K., and Reinberg, D. (2005). Histone variants meet their match. Nature reviews Molecular cell biology 6, 
139-149. 
Sartor, A. O., Hricak, H., Wheeler, T. M., Coleman, J., Penson, D. F., Carroll, P. R., Rubin, M. A., and Scardino, 
P. T. (2008). Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 72, S12-
24. 
Sasaki, M., Tanaka, Y., Perinchery, G., Dharia, A., Kotcherguina, I., Fujimoto, S., and Dahiya, R. (2002). 
Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. Journal of the 
National Cancer Institute 94, 384-390. 
Satijn, D. P., Hamer, K. M., den Blaauwen, J., and Otte, A. P. (2001). The polycomb group protein EED 
interacts with YY1, and both proteins induce neural tissue in Xenopus embryos. Mol Cell Biol 21, 1360-1369. 
Savla, U., Benes, J., Zhang, J., and Jones, R. S. (2008). Recruitment of Drosophila Polycomb-group proteins by 
Polycomblike, a component of a novel protein complex in larvae. Development 135, 813-817. 
Schepeler, T., Reinert, J. T., Ostenfeld, M. S., Christensen, L. L., Silahtaroglu, A. N., Dyrskjot, L., Wiuf, C., 
Sorensen, F. J., Kruhoffer, M., Laurberg, S., et al. (2008). Diagnostic and prognostic microRNAs in stage II 
colon cancer. Cancer Res 68, 6416-6424. 
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-
Shushan, E., Reubinoff, B. E., et al. (2007). Polycomb-mediated methylation on Lys27 of histone H3 pre-marks 
genes for de novo methylation in cancer. Nat Genet 39, 232-236. 
Schoeftner, S., Sengupta, A. K., Kubicek, S., Mechtler, K., Spahn, L., Koseki, H., Jenuwein, T., and Wutz, A. 
(2006). Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. 
EMBO J 25, 3110-3122. 
Schotta, G., Lachner, M., Sarma, K., Ebert, A., Sengupta, R., Reuter, G., Reinberg, D., and Jenuwein, T. (2004). 
A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes & 
development 18, 1251-1262. 
Schuebel, K. E., Chen, W., Cope, L., Glockner, S. C., Suzuki, H., Yi, J. M., Chan, T. A., Van Neste, L., Van 
Criekinge, W., van den Bosch, S., et al. (2007). Comparing the DNA hypermethylome with gene mutations in 
human colorectal cancer. PLoS genetics 3, 1709-1723. 
Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B., and Cavalli, G. (2007). Genome regulation by 
polycomb and trithorax proteins. Cell 128, 735-745. 
Schwartz, Y. B., and Pirrotta, V. (2007). Polycomb silencing mechanisms and the management of genomic 
programmes. Nature reviews Genetics 8, 9-22. 
5 References 
__________________________________________________________________________________________ 
259 
Schwartzentruber, J., Korshunov, A., Liu, X. Y., Jones, D. T., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., 
Quang, D. A., Tonjes, M., et al. (2012). Driver mutations in histone H3.3 and chromatin remodelling genes in 
paediatric glioblastoma. Nature 482, 226-231. 
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., and Kurdistani, S. K. (2005). Global histone 
modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266. 
Shain, A. H., and Pollack, J. R. (2013). The spectrum of SWI/SNF mutations, ubiquitous in human cancers. 
PLoS One 8, e55119. 
Shen, H., Powers, N., Saini, N., Comstock, C. E., Sharma, A., Weaver, K., Revelo, M. P., Gerald, W., Williams, 
E., Jessen, W. J., et al. (2008a). The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate 
cancer. Cancer Res 68, 10154-10162. 
Shen, M. M., and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old 
challenges. Genes & development 24, 1967-2000. 
Shen, X., Kim, W., Fujiwara, Y., Simon, M. D., Liu, Y., Mysliwiec, M. R., Yuan, G. C., Lee, Y., and Orkin, S. 
H. (2009). Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 139, 
1303-1314. 
Shen, X., Liu, Y., Hsu, Y. J., Fujiwara, Y., Kim, J., Mao, X., Yuan, G. C., and Orkin, S. H. (2008b). EZH1 
mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and 
executing pluripotency. Mol Cell 32, 491-502. 
Sherr, C. J. (2001). The INK4a/ARF network in tumour suppression. Nature reviews Molecular cell biology 2, 
731-737. 
Sheu, J. J., Choi, J. H., Yildiz, I., Tsai, F. J., Shaul, Y., Wang, T. L., and Shih Ie, M. (2008). The roles of human 
sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res 68, 4050-
4057. 
Shi, Y. (2007). Histone lysine demethylases: emerging roles in development, physiology and disease. Nature 
reviews Genetics 8, 829-833. 
Simon, J. A., and Kingston, R. E. (2009). Mechanisms of polycomb gene silencing: knowns and unknowns. 
Nature reviews Molecular cell biology 10, 697-708. 
Simon, J. A., and Lange, C. A. (2008). Roles of the EZH2 histone methyltransferase in cancer epigenetics. 
Mutation research 647, 21-29. 
Sing, A., Pannell, D., Karaiskakis, A., Sturgeon, K., Djabali, M., Ellis, J., Lipshitz, H. D., and Cordes, S. P. 
(2009). A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell 138, 885-
897. 
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, 
A. V., Richie, J. P., et al. (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 
203-209. 
Smith, Z. D., and Meissner, A. (2013). DNA methylation: roles in mammalian development. Nature reviews 
Genetics 14, 204-220. 
Sparmann, A., and van Lohuizen, M. (2006). Polycomb silencers control cell fate, development and cancer. Nat 
Rev Cancer 6, 846-856. 
Sporn, J. C., Kustatscher, G., Hothorn, T., Collado, M., Serrano, M., Muley, T., Schnabel, P., and Ladurner, A. 
G. (2009). Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene 28, 3423-3428. 
5 References 
__________________________________________________________________________________________ 
260 
Stiles, B., Groszer, M., Wang, S., Jiao, J., and Wu, H. (2004). PTENless means more. Developmental biology 
273, 175-184. 
Stock, J. K., Giadrossi, S., Casanova, M., Brookes, E., Vidal, M., Koseki, H., Brockdorff, N., Fisher, A. G., and 
Pombo, A. (2007). Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes 
in mouse ES cells. Nat Cell Biol 9, 1428-1435. 
Strahl, B. D., and Allis, C. D. (2000). The language of covalent histone modifications. Nature 403, 41-45. 
Strohner, R., Nemeth, A., Jansa, P., Hofmann-Rohrer, U., Santoro, R., Langst, G., and Grummt, I. (2001). 
NoRC--a novel member of mammalian ISWI-containing chromatin remodeling machines. Embo J 20, 4892-
4900. 
Struhl, G. (1981). A gene product required for correct initiation of segmental determination in Drosophila. 
Nature 293, 36-41. 
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D. A., Jones, D. T. W., Konermann, C., Pfaff, E., Tonjes, 
M., Sill, M., Bender, S., et al. (2012). Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and 
Biological Subgroups of Glioblastoma. Cancer Cell 22, 425-437. 
Sui, G., Affar el, B., Shi, Y., Brignone, C., Wall, N. R., Yin, P., Donohoe, M., Luke, M. P., Calvo, D., and 
Grossman, S. R. (2004). Yin Yang 1 is a negative regulator of p53. Cell 117, 859-872. 
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. 
R., Aravind, L., and Rao, A. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian 
DNA by MLL partner TET1. Science 324, 930-935. 
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Theodore, C., James, N. 
D., Turesson, I., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate 
cancer. The New England journal of medicine 351, 1502-1512. 
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., and Patel, D. J. (2007). How chromatin-binding modules 
interpret histone modifications: lessons from professional pocket pickers. Nature structural & molecular biology 
14, 1025-1040. 
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., 
Cerami, E., Reva, B., et al. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-
22. 
Thillainadesan, G., Chitilian, J. M., Isovic, M., Ablack, J. N., Mymryk, J. S., Tini, M., and Torchia, J. (2012). 
TGF-beta-dependent active demethylation and expression of the p15ink4b tumor suppressor are impaired by the 
ZNF217/CoREST complex. Mol Cell 46, 636-649. 
Tomlins, S. A., Laxman, B., Dhanasekaran, S. M., Helgeson, B. E., Cao, X., Morris, D. S., Menon, A., Jing, X., 
Cao, Q., Han, B., et al. (2007a). Distinct classes of chromosomal rearrangements create oncogenic ETS gene 
fusions in prostate cancer. Nature 448, 595-599. 
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, 
J. T., Rubin, M. A., Pienta, K. J., et al. (2007b). Integrative molecular concept modeling of prostate cancer 
progression. Nat Genet 39, 41-51. 
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X. W., Varambally, S., Cao, X., 
Tchinda, J., Kuefer, R., et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in 
prostate cancer. Science 310, 644-648. 
Tomlins, S. A., Rhodes, D. R., Yu, J., Varambally, S., Mehra, R., Perner, S., Demichelis, F., Helgeson, B. E., 
Laxman, B., Morris, D. S., et al. (2008). The role of SPINK1 in ETS rearrangement-negative prostate cancers. 
Cancer Cell 13, 519-528. 
5 References 
__________________________________________________________________________________________ 
261 
Torchia, J., Rose, D. W., Inostroza, J., Kamei, Y., Westin, S., Glass, C. K., and Rosenfeld, M. G. (1997). The 
transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387, 677-684. 
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., and Issa, J. P. (1999). CpG island 
methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96, 8681-8686. 
Trojer, P., Li, G., Sims, R. J., 3rd, Vaquero, A., Kalakonda, N., Boccuni, P., Lee, D., Erdjument-Bromage, H., 
Tempst, P., Nimer, S. D., et al. (2007). L3MBTL1, a histone-methylation-dependent chromatin lock. Cell 129, 
915-928. 
Trojer, P., and Reinberg, D. (2008). Beyond histone methyl-lysine binding: how malignant brain tumor (MBT) 
protein L3MBTL1 impacts chromatin structure. Cell Cycle 7, 578-585. 
True, L., Coleman, I., Hawley, S., Huang, C. Y., Gifford, D., Coleman, R., Beer, T. M., Gelmann, E., Datta, M., 
Mostaghel, E., et al. (2006). A molecular correlate to the Gleason grading system for prostate adenocarcinoma. 
Proc Natl Acad Sci U S A 103, 10991-10996. 
van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., 
O'Meara, S., Teague, J., et al. (2009). Somatic mutations of the histone H3K27 demethylase gene UTX in human 
cancer. Nat Genet 41, 521-523. 
Van Holde, K. E., Allen, J. R., Tatchell, K., Weischet, W. O., and Lohr, D. (1980). DNA-histone interactions in 
nucleosomes. Biophysical journal 32, 271-282. 
van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and Berns, A. (1991). 
Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65, 737-752. 
Varambally, S., Cao, Q., Mani, R. S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., 
Ramnarayanan, K., et al. (2008). Genomic loss of microRNA-101 leads to overexpression of histone 
methyltransferase EZH2 in cancer. Science 322, 1695-1699. 
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., 
Pienta, K. J., Sewalt, R. G., Otte, A. P., et al. (2002). The polycomb group protein EZH2 is involved in 
progression of prostate cancer. Nature 419, 624-629. 
Vella, P., Barozzi, I., Cuomo, A., Bonaldi, T., and Pasini, D. (2012). Yin Yang 1 extends the Myc-related 
transcription factors network in embryonic stem cells. Nucleic acids research 40, 3403-3418. 
Versteege, I., Sevenet, N., Lange, J., Rousseau-Merck, M. F., Ambros, P., Handgretinger, R., Aurias, A., and 
Delattre, O. (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203-206. 
Vire, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., 
Vanderwinden, J. M., et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. 
Nature 439, 871-874. 
Vivanco, I., and Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat 
Rev Cancer 2, 489-501. 
Voncken, J. W., Roelen, B. A., Roefs, M., de Vries, S., Verhoeven, E., Marino, S., Deschamps, J., and van 
Lohuizen, M. (2003). Rnf2 (Ring1b) deficiency causes gastrulation arrest and cell cycle inhibition. Proc Natl 
Acad Sci U S A 100, 2468-2473. 
Voo, K. S., Carlone, D. L., Jacobsen, B. M., Flodin, A., and Skalnik, D. G. (2000). Cloning of a mammalian 
transcriptional activator that binds unmethylated CpG motifs and shares a CXXC domain with DNA 
methyltransferase, human trithorax, and methyl-CpG binding domain protein 1. Mol Cell Biol 20, 2108-2121. 
Wade, P. A. (2001). Methyl CpG-binding proteins and transcriptional repression. BioEssays : news and reviews 
in molecular, cellular and developmental biology 23, 1131-1137. 
5 References 
__________________________________________________________________________________________ 
262 
Walker, E., Chang, W. Y., Hunkapiller, J., Cagney, G., Garcha, K., Torchia, J., Krogan, N. J., Reiter, J. F., and 
Stanford, W. L. (2010). Polycomb-like 2 associates with PRC2 and regulates transcriptional networks during 
mouse embryonic stem cell self-renewal and differentiation. Cell stem cell 6, 153-166. 
Wang, H., Wang, L., Erdjument-Bromage, H., Vidal, M., Tempst, P., Jones, R. S., and Zhang, Y. (2004a). Role 
of histone H2A ubiquitination in Polycomb silencing. Nature 431, 873-878. 
Wang, P., Lin, C., Smith, E. R., Guo, H., Sanderson, B. W., Wu, M., Gogol, M., Alexander, T., Seidel, C., 
Wiedemann, L. M., et al. (2009). Global analysis of H3K4 methylation defines MLL family member targets and 
points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA 
polymerase II. Mol Cell Biol 29, 6074-6085. 
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, 
P. S., et al. (2003). Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic 
prostate cancer. Cancer Cell 4, 209-221. 
Wang, Y., Fischle, W., Cheung, W., Jacobs, S., Khorasanizadeh, S., and Allis, C. D. (2004b). Beyond the double 
helix: writing and reading the histone code. Novartis Foundation symposium 259, 3-17; discussion 17-21, 163-
169. 
Weikert, S., Christoph, F., Kollermann, J., Muller, M., Schrader, M., Miller, K., and Krause, H. (2005). 
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive 
potential of bladder carcinomas. International journal of molecular medicine 16, 349-353. 
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., 
Widschwendter, M., Weener, D., Buchanan, D., et al. (2006). CpG island methylator phenotype underlies 
sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 
38, 787-793. 
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., 
Campan, M., Young, J., Jacobs, I., and Laird, P. W. (2007). Epigenetic stem cell signature in cancer. Nat Genet 
39, 157-158. 
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., 
Anglesio, M. S., Kalloger, S. E., et al. (2010). ARID1A mutations in endometriosis-associated ovarian 
carcinomas. The New England journal of medicine 363, 1532-1543. 
Wilson, A. S., Power, B. E., and Molloy, P. L. (2007). DNA hypomethylation and human diseases. Biochimica 
et biophysica acta 1775, 138-162. 
Wilson, B. G., and Roberts, C. W. (2011). SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11, 
481-492. 
Wolf, S. F., Jolly, D. J., Lunnen, K. D., Friedmann, T., and Migeon, B. R. (1984). Methylation of the 
hypoxanthine phosphoribosyltransferase locus on the human X chromosome: implications for X-chromosome 
inactivation. Proc Natl Acad Sci U S A 81, 2806-2810. 
Woo, C. J., Kharchenko, P. V., Daheron, L., Park, P. J., and Kingston, R. E. (2010). A region of the human 
HOXD cluster that confers polycomb-group responsiveness. Cell 140, 99-110. 
Wu, G., Broniscer, A., McEachron, T. A., Lu, C., Paugh, B. S., Becksfort, J., Qu, C., Ding, L., Huether, R., 
Parker, M., et al. (2012). Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-
brainstem glioblastomas. Nat Genet 44, 251-253. 
Wu, H., Coskun, V., Tao, J., Xie, W., Ge, W., Yoshikawa, K., Li, E., Zhang, Y., and Sun, Y. E. (2010). Dnmt3a-
dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 329, 444-448. 
5 References 
__________________________________________________________________________________________ 
263 
Wu, S., Shi, Y., Mulligan, P., Gay, F., Landry, J., Liu, H., Lu, J., Qi, H. H., Wang, W., Nickoloff, J. A., and Wu, 
C. (2007). A YY1-INO80 complex regulates genomic stability through homologous recombination-based repair. 
Nature structural & molecular biology 14, 1165-1172. 
Wu, S. C., and Zhang, Y. (2010). Active DNA demethylation: many roads lead to Rome. Nature reviews 
Molecular cell biology 11, 607-620. 
Wysocka, J., Swigut, T., Xiao, H., Milne, T. A., Kwon, S. Y., Landry, J., Kauer, M., Tackett, A. J., Chait, B. T., 
Badenhorst, P., et al. (2006). A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin 
remodelling. Nature 442, 86-90. 
Xi, H., Yu, Y., Fu, Y., Foley, J., Halees, A., and Weng, Z. (2007). Analysis of overrepresented motifs in human 
core promoters reveals dual regulatory roles of YY1. Genome research 17, 798-806. 
Xiao, Y. (2011). Enhancer of zeste homolog 2: A potential target for tumor therapy. The international journal of 
biochemistry & cell biology 43, 474-477. 
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S. H., Ito, S., Yang, C., Xiao, M. T., Liu, L. X., et al. 
(2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent 
dioxygenases. Cancer Cell 19, 17-30. 
Yamada, Y., Warren, A. J., Dobson, C., Forster, A., Pannell, R., and Rabbitts, T. H. (1998). The T cell leukemia 
LIM protein Lmo2 is necessary for adult mouse hematopoiesis. Proc Natl Acad Sci U S A 95, 3890-3895. 
Yamashita, K., Upadhyay, S., Osada, M., Hoque, M. O., Xiao, Y., Mori, M., Sato, F., Meltzer, S. J., and 
Sidransky, D. (2002). Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in 
esophageal squamous cell carcinoma. Cancer Cell 2, 485-495. 
Yan, X. J., Xu, J., Gu, Z. H., Pan, C. M., Lu, G., Shen, Y., Shi, J. Y., Zhu, Y. M., Tang, L., Zhang, X. W., et al. 
(2011). Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute 
monocytic leukemia. Nat Genet 43, 309-315. 
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., 
Yokota, J., Tanaka, T., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and 
prognosis. Cancer Cell 9, 189-198. 
Yang, Z. Q., Imoto, I., Fukuda, Y., Pimkhaokham, A., Shimada, Y., Imamura, M., Sugano, S., Nakamura, Y., 
and Inazawa, J. (2000). Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently 
detected in esophageal cancer cell lines. Cancer Res 60, 4735-4739. 
Yap, K. L., Li, S., Munoz-Cabello, A. M., Raguz, S., Zeng, L., Mujtaba, S., Gil, J., Walsh, M. J., and Zhou, M. 
M. (2010). Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by 
polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38, 662-674. 
Yegnasubramanian, S., Haffner, M. C., Zhang, Y., Gurel, B., Cornish, T. C., Wu, Z., Irizarry, R. A., Morgan, J., 
Hicks, J., DeWeese, T. L., et al. (2008). DNA hypomethylation arises later in prostate cancer progression than 
CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68, 8954-8967. 
Yegnasubramanian, S., Kowalski, J., Gonzalgo, M. L., Zahurak, M., Piantadosi, S., Walsh, P. C., Bova, G. S., 
De Marzo, A. M., Isaacs, W. B., and Nelson, W. G. (2004). Hypermethylation of CpG islands in primary and 
metastatic human prostate cancer. Cancer Res 64, 1975-1986. 
Yoo, C. B., and Jones, P. A. (2006). Epigenetic therapy of cancer: past, present and future. Nature reviews Drug 
discovery 5, 37-50. 
Yu, J., Rhodes, D. R., Tomlins, S. A., Cao, X., Chen, G., Mehra, R., Wang, X., Ghosh, D., Shah, R. B., 
Varambally, S., et al. (2007). A polycomb repression signature in metastatic prostate cancer predicts cancer 
outcome. Cancer Res 67, 10657-10663. 
5 References 
__________________________________________________________________________________________ 
264 
Zgouras, D., Becker, U., Loitsch, S., and Stein, J. (2004). Modulation of angiogenesis-related protein synthesis 
by valproic acid. Biochemical and biophysical research communications 316, 693-697. 
Zhang, Y., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Bird, A., and Reinberg, D. (1999). Analysis of the 
NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes & 
development 13, 1924-1935. 
Zhang, Y., and Reinberg, D. (2001). Transcription regulation by histone methylation: interplay between different 
covalent modifications of the core histone tails. Genes & development 15, 2343-2360. 
Zhao, J., Ohsumi, T. K., Kung, J. T., Ogawa, Y., Grau, D. J., Sarma, K., Song, J. J., Kingston, R. E., Borowsky, 
M., and Lee, J. T. (2010). Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell 40, 
939-953. 
Zhao, J., Sun, B. K., Erwin, J. A., Song, J. J., and Lee, J. T. (2008). Polycomb proteins targeted by a short repeat 
RNA to the mouse X chromosome. Science 322, 750-756. 
Zhao, X. D., Han, X., Chew, J. L., Liu, J., Chiu, K. P., Choo, A., Orlov, Y. L., Sung, W. K., Shahab, A., 
Kuznetsov, V. A., et al. (2007). Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals 
distinct genomic compartments in human embryonic stem cells. Cell Stem Cell 1, 286-298. 
Zhou, Y., and Grummt, I. (2005). The PHD finger/bromodomain of NoRC interacts with acetylated histone 
H4K16 and is sufficient for rDNA silencing. Current biology : CB 15, 1434-1438. 
Zhou, Y., Santoro, R., and Grummt, I. (2002). The chromatin remodeling complex NoRC targets HDAC1 to the 
ribosomal gene promoter and represses RNA polymerase I transcription. Embo J 21, 4632-4640. 
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K. P., and Gottlicher, M. (2004). Induction of HDAC2 
expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455-463. 
Ziemin-van der Poel, S., McCabe, N. R., Gill, H. J., Espinosa, R., 3rd, Patel, Y., Harden, A., Rubinelli, P., 
Smith, S. D., LeBeau, M. M., Rowley, J. D., and et al. (1991). Identification of a gene, MLL, that spans the 
breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A 88, 10735-
10739. 
Ziller, M. J., Muller, F., Liao, J., Zhang, Y., Gu, H., Bock, C., Boyle, P., Epstein, C. B., Bernstein, B. E., 
Lengauer, T., et al. (2011). Genomic distribution and inter-sample variation of non-CpG methylation across 
human cell types. PLoS genetics 7, e1002389.  
6 Curriculum vitae 
__________________________________________________________________________________________ 
265 
6 Curriculum vitae 
PERSONAL INFORMATION 
Surname    Frommel 
Name     Sandra Carina 
Date of Birth   May 6, 1985 
Hometown   Grenzach-Wyhlen 
Nationality   German 
 
EDUCATION 
2011 – present  Doctoral Thesis in Molecular Biology (Dr. sc. nat./Ph.D.) 
      Institute of Veterinary Biochemistry and Molecular Biology, University 
      of Zurich, Switzerland 
2009 – 2011   Master studies in Biology (M. Sc.) 
      Technische Universität München, Germany 
2006 – 2009   Bachelor studies in Biology (B. Sc.) 
      Technische Universität München, Germany 
2005 – 2006   Voluntary Year of Social Service 
      German Red Cross, Rheinfelden (Baden), Germany 
2002 – 2005   High school (Abitur) 
      Biotechnologisches Gymnasium Lörrach, Germany 
1996 – 2002   Middle school 
      Realschule Efringen-Kirchen, Germany 
1992 – 1996   Primary school 
      Grundschule Istein, Germany 
 
AWARDS 
2015     1-year Fellowship from Sassella Stiftung, Zurich, Switzerland 
2014     Best Poster Award, Symposium on Medical Epigenetics 2014, April 7-9, 
      Freiburg i. B., Germany 
2012     1-year Müller Fellowship, Molecular Life Sciences PhD Program,   
      LSZGS Zurich, Switzerland 
6 Curriculum vitae 
__________________________________________________________________________________________ 
266 
PUBLICATIONS 
Haedke, U.R., Frommel, S.C., Hansen, F., Hahne, H., Kuster, B., Bogyo, M. & Verhelst, S.H. Phos-
phoramidates as novel activity-based probes for serine proteases. ChemBioChem (2014) 15, 1106-
1110. 
 
Bachmann, S.B., Frommel, S.C., Camicia, R., Winkler, H.C., Santoro, R. & Hassa, P.O. DTX3L and 
ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of 
metastatic prostate cancer cells. Molecular Cancer (2014) 13:125. 
 
Savić N., Bär D., Leone S., Frommel S.C., Weber F.A., Vollenweider E., Ferrari E., Ziegler U., Kaech 
A., Shakhova O., Cinelli P. & Santoro R. lncRNA maturation to initiate heterochromatin formation in 
the nucleolus is required for exit from pluripotency in ESCs. Cell Stem Cell (2014), 15(6):720-34. 
 
Frommel S.C., Gu L., Oakes C.C., Simon R., Grupp K., Gerig C.Y., Bär D., Robinson M.D., Baer C., 
Weiss M., Gu Z., Schapira M., Kuner R., Sültmann H., Provenzano M.; ICGC Project on Early Onset 
Prostate Cancer, Yaspo M.L., Brors B., Korbel J., Schlomm T., Sauter G., Eils R., Plass C. & Santoro 
R. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression pre-
dicts disease recurrence. Nature Genetics (2015) 47(1):22-30. 
 
Zingg D., Debbache J., Schaefer S.M., Tuncer E., Frommel S.C., Cheng P., Arenas-Ramirez N., Hae-
usel J., Zhang Y., Bonalli M., McCabe M.T., Creasy C.L., Levesque M.P., Boyman O., Santoro R., 
Shakhova O., Dummer R. & Sommer L. The epigenetic modifier EZH2 controls melanoma growth 
and metastasis through silencing of distinct tumour suppressors. Nature Communications (2015) 
6:6051. 
 
Cheng P. F., Shakhova O., Widmer D.S., Eichhoff O.M., Zingg D., Frommel S.C., Belloni B., 
Raaijmakers M.I.G., Goldinger S.M., Santoro R., Hemmi S., Sommer L., Dummer R. & Levesque 
M.P. Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a 
negative prognostic factor in advanced melanoma. Genome Biology (2015), 16:42
  
  
 
